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Abstract 
The inflammatory response can be broken down into the pro-inflammatory phase, 
followed by the resolution phase. Both phases are regulated by the expression or 
release of immunomodulatory mediators such as cytokines e.g. TNFα and IL-10. The 
two phases are also associated with different macrophage polarization states where 
the M1 phenotype is seen during the pro-inflammatory phase and M2 during 
resolution. Whereas much focus has been on the pro-inflammatory phase, more 
recently, emphasis has been placed on initiating the resolution phase of inflammation. 
Historically one of the classical signs of inflammation is the expression of the COX-2 
enzyme in neutrophils and macrophages early in the pro-inflammatory phase. 
However, over the last 20 years, a few research groups have observed a delayed but 
elevated expression of COX-2 in macrophages, along with a range of cytokines such 
as IL-10, normally associated with the resolution of inflammation. In addition, other 
researchers have found that administration of COX-2 inhibitors late in the inflammatory 
process can exacerbate some chronic inflammatory diseases in vivo. The concept of 
an anti-inflammatory COX-2 was further supported by studies that showed prolonged 
exposure to diclofenac in vitro, induced a COX-2 enzyme and high levels of anti-
inflammatory cytokines at a time when resolution would be expected. These 
observations led to the suggestion that the expression of COX-2 in the resolution 
phase may in fact be a key mediator of the resolution process. To explore these ideas 
further, this study focuses on the effects of IL-4, an anti-inflammatory cytokine that is 
widely associated with the resolution phase of inflammation.  A key objective will be to 
investigate the role of other factors such as peroxisome proliferator-activated receptor 
gamma (PPARγ), cyclic adenosine monophosphate (cAMP) and p38 mitogen 
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activated kinase (MAPK) in the signalling pathways through which IL-4 could 
potentially induce COX-2 protein and other mediators of resolution.  
 
The experiments were designed to investigate whether there are similarities 
between the induction of COX-2 and the polarisation of macrophages down an anti-
inflammatory line. As such, the macrophage J774.2 cell line was treated with 1μg/ml 
lipopolysaccharide (LPS), 500μM diclofenac or 10ng/ml IL-4 for 24 and 48 hours. 
These cells were assessed for COX-2 expression and activity, the production of the 
pro-inflammatory cytokine, tumour necrosis factor alpha (TNFα) and the anti-
inflammatory cytokine, interleukin 10 (IL-10) respectively and the anti-inflammatory 
mediator, cAMP. The importance of p38 and PPAR was assessed using the specific 
p38 inhibitor, SB203580 and a PPAR antagonist, Bisphenol A diglycidyl ether 
(BADGE). Following preliminary pharmacology experiments, the working 
concentration of each drug was decided: 10μM SB203580 and 150μM BADGE. In a 
subset of experiments, the effect of inhibition of COX-2 by 0.1-100μM acetaminophen, 
1-100μM indomethacin and 1-5μM dexamethasone (DEX) was also investigated; with 
the aim of identifying differential effects depending on the stimulant. 
 
LPS treated macrophages produced high levels of TNFα and low levels of IL-
10 within 24 hours of exposure. By contrast IL-4 produced high IL-10 and low TNFα 
levels at 48 hours. This confirms the opposing phenotypic state of the macrophages 
post-stimulation. Following IL-4 stimulation, the studies identified a possible sequence 
of events leading up to the induction of COX-2 and prostaglandin E2 (PGE2) synthesis.  
Adding antagonists of cAMP, PPAR or p38 MAPK to cells stimulated with IL-4 
reduced or blocked COX-2 expression and activity leading to the conclusion that these 
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factors become activated upstream to COX-2 induction by IL-4. In addition, cAMP was 
regulated at the level of both PPAR and p38 while PPAR was regulated by p38. 
Exposure to indomethacin reduced and blocked TNFα and IL-10 induced by LPS and 
IL-4 respectively. DEX specifically blocked TNFα secretion but induced IL-10 
secretion.  
 
Blocking both p38 and PPAR in IL-4 treated cells, prevents secretion of anti-
inflammatory cytokine IL-10. The novel finding that the p38 kinase and PPAR receptor 
are required for both the induction of COX-2 and secretion of IL-10, suggests an 
overlap between macrophage polarisation to an anti-inflammatory phenotype and late 
COX-2 induction pathways. P38, PPAR and cAMP would therefore be reasonable 
drugs targets to induce resolution. These studies suggest that in addition to being 
involved in driving inflammation, COX-2 may also drive resolution; however, this is yet 
to be confirmed with further experiments. These studies may go some way to 
explaining the adverse reactions and an impaired immune response reported in some 
individuals administered COX-2 inhibiting NSAIDs.  
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Chapter 1: Introduction 
 
1.1 The inflammatory response  
Inflammation is a protective host response to physical stress, microorganisms 
or foreign bodies with the intention of eliminating the noxious stimuli. Discovery of 
mediators such as cytokines and eicosanoids has improved the current understanding 
of the complex nature of the immune response. The inflammatory response aims for 
survival during infection in order to uphold tissue homeostasis (see review: (Kopitar-
Jerala, 2017)). Typically, there are 4 parts to the inflammatory response. The signal 
inducer (bacteria), the sensor (macrophage), the inflammatory mediating molecule 
(tumour necrosis factor (TNFα)) and the target infected tissue (skin). 
 
There are 5 cardinal signs of inflammation: dolor (pain), rubor (redness), tumor 
(swelling), calor (heat) and functio laesa (loss of function). Inflammation is 
characterised by changes in microcirculation, fluid exudation and the movement of 
leukocytes from blood vessels into tissues (see for reviews: (Lawrence et al., 2002, 
Maskrey et al., 2011)). Immune cells involved in this process include: neutrophils, 
monocytes, macrophages, basophils, mast cells, T cells and B cells amongst others 
(see for review: (Punchard et al., 2004)). The sequential cascade of events control the 
inflammatory process.  
 
Inflammation is divided into two main processes: the pro-inflammatory phase 
and the anti-inflammatory phase (resolution) both of which are regulated by 
immunomodulatory compounds such as cytokines (see for reviews: (Lawrence et al., 
2002, Maskrey et al., 2011)). The pro-inflammatory phase encompasses the influx and 
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accumulation of polymorphonuclear (PMN) leukocytes and chemical mediators such 
as acute phase proteins. Resolution includes apoptosis of PMN leukocytes, removal 
of pro-inflammatory mediators and the production of anti-inflammatory mediators and 
cytokines such as interleukin (IL)-10 (See for reviews: (Lawrence et al., 2002, Osiecki, 
2004, Maskrey et al., 2011)). Neutrophil and macrophage production and secretion of 
cytokines are highly regulated at a transcriptional level and in some cases post-
transcriptional level (see review: (Kopitar-Jerala, 2017)). 
 
1.1.1 Acute Inflammation 
Acute inflammation is considered the first line of defence and is highly non-
specific. There is an orchestration of events including an influx of PMN leukocytes to 
the site of inflammation, activation of endothelial cells and platelet activation and 
aggregation. Although previously believed to be a passive process, resolution is now 
regarded as an active process (see for review: (Serhan et al., 2008)). Acute 
inflammation self-resolves i.e. the inflammatory response comes to a stop. The 
resolution phase is characterised by the termination of PMN leukocyte emigration, 
fibrinolysis and the influx of monocytes which differentiate into macrophages (see for 
reviews: (Lawrence et al., 2002, Maskrey et al., 2011)). The resolution phase 
macrophages secrete chemo-attractants and pro-resolving mediators that stimulate 
phagocytosis of apoptotic cells (Stables et al., 2011). During this late phase, pro-
inflammatory cytokine levels decline and the levels of anti-inflammatory cytokines such 
as tumour growth factor-beta (TGFβ), IL-10 and IL-4 increase (see for review: 
(Lawrence et al., 2002)). The resolution of inflammation is important because failure 
of the inflammatory response to subside and self-resolve can lead to permanent tissue 
remodelling and chronic inflammatory diseases such as cardiovascular disease (CVD) 
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(see for review: (Osiecki, 2004)), rheumatoid arthritis (RA) (see for review: (Chimenti 
et al., 2015)) and Alzheimer’s disease (AD) (see for review: (Rubio-Perez and Morillas-
Ruiz, 2012)). 
 
1.1.2 Chronic inflammation 
Chronic inflammation is a result of continuous drive of the adaptive immune 
system. Ineffectual efficiency in the dampening of pro-inflammatory signals sustains 
and perpetuates inflammation. This leads to failed tissue healing (see for reviews: 
(Lawrence et al., 2002, Maskrey et al., 2011)). Chronic inflammatory diseases remain 
a human, economic and social burden on a global scale. Examples of chronic 
conditions include arthritis. According to Arthritis Research UK, 400,000 people in the 
UK suffered from arthritis with 2.46 million sufferers of hip osteoarthritis in England 
(Arthritis Research UK, 2014). In England, the prevalence of coronary heart disease 
(CHD) remained at 3% and hospital admissions increased by over 46,000 between 
2010 and 2014 (Bhatnagar et al., 2016). In 2012, CVD was the leading cause of death 
in women. England spent approximately £6.8 billion between 2012 and 2013 
(Bhatnagar et al., 2015) highlighting the need to control these conditions. Both RA and 
CHD reflect a chronic inflammatory condition, through activation of a circuit of 
signalling molecules, which, via positive feedback mechanisms, perpetuate disease 
(see for reviews: (Chimenti et al., 2015, Kraakman et al., 2016)).  
 
It is therefore evident that there exists a necessity to explore the mechanism(s) 
by which the inflammatory response becomes protracted and an understanding of how 
the resolution phase is obscured; leading to chronic disease. This will unravel novel 
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therapeutic targets to instigate the resolution phase by understanding the transition 
from acute to chronic inflammation. 
 
1.2 Macrophages in inflammation 
 The immune cell of interest in the current study was macrophages. This project 
was carried out using the macrophage J774.2 cell line. These are semi-adherent 
macrophages obtained from BALB/C mouse which partially adhere to the surface of 
the flask but can also be grown in suspension. Monocytes are derived from bone 
marrow progenitor cells and move from the blood into specific tissues. Here, they 
differentiate into macrophages and survey their immediate surroundings. 
Macrophages are imperative in physiology and pathophysiology as they contribute to 
a multitude of bodily changes. These cells form part of the innate immune system and 
are present in essentially all tissues; serving a diverse range of functions (see for 
review:(Chen and Zhang, 2017)). One such function which highlights the relevance of 
macrophage is wound healing. Wound healing is comprised of 4 stages: haemostasis 
(blood clot), inflammation (activation of the immune cells), proliferation (proliferation of 
keratinocytes and fibroblasts) and remodelling (macrophage release enzymes which 
remodel the extracellular matrix). Removal of macrophages during the mid-healing 
stage impairs the process whilst inducing haemorrhages. This highlights the 
importance of macrophages here (see for review: (Hesketh et al., 2017)).  
 
A well-established crucial role of macrophages is phagocytosis and clearance 
of apoptotic granulocytes and effete cells (see for review: (Oishi and Manabe, 2016)). 
It has been suggested that dysfunctional macrophage phagocytic activity leads to 
impaired resolution (see 1.1.1); also highlighting its importance in aging and disease 
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(see for review: (Oishi and Manabe, 2016)).  Despite being present in the resolution 
phase of inflammation, macrophages have typically been observed as the pro-
inflammatory immune cell that produce pro-inflammatory cytokines and further 
activate other immune cells. In several chronic conditions, activated macrophages 
have been reported. Recent focus has been on macrophage phenotype present during 
the pro-inflammatory and resolution phase of inflammation. 
 
1.2.1 Macrophage polarisation 
Macrophage polarisation is a relatively new concept that has emerged from 
identifying plasticity in the macrophage phenotypes during the inflammatory response. 
The classically activated macrophages (CAM) are denoted M1 and activate the Th1 
response, while the alternatively activated macrophages (AAM) are denoted M2 and 
activate the Th2 response (see for review: (Lawrence and Natoli, 2011, Sica and 
Mantovani, 2012, Tugal et al., 2013, Oishi and Manabe, 2016, Chen and Zhang, 
2017)) (fig 1.2.1.1). The M1 subtype can be activated by pro-inflammatory stimuli such 
as TNFα and interferon gamma (IFNγ). Whereas it was believed that IL-4 and IL-13 
were inhibitors of macrophage activation, it is now widely accepted that these anti-
inflammatory cytokines activate a distinct subtype of macrophages (M2) (see for 
review: (Lawrence and Natoli, 2011, Hoeksema et al., 2012, Tugal et al., 2013, Liu et 
al., 2014, Chen and Zhang, 2017)) (fig 1.2.1.1).  
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Figure 1.2.1.1: Diagram portraying the macrophage polarisation paradigm 
whereby macrophages take an anti-inflammatory or pro-inflammatory 
phenotype depending on the stimulus.  
Interferon Gamma (IFNγ) and lipopolysaccharide (LPS) bind to their receptors, 
interferon gamma receptor and toll like receptor 4 respectively. This polarises the 
macrophages to classically activated M1 macrophages. This requires activation of 
STAT1. Alternatively activated M2 macrophage are obtained following IL-4 and IL-13 
via STAT6 activation.  
  
Both macrophage phenotypes express differential markers that facilitate the 
identification of the macrophage present (see for review: (Liu et al., 2014)); Following 
both in vivo and in vitro experiments, it has been suggested that the macrophage 
phenotype is dictated by the dominating inflammatory microenvironment (see for 
reviews: (Italiani and Boraschi, 2014, Van Overmeire et al., 2014)) which includes the 
cytokine profile (see for review: (Italiani and Boraschi, 2014)), lipid mediators (see for 
review: (Lawrence and Natoli, 2011)) and the other immune cells present (see for 
review: (Lawrence and Natoli, 2011, Italiani and Boraschi, 2014, Van Overmeire et al., 
2014)). This highlights the role of the stimuli on the macrophage phenotypic nature. 
 
Although cAMP was shown to be a critical determinant for the conversion of 
macrophages from a pro-inflammatory to an anti-inflammatory phenotype (Ghosh et 
al., 2016), this molecule was shown to be downstream to the initiation of resolution 
Classically 
activated 
macrophage 
(M1) 
IFNγ 
STAT 1 becomes activated and 
induces pro-inflammatory gene 
expression  
LPS 
Alternatively 
activated 
macrophage 
(M2) 
IL-4 
STAT 6 becomes activated and 
induces anti-inflammatory gene 
expression  
IL-13 
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(Bystrom et al., 2008). Bystrom et al. (2008) used an in vivo model for acute 
inflammation and showed that the macrophages found during the resolution phase are 
the same as the cells that had migrated into the inflamed site during the pro-
inflammatory phase (~24 hours from onset of inflammation). This was determined 
using the phagocyte-specific dye PKH26-PCLred and PKH26-PCLgreen, as a tool to 
identify macrophage trafficking. There appears to be a novel induction pathway for 
both macrophage phenotypes through the activation of specific transcription factors 
such as signal transducer and activator of transcription (STAT) (see for review: (Chen 
and Zhang, 2017)) (fig 1.2.1.1). Despite this M1 M2 paradigm, depending on the site 
of inflammation, a mixed population of macrophages was reported. This macrophage 
heterogeneity showed embryonic and haematopoietic macrophages each with 
different receptors (see for review: (Gordon and Pluddemann, 2017)). The adaptability 
and plasticity of macrophages came from their receptor repertoire and versatile 
responsiveness to heterogenic environments (see for review: (Geissmann et al., 
2010)). Use of antibodies for these receptors have strengthened the notion for 
macrophage heterogeneity (see for review: (Gordon and Taylor, 2005)). 
 
1.2.2 Signalling pathways involved in macrophage polarisation  
Macrophages are polarised to the pro-inflammatory M1 phenotype when IFNγ 
binds to its receptor, which activate the Janus kinase (JAK). JAK dimerise and cross 
phosphorylate each other at the tyrosine residue which phosphorylates the tyrosine 
residue of the receptor tail. The SH2 domain of inactivated STAT1, a pro-inflammatory 
transcription factor, recognises the phosphotyrosine sequence on the activated IFNγ 
receptor and binds to tyrosine phosphate receptors. The carboxy terminus of STAT1 
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becomes phosphorylated by JAK and dimerises; allowing translocation into the 
nucleus where it can drive the expression of pro-inflammatory genes.  
 
To achieve the anti-inflammatory M2 phenotype, IL-4 (or IL-13) binds to its 
receptor. This activates JAK to phosphorylate and activate the STAT6 transcription 
factor which drives anti-inflammatory gene expression such as mannose receptor (see 
for reviews: (Lawrence and Natoli, 2011, Hoeksema et al., 2012, Tugal et al., 2013, 
Liu et al., 2014, Chen and Zhang, 2017). For robust polarisation to M2 macrophages 
by IL-4, cyclic adenosine monophosphate (cAMP) is critical, as it has been shown to 
increase expression of arginase (Arg-1) in microglial cells (Ghosh et al., 2016), and 
production of anti-inflammatory cytokines (Bystrom et al., 2008). 
 
1.2.3 IL-4 signalling 
IL-4 was initially regarded a stimulator of B cells and a survival factor for 
lymphocytes by protecting them from apoptosis (Luzina et al., 2012). Th2 cells, the 
analogy for M2 macrophages, produce IL-4, however, IL-4R was found on various cell 
types in addition to haematopoietic cells (Nelms et al., 1999). The tight control of IL-4 
induced tissue repair was evaluated in bone marrow derived macrophages (BMDM), 
where apoptotic neutrophils were required for IL-4 mediated repair. Macrophages can 
detect these apoptotic cells by identifying phosphatidylserine (Bosurgi et al., 2017) 
which signals them to engulf the cells. This highlights the importance of IL-4 during the 
resolution of inflammation.  
 
IL-4 is one of the key drivers of macrophage polarisation. IL-4 is well known for 
naïve cell differentiation where IL-4 drives Th2 differentiation and Th1 inhibition during 
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parasitic infection. These effects are primarily mediated via STAT6 transcription factor 
activation (Levings and Schrader, 1999). This cytokine regulates a profusion of 
biological functions e.g. proliferation and apoptosis. Thus, the pleiotropic downstream 
effects of IL-4 highlight its importance in immune responses. IL-4 has been reported 
to be protective in collagen induced RA murine models, which is an example of chronic 
inflammation (Morita et al., 2001), by dampening Th1 mediated responses. It mediates 
its effects via IL-4R which is expressed on a variety of haematopoietic and non-
hematopoietic cells (see for review: (Zamorano J, 2003)).  
 
The type 1 receptor consists of IL-4R with an α and γ chain. The IL-4Rα chain 
does not possess enzymatic activities until IL-4 activation. The γ chain associates with 
IL-4Rα following binding of the ligand. The heterodimerisation of the subunits initiate 
a signalling machinery via activation of kinases that associate with this complex.  
 
It is lethal to block the pro-inflammatory STATs involved in M1 polarisation 
because blocking the production of pro-inflammatory genes would impair the ability to 
combat infections (see for review (Mitchell and John, 2005)). Furthermore, activating 
the M2 phenotype consistently will promote tumour formation similar to Th2 cells 
because of the tumorigenic properties of the M2 subtype (see for review: (Chen and 
Zhang, 2017)). Therefore, fully understanding how the transition from the pro-
inflammatory macrophage to the resolution macrophage is inhibited in chronic 
inflammation would provide novel targets in the treatment of chronic diseases. A small 
but highly significant part of this is cyclooxygenase (COX)-2 and the prostaglandins 
(PG) involved in inflammation. 
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1.3 Production of prostaglandins (PG) 
In the early 1990s, lipopolysaccharide (LPS)-treated human monocytes in vitro 
(Fu et al., 1990) and mouse peritoneal macrophages in vivo (Masferrer et al., 1990) 
were shown to up-regulate PG synthesis in inflammation. Lipid compounds called 
prostanoids are derived from the poly-unsaturated fatty acid, arachidonic acid (AA). 
AA is enzymatically obtained from the phospholipid through cleavage by 
phospholipase A (PLA2). Prostanoids consist of PG, prostacyclin (PGI2) and 
thromboxane (TXA2). AA is metabolised by COX enzymes, also known as 
prostaglandin-endoperoxide synthase (PTGS). COX is an integral membrane 
glycoprotein that is abundant in the nuclear envelope and endoplasmic reticulum. COX 
has two active sites: the COX active site and the peroxidase active site (see for 
reviews: (Bjorkman, 1998, Simmons et al., 2004)). COX enzymes must be in their 
oxidised state to be active. Tyrosine-385 in the COX active site of the enzyme is 
oxidised by a tyrosyl radical (Hanel and Lands, 1982). This is generated at the 
peroxidase active site through the reduction of a lipid hydroperoxide (LHP) substrate. 
Constant supply of LHP therefore sustains COX in its oxidised state. This generates 
hydroperoxy endoperoxide prostaglandin G2 (PGG2) which is reduced to PGH2 via the 
peroxidase reaction. PGH2 is the precursor for the synthesis of PGE2, PGI2, PGD2, 
PGF2α and TXA2 which are ubiquitously produced and biologically active (Bjorkman, 
1998). 
 
Opposing PG functions and varied temporal release throughout the 
inflammatory process has been recorded. Each PG are known to play a significant 
role in governing the inflammatory response (see for review: (Willoughby et al., 2000)). 
Augmented levels of PGE2 and PGI2 in inflamed tissues contribute to the cardinal signs 
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of inflammation (see for review: (Ricciotti and FitzGerald, 2011)). PGE2 has been 
shown to have a key role in exudate formation in acute inflammation (Katori et al., 
1998). PGD2 is predominant in the brain and is metabolised into the J series 
cyclopentanone PG (cyPG), 15-Deoxy-Delta-12,14-prostaglandin J2 15d-PGJ2, via a 
dehydration step (see for review: (Scher and Pillinger, 2005)). Thus, it is clear that 
there is temporal emphasis on PG synthesis and this is key to impacting the course of 
inflammation.  
 
1.4 The discovery of the COX-2 protein and its role in inflammation 
Research into the COX enzymes peaked in the 1990s with the discovery of an 
inducible COX isoform. Initially, a 2.7 kb COX protein was identified and regarded as 
the only COX enzyme present. Habenicht et al. (1985) induced this enzyme in mouse 
Swiss 3T3 fibroblasts with platelet-derived-growth-factor (PGDF) and observed 2 PG 
peaks; one at 10 minutes and another at 2-4 hours. Addition of the translational 
inhibitor, cycloheximide, blocked only the late peak, suggesting a pool of induced COX 
protein. Fu et al. (1990) revealed that dexamethasone (DEX) was more able to inhibit 
LPS-induced COX activity compared to unstimulated COX in monocytes, reinforcing 
the potential for a pool of COX with differential properties. DEX is a glucocorticoid (GC) 
that down-regulates inflammation. LPS is found on the outer membrane of gram 
negative bacteria and elicits an immune response. Xie et al. (1991) provided 
compelling evidence for an inducible ~5.0 kb COX enzyme, whose features were 
distinct from that of the 2.7 kb COX. This was represented by biphasic elevation of 
~5.0 kb COX in fibroblasts. Interestingly, Xie et al. (1991) showed that in the presence 
of translational inhibitors, inducible COX mRNA increased, alluding that this ~5.0 kb 
COX is synthesised de novo. 
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  Two COX isoforms have been identified: COX-1 which is expressed 
constitutively and COX-2 which is inducible (Xie et al., 1991, Katori et al., 1998). 
Constitutive COX-1 has primary roles in physiological function such as gastric cyto-
protection by producing PGE2 and PGI2 which mediate vasodilation and reduced 
gastric acid secretion (see for reviews: (Bjorkman, 1998, Simmons et al., 2004)). COX-
2 enzymes are induced by pro-inflammatory cytokines and are highly expressed and 
active during the inflammatory response (Lawrence et al., 2002). Ongoing research 
has provided mounting evidence for the involvement of COX-2 in pyrexia, pain, CVD, 
cancer and AD (see for review: (Simmons et al., 2004)). This knowledge has been a 
key clinical advancement, as it provided a new drug target for several inflammatory 
conditions. 
 
 
 
 
 
 
 
 
 
Figure 1.4.1: Diagram showing the induction of COX-2 when LPS binds to its 
receptor. 
Following the binding of a pro-inflammatory molecule such as LPS to its 
receptor, pro-inflammatory transcription factors such as NFκB become activated. This 
induced COX-2 and stimulates the release of arachidonic acid from the phospholipid 
bilayer. COX-2 produce prostaglandin products which have various effects depending 
on the receptor it binds to. Image taken from (Bodas and Vij, 2010). 
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1.5.1 Biphasic expression of COX-2 
In rat carrageenan induced pleurisy model for acute inflammation, during the 
early phase, high levels of PGE2 were observed followed by a shift towards PGF2α as 
the response waned (Capasso et al., 1975). This again, highlights the temporal factor 
of PG synthesis throughout the course of inflammation. Using the same model as 
Capasso et al. (1975), Gilroy et al. (1999) reported induction of COX-2 protein with 
maximal PGE2 release at 2 hours, where PMN leukocytes are dominant. This was 
followed by marginal PGE2 synthesis and a second peak in COX-2 protein expression 
at 48 hours; 350% greater than that observed at 2 hours. This biphasic paradigm of 
COX-2 induction was previously reported in chicken embryo fibroblasts (CEF) at 1 
hour and again to a higher level at 4 hours (Xie et al., 1991). This again highlights the 
temporal regulation on the expression of COX-2. Gilroy et al. (1999) showed that PGD2 
and 15d-PGJ2 levels peaked at 2 hours followed by a decline during the course of 
inflammation and a subsequent incline at 48 hours. It is yet to be clarified, whether 
endogenous concentrations of 15d-PGJ2, being a natural ligand for peroxisome 
proliferator activated receptor gamma (PPAR), initiates an anti-inflammatory route for 
COX-2 function. Bystrom et al. (2008) reported COX-2 expression on what was 
regarded as resolution macrophages, despite its expression being observed on pro-
inflammatory macrophages (see for review: (Sica and Mantovani, 2012)). 
 
1.5.2 COX-2 inhibition amplifies inflammation 
COX-2 inhibitors were shown to exacerbate disease by blocking PG (see for 
review: (Yedgar et al., 2007)). Attenuated inflammation was observed at 2 hours 
following the addition of NS-398 and indomethacin; a selective COX-2 inhibitor and a 
dual COX-1/2 inhibitor respectively, (Gilroy et al., 1999). Exacerbated inflammation 
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was detected at 48 hours with reduced 15d-PGJ2 levels, following treatment with NS-
398. The authors were unable to detect COX-1 and suggested late induced COX-2 to 
govern the resolution phase. These findings agree with Chan and Moore (2010) who 
reported COX-2 mRNA to be elevated during the resolution phase in murine collagen 
induced arthritis, another inflammatory model. NS-398, given in early stages, 
attenuated arthritic symptoms while inflammation was perpetuated when given in later 
stages (Chan and Moore, 2010). These key findings emphasise the temporal 
importance of COX-2 expression and the time of NSAID administration. 
 
Pulmonary expression of COX is elevated in ovalbumin induced allergic 
inflammation and it was commonly conceived that COX products had pernicious 
effects on the lung. Despite this, PGE2 was found to subdue immunoglobulin (Ig)E 
production and block allergen induced asthmatic responses (Gavett et al., 1999). 
Lungs from COX-2 deficient mice exhibited inflammation of greater intensity compared 
to the wild-type mice. These mice also displayed impaired alveolar septae. When 
measuring the degree of lung inflammation, it was evident that COX-2 deficient mice 
had a significantly greater degree of lung inflammation (Gavett et al., 1999). This was 
in many ways similar to work carried out by Wallace et al. (2000).  Wallace et al. (2000) 
showed COX-2 derived PG to contribute to the gastric defense system. It was made 
clear that non-steroidal anti-inflammatory drug (NSAID) blockage of COX-2 as well as 
COX-1 contributed to mucosal damage. Collectively, these studies highlight the role 
of COX-2 and PGE2 in the resolution of the acute inflammatory response. 
 
Whereas in COX-2 deficient mice, no clinical manifestations were reported and 
the colon mucosal integrity was preserved (Morteau et al., 2000), the addition of 
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dextran sodium sulfate (DSS) induced colitis. COX-2 deficiency showed reduced 
PGE2, as expected. Morteau et al. (2000) found lack of COX-2 to accelerate severe 
colitis, as shown by aggressive injury; whilst also increasing death. This may have 
been driven by COX-2 deficient IL-1β induction, which is produced as part of the innate 
immune response (Morteau et al., 2000). Morteau et al. (2000) predicted that COX-2 
derived PGE2 is therefore critical in aggressive colitis, as it assists with the healing 
process and encourages mucosal protection.  
 
 Skeletal muscle cells that were exposed to palmitate and NS-398 exhibited 
increased levels of IL-6 and TNFα mRNA with reduced PGE2, compared to cells 
treated with palmitate alone (Coll et al., 2010). Furthermore, when PGE2 was co-
treated with NS-398 and palmitate, induction of nuclear factor kappa B (NFκB), a 
transcription factor involved in pro-inflammatory pathways, was attenuated. This was 
not observed in the absence of PGE2, thus suggesting PGE2 to mediate this anti-
inflammatory effect. PGE2 was also able to reduce TNFα when these cells were treated 
with NS-398 and palmitate. Coll et al. (2010) proposed that increased AA, due to 
blockage of COX, was available to be metabolised into 12-hydroxyeicosatetraenoic 
acid (12-HEPE) which evokes pro-inflammatory effects (Coll et al., 2010).  
 
The anti-inflammatory properties of the COX-2 derived PGE2 suggest the ‘late’ 
COX-2 may be different to the ‘early’ COX-2. The effects seen above may be due to 
inhibition of COX-2 with different biochemical properties.  
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1.6  Sensitivity of COX-2 for inhibition   
1.6.1 Inhibition of COX-2 by acetaminophen 
Simmons et al. (1999) gave evidence for acetaminophen (paracetamol) to 
inhibit diclofenac induced COX-2 activity in a dose dependent manner; however, this 
effect was not observed in LPS-induced COX-2. Furthermore, LPS induced COX-2 
was more sensitive to NSAIDs compared to the diclofenac induced COX-2 (Simmons 
et al., 1999). Ten years later, Ayoub et al. (2009) observed comparable findings, 
suggesting two induced COX-2 proteins which possess different selectivity for 
inhibition.  
 
Acetaminophen is widely used as a first line of treatment for antipyretic and 
analgesic therapy and can be obtained over the counter (see for reviews: (Botting, 
2000, Sharma, 2013)). To date, the mechanism by which acetaminophen produces 
these effects remains ambiguous, however studies have reflected acetaminophen as 
a weak inhibitor of COX enzymes (Mitchell et al., 1993). Suggestions have been made 
associating limited anti-inflammatory properties with decreased COX inhibition in the 
periphery because of a high LHP tone; which is the intermediates of lipid peroxidative 
reactions. This differs to the CNS where there is a low LHP tone and COX activity can 
be inhibited by acetaminophen, thus acetaminophen has antipyretic and analgesic 
properties. As mentioned previously, COX activity requires the enzyme to be in an 
oxidised state and acetaminophen is a reducing agent that reduces COX into an 
inactive state, thereby reducing PG synthesis (Ouellet and Percival, 2001). This 
paradigm may explain the increased potency of acetaminophen to inhibit COX enzyme 
activity in dog and rabbit brain compared to dog spleen (Flower and Vane, 1972). In 
contrast, Ayoub et al. (2011) showed diclofenac induced COX-2, but not LPS induced 
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COX-2, in J774.2 macrophages to be inhibited by acetaminophen regardless of the 
LHP tone (Ayoub et al., 2011). A high LHP tone induced by J774.2 macrophages 
treated with diclofenac and a LHP donor (T-butyl hydroperoxide), did not antagonise 
the inhibition of diclofenac induced COX-2 by acetaminophen. On the other hand, 
acetaminophen did not inhibit LPS-induced COX-2 where the LHP remained relatively 
low (Ayoub et al., 2011). NSAIDs, however, behaved as potent inhibitors of LPS 
induced COX-2 but not diclofenac induced COX-2 (Simmons et al., 1999). This 
suggests that diclofenac induced COX-2 may be biochemically different hence the 
differential selectivity for inhibition by acetaminophen.  
 
1.6.2 Inhibition of COX-2 by Indomethacin 
COX-2 is the target for NSAIDs and has been accepted in the medical 
community for the treatment of chronic inflammatory diseases (Maskrey et al., 2011). 
The clinical efficacy of NSAID and their inhibitory properties on prostanoids stress the 
precedence of these mediators in pain, fever and inflammation (see for review: 
(Ricciotti and FitzGerald, 2011)). This class of drugs produce both therapeutic (Katori 
et al., 1998, Kotilinek et al., 2008) and toxic activities (see for review: (Hoppmann et 
al., 1991)) by inhibiting PG synthesis.  
 
NSAIDs bind to the COX site, with no effect on the peroxidase site, to shut down 
prostanoid generation. This can only occur at one of the monomers that form the COX 
dimer. Aspirin is a non-selective NSAID that diffuse into the COX active site and 
acetylates serine-530 in COX-1 irreversibly. Aspirin inhibition of COX-2 is somewhat 
less efficient due to the larger catalytic pocket (see for reviews: (Bjorkman, 1998, Vane 
and Botting, 1998, Simmons et al., 2004)). Development of NSAIDs that share the 
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therapeutic aspect of aspirin was targeted by the pharmaceutical industry. To this end, 
indomethacin was produced to serve this purpose. Inhibition of COX-1 by NSAIDs 
interfere with the cellular function and cause adverse side effects such as 
gastrointestinal toxicity (see for review: (Kawai, 1998, Ricciotti and FitzGerald, 2011)). 
Selective COX-2 inhibitors such as celecoxib, have been developed to achieve 
antipyretic, analgesic and anti-inflammatory effects, without the side effects seen with 
non-selective COX inhibition (Warner et al., 1999). 
 
Wallace et al. (2000) confirmed that celecoxib inhibited COX-2 without 
impacting COX-1, while SC-560 inhibited COX-1 without impacting COX-2. Of interest, 
indomethacin, the drug used by Gilroy et al. (1999), was reported to inhibit COX-1 and 
COX-2 to similar amplitudes. Thus, indomethacin behaves as a pan COX inhibitor. 
Derivatives of indomethacin were found to bind to COX (Remmel et al., 2004). 
Although IL-1β and COX-2 were induced in pentylenetetrazole (PTZ) evoked seizures 
in zebra fish, exposure to indomethacin before PTZ treatment forced a down-
regulation in both IL-1β and COX-2. Administration of indomethacin also reduced the 
behavioural signs associated with seizures (Barbalho et al., 2016). Thus, 
indomethacin was used in this project to inhibit COX-2. 
 
1.6.3 Inhibition of COX-2 by dexamethasone  
 DEX is a GC that has been widely recognised as an effective treatment method 
in the prevention of rejection in transplants, inflammatory and autoimmune disease. 
GC were not produced with the intention of relieving pain; rather they served to repress 
inflammation (see for review: (Punchard et al., 2004)). The clinical efficacy of DEX 
becomes paradoxical as long-term treatment leads to diabetes, osteoporosis and 
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some other inflammatory conditions (see for review: (Coutinho and Chapman, 2011)). 
Furthermore, a drawback of cortisol and synthetic GC agents like DEX was that they 
produced therapeutic effects at supra-physiological concentrations therefore, 
adversities were ineluctable (see for review: (Punchard et al., 2004)). 
 
 GC exerts its effects by binding to glucocorticoid receptor (GR) which behave 
as a regulator of gene expression. GR homodimerization allow it to bind to GC-
response elements (GRE)s. GR activation was reported to dampen PPARγ expression 
(Inoue et al., 2000), a receptor which was shown as a requirement for COX-2 induction 
by diclofenac (Ayoub et al., 2009). It is believed that GC mediated immunosuppressive 
effects are attributed to repressed transcription of immunomodulatory factors such as 
NFκB. GC reduce vasodilation and oppose increased permeability which is seen 
during inflammation. Furthermore, GC was reported to reduce leukocyte emigration 
(see for review: (Coutinho and Chapman, 2011)). DEX exerts some of its anti-
inflammatory effects, such as IL-10 production, via phosphorylation of ERK (Xia et al., 
2005). GC induced IL-10 has been commonly noted in monocytes and macrophages 
(see for review: (Coutinho and Chapman, 2011)). Furthermore, it remains enigmatic 
whether IL-10 is produced because of GC induced differentiation or whether this IL-10 
amplifies some of GC effects (see for review: (Coutinho and Chapman, 2011)).  
 
In LPS treated keratocytes, the levels of TNFα, IL-6 and IL-1β was elevated. 
Following a 48-hour DEX treatment, levels of these pro-inflammatory cytokines 
dropped significantly (Yan et al., 2017). Similarly, whereas LPS stimulated TNFα in 
PMN leukocytes from new borns, this was inhibited 55% by DEX. IL-1β induced by 
LPS was inhibited 70% by DEX. This concentration was unable to impact 
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chemokinesis and chemoxtaxis; thus, positing its anti-inflammatory effects are 
mediated by impacting the cytokine release. Therefore, DEX may exert its anti-
inflammatory effects on COX-2 in a similar manner.  
 
On top of the anti-inflammatory role of DEX, this GC has also been associated 
with COX-2. Masferrer et al. (1992) gave evidence for DEX to regulate only inducible 
COX in sham-adrenalectomised kidneys. This steroid had no effect on the constitutive 
COX. LPS is an entrenched inducer of COX-2. Typically, DEX has been regarded to 
work antagonistically to LPS induced effects (Fu et al., 1990, Barrios-Rodiles and 
Chadee, 1998, Inoue et al., 2000, Abraham et al., 2006, Yano et al., 2007). As such, 
DEX blocks COX-2 induction (Barrios-Rodiles and Chadee, 1998). As we characterize 
the LPS induced ‘early COX-2’ and the ‘late COX-2’ as different, the effect of DEX on 
these two inductions of COX-2 is key.  
 
1.7 Transcription factors involved in COX-2 induction 
 The transcription factors NFĸB and PPARγ are believed to be involved in COX-
2 protein induction, depending on the stimuli (Ayoub et al., 2009). NFĸB was shown to 
shut down PPARγ (Chistyakov et al., 2015) suggesting a paradoxical relationship as 
both transcription factors are associated with the induction of COX-2.  
 
1.7.1 NFĸB in inflammation 
NFĸB has been suggested to be the “master” regulator of the inflammatory 
response (see for review: (Lin et al., 2017)). This is pertinent to the induction of COX-
2 by LPS and also a member of the group of transcription factors involved in 
polarisation of macrophages towards the M1 phenotypic state. The inhibitor of NFĸB 
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(IĸB) kinase (IKK) phosphorylation-directed degradation of IĸB activates NFĸB which 
translocates to the nucleus and induces pro-inflammatory gene expression. Such 
target genes include TNFα and IL-1 which contribute to tissue damage (see for review: 
(Luo and Zhang, 2017)). Through a positive feedback program, TNFα increases NFĸB 
by binding to the TNFα receptor  (see for review: (Luo and Zhang, 2017)).  
 
1.7.2 PPARγ transcription factor 
PPARγ is one of three types of steroid nuclear receptors with roles in glucose 
metabolism and inflammation. Following activation, PPAR-γ forms heterodimers with 
retinoid-X receptor to drive gene transcription and has pro-apoptotic properties (Wick 
et al., 2002). A class of drugs, called thiazolidines, are used in the treatment of 
diabetes. These drugs primarily increase insulin secretion from the pancreas by 
targeting PPARγ.  
 
Low levels of PPAR-γ have been reported in unstimulated macrophages 
followed by a subsequent increase in activated peritoneal macrophages (Rossi et al., 
2000). In AD brains, increased hippocampal PPARγ during inflammation was 
suggested to be a compensatory mechanism for a decrease in anti-inflammatory 
mediators (Wang et al., 2014). This suggests a potentially anti-inflammatory role for 
this receptor in inflammation.  
 
Microarray analysis showed IL-4 induced STAT6 to be required for PPARγ 
target gene expression (Szanto et al., 2010). Studies have given evidence for IL-4 to 
induce STAT6 and bind to the promoter region of PPARγ target genes e.g. fatty acid 
binding protein (FABP4) (see for reviews: (Szanto et al., 2010, Sica and Mantovani, 
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2012, Tugal et al., 2013)). Furthermore, IL-4 induced STAT6 activates kruppel-like 
factor 4 (KLF4), another transcription factor. This was found to induce PPARγ (Liao et 
al., 2011) (see for reviews: (Sica and Mantovani, 2012, Tugal et al., 2013)). Thus, 
whereas LPS reduced KLF4, IL-4 significantly increased this (Liao et al., 2011); 
reiterating a signalling pathway between IL-4 and PPARγ. STAT6 deficiency stops the 
ability to inhibit pro-inflammatory cytokines such as TNFα (Levings and Schrader, 
1999) and showed the inability to express M2 markers such as Ym1 (Szanto et al., 
2010) (fig 1.2.2.1). Similarly, KLF4 deficient macrophages significantly reduce PPARγ 
levels (Liao et al., 2011). This emphasises the anti-inflammatory role of both IL-4 and 
PPARγ in inflammatory cell phenotype.  
 
 IL-4 binding to its receptor has been shown to increase 12/15-lipoxygenase 
activity which produces the endogenous ligand for PPAR-γ, 15d-PGJ2 (Szanto et al., 
2010). Interestingly, repression of LPS-induced NFkB transcription was noted in the 
presence of PPAR-γ and the COX-2 product, 15d-PGJ2, which activates PPAR-γ 
(Ricote et al., 1998). This implies a signalling axis between the anti-inflammatory 
cytokine and nuclear receptor that shuts down the pro-inflammatory transcription 
factor NFĸB. 
 
1.7.3 Relevance of PPARγ and NFĸB in COX-2 induction 
Diclofenac is an NSAID and has previously been observed as an inducer of 
COX-2, in macrophage J774.2 cells (Simmons et al., 1999, Ayoub et al., 2009). 
Treatment of this cell line with diclofenac stimulated the cells to produce the anti-
inflammatory cytokines: TGFβ and IL-10 with low levels of pro-inflammatory cytokines: 
IL-6 and TNFα. Whereas LPS induced COX-2 as early as 6 hours, diclofenac could 
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only induce COX-2 at 48 hours and this COX-2 was termed the ‘late COX-2’ (Ayoub 
et al., 2009). In the diclofenac induction of COX-2 pathway, NFkB inhibition had no 
notable effect on COX-2 expression but blocked LPS induced COX-2 (Ayoub et al., 
2009). The PPARγ antagonist, Bisphenol A diglycidyl ether (BADGE), reduced 
diclofenac, but not LPS-induced COX-2 expression. These results suggest PPARγ is 
required for diclofenac-induced COX-2 protein induction while NFĸB is key in the LPS 
pathway leading to the expression of COX-2 (Ayoub et al., 2009). This study along 
with research conducted by Gilroy et al. (1999) and Lawrence et al. (2001) provide 
compelling evidence towards a pool of ‘late COX-2’ distinct from the ‘early COX-2’.  
 
1.8 Mediators involved in the induction of COX-2 
1.8.1 Mitogen-activated protein kinases (MAPK) 
Some studies reflect a relation between PPARγ and a protein kinase. Mitogen 
activated protein kinases (MAPK) are key players in inflammation and have been 
identified as targets in chronic inflammation (Campbell et al., 2004) (see for reviews: 
(Cuenda and Rousseau, 2007, Huang et al., 2009, Cuadrado and Nebreda, 2010, Fisk 
et al., 2014)). The MAPK relay extracellular signals into intracellular responses via 
phosphorylation and engender a plethora of effects. This sophisticated relay 
mechanism allows for appropriate responses to be orchestrated. Phosphorylation is 
the transfer of a phosphate group from a phosphate donating molecule such as ATP 
to the threonine (thr), tyrosine (tyr) and/or serine (ser) of a substrate. Conventional 
MAPK include, ERK1, ERK2, JNK1, JNK2, JNK3, p38 which exists in 4 isoforms: α, β, 
γ and δ. P38 α and β are expressed ubiquitously in tissues however p38 γ and δ are 
not. These MAPK can be activated by various stimuli including environmental stress, 
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growth factors, hypoxia, ischaemia and cytokines (see for review: (Zarubin and Han, 
2005(Huang et al., 2009)).   
 
There are 3 evolutionarily conserved kinases which act in a sequential manner. 
MAPK, MAPK kinase (MAP2K) and MAPKK kinase (MAP3K). Following activation by 
a stimulus, example TNFα, MAP3K becomes activated. This phosphorylates ser/thre 
region and activates the MAP2K: either MKK3 or MKK6. MAP2K activate p38 via 
phosphorylation. This phosphorylation occurs on the activation loop at the Thr-Gly-Try 
motif. Activated p38 phosphorylates and activates MAPKAPK-2 (MK2), MAPKAPK-3 
(MK3) as well as various other transcription factors. These are collectively termed 
MAPK-activated protein kinase (MAPKAPK).  
 
1.8.1.1 p38 MAPK 
This research shows particular interest in p38 MAPK due to its relevance in 
inflammatory signalling pathways and regulation of PPARγ. p38 has historically been 
associated with the production of pro-inflammatory cytokines by regulating their 
expression via transcription factor regulation such as NFkB or by modulating the 
mRNA stability and translation (see for review: (Cuenda and Rousseau, 2007, 
Coulthard et al., 2009, Cuadrado and Nebreda, 2010)). p38α activation is stimuli and 
cell type specific. p38α has been shown to possess pro-inflammatory properties as 
shown in RA patients (Korb et al., 2006) and can be phosphorylated downstream to 
LPS binding its receptor. Although LPS activates p38, p38 does not stabilise all LPS 
target genes. Despite genes being destabilised by a p38 inhibitor, they were not 
upregulated by LPS (Briata et al., 2005). This suggests both p38 and LPS do not share 
a mutualistic relationship i.e. they do not activate each other.  
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 A large body of evidence pointed towards p38, specifically the  isoform, to be 
pro-inflammatory. This led p38 to be considered as a promising drug target in chronic 
inflammation. Korb et al. (2006) used immunoprecipitation to show the  and  isoform 
to be activated and expressed in RA synovial fluid but not in the control. The compound 
SB203580 acts as a specific competitive ATP binding inhibitor for p38 α and β (Davies 
et al., 2000).This compound has been used in animal models for RA, AD, inflammatory 
bowel disease among others, due to its ability to reduce pro-inflammatory cytokine 
expression (see for review: (Kumar et al., 2003, Fisk et al., 2014)). Nevertheless, 
safety risks reflected p38 MAPK as a poor therapeutic target (Denise Martin et al., 
2012).  
 
Despite the general view that p38 is pro-inflammatory, a recent publication has 
provided controversial data showing p38 inhibition to suppress typical anti-
inflammatory macrophage markers: Arg-1, Ym-1 and Fizz-1 (Jimenez-Garcia et al., 
2015). Additionally, inhibition of p38 inhibited phosphorylation of STAT6, a key 
transcription factor involved in AAM (see 1.2.1.1). Inhibition of p38 leading to inhibition 
of phospho-STAT6 expression suggests that STAT6 is activated downstream to p38 
MAPK in an anti-inflammatory signalling cascade (Jimenez-Garcia et al., 2015). The 
data from this paper provided both in vitro and in vivo evidence for the involvement of 
p38 MAPK in polarisation towards the AAM. In conjunction with this, Kim et al. (2008) 
showed p38α dependent expression of IL-10 amongst its tier of target genes; thus, 
accentuating a role for this kinase in anti-inflammatory pathways. This may explain 
poor therapeutic benefits inspected by Guma et al. (2012) when p38α was blocked in 
macrophage dominating inflammatory disease. 
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p38 MAPK has been associated with PPARγ making it highly relevant in this 
project. Schild et al. (2006) showed that p38 inhibition reduced PPARγ activity in 
human primary trophoblasts whereas PPARγ did not affect p38 MAPK expression. 
Moreover, p38 was required for PPARγ stability as p38 inhibition reduced the 
expression of this transcription factor. Thus, Schild et al. (2006) gave evidence for p38 
MAPK to regulate PPARγ expression and activity. Correspondingly, both Yano et al. 
(2007) and Chistyakov et al. (2015) corroborated the regulatory control of p38 on 
PPARγ because the introduction of SB203580 inhibited PPARγ.  
 
1.8.2 cAMP as a second messenger 
Like p38 MAPK, interest in cAMP was shed due to its involvement in immune 
function (see for review: (Daniel et al., 1998)). Integrating extracellular and intracellular 
signals, cAMP allows cellular adaptation by amplifying the signal of the initial stimulus. 
cAMP is a potent regulator of adaptive and innate immune functions. It is key in 
pathogenic disease and so a promising therapeutic drug target (see review: (Raker et 
al., 2016)). Elevated levels of cAMP typically weaken pro-inflammatory responses and 
phagocytosis (see for review: (Serezani et al., 2008, Yan et al., 2016)). Concomitantly, 
cAMP encourages increase in anti-inflammatory markers and cytokines (Bystrom et 
al., 2008). In a self-contained system, cAMP increase phosphodiesterase (PDE) 
activity, which negatively regulate cAMP by degrading intracellular cAMP. Thus, PDE 
behave as an inflammatory response mediator (see for review: (Omori and Kotera, 
2007)) and PDE inhibitors can curtail the inflammatory response. Development of PDE 
inhibitors, although an attractive approach, has demonstrated excessive side effects 
including abdominal pain and nausea (see for review: (Raker et al., 2016)). 
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PGE2 is a ligand for G protein-coupled receptor (GPCR). Being a product of 
COX-2, it is believed to possess pro-inflammatory properties. Binding of PGE2 to its 7 
transmembrane-spanning GPCR leads to the exchange of a phosphate molecule from 
guanine triphosphate (GTP) to guanine diphosphate (GDP). The ligand binding forces 
a conformational change and the disassociation of G protein alpha subunit (Gαs) from 
the β and γ subunit; which, activates adenyl cyclase (AC). AC is responsible for the 
generation and modulation of cAMP by catalysing the conversion of adenosine 
triphosphate (ATP) to cAMP (see for review:(Serezani et al., 2008, Yan et al., 2016)). 
Activated cAMP can bind the regulatory subunit of protein kinase A (PKA). The 
catalytic subunit of PKA serves to phosphorylate serine and threonine sites of target 
cAMP response element binding proteins. H89 is an inhibitor of PKA which blocks LPS 
induced PGE2 and blocks MAPK by inhibiting the CREB mediated mRNA (see for 
review: (Yan et al., 2016)). Thus, the significance of cAMP in both PGE2 and p38 
mediated effects, makes this molecule key in the project.  
 
1.8.2.1 The role of cAMP in macrophage polarisation 
cAMP is recognised to abate a multitude of inflammatory responses (see for 
reviews: (Serezani et al., 2008, Raker et al., 2016, Yan et al., 2016)). PDE4 inhibitors 
led to the inhibition of pro-inflammatory molecules such as TNFα and NFκB (see for 
review: (Spadaccini et al., 2017)) via cAMP upregulation, suggesting cAMP to have 
some regulatory/stimulatory effects on cytokines. cAMP has been targeted as a 
mediator in macrophage polarisation as, addition of dibutyryl, the cAMP analog (db-
cAMP), to pro-inflammatory macrophages showed an increase in IL-10 and reduced 
TNFα production. In the presence of rp-cAMP, the cAMP antagonist, TNFα production 
was increased (Bystrom et al., 2008). Thus, Bystrom et al. (2008) showed the 
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macrophage phenotype to be altered by variations in the intracellular cAMP levels by 
using agonists. The conversion from M1 to M2 may be mediated by PKA, as PKA 
specific cAMP analogs co-treated with IL-4, induced Arg-1 in M1 microglial cells 
(Ghosh et al., 2016).  
 
It is evident that cAMP provides synergism with IL-4 in polarising macrophages 
from an M1 to an M2 phenotype. This gave impetus to further understand the 
relevance of cAMP in macrophage polarisation and the expression of COX-2 in the 
anti-inflammatory macrophages. 
 
There is evidence suggesting that binding of PGE2 to the EP4 receptor exerts 
anti-inflammatory downstream effects (Sokolowska et al., 2015) (see for review: (Luo 
and Zhang, 2017)). Pre-treatment of cells with PGE2 inhibits LPS induced NFkB1 p105 
phosphorylation in mouse BMDM via EP4 (Minami et al., 2008). Silencing the EP4 
associated proteins in RAW264.7 cells show impaired inhibition of LPS induced p105 
phosphorylation. This suggests that targetting the PGE2-EP4 receptor axis, removes 
the EP4 induced inhibition on LPS induced NFkB activation (Minami et al., 2008). EP4 
knockout mice showed significantly increased cellular infiltration following LPS 
challenge (Minami et al., 2008). This suggests PGE2 acting via the EP4 receptor to 
possess an endogenous anti-inflammatory function. This agrees with previous studies 
that have shown EP4 to reduce TNFα production (Katsuyama et al., 1998). Low levels 
of Ono-AE2-227, the EP4 antagonist, induces a right-hand shift in TNFα inhibition 
against the log concentration of PGE2. This suggests EP4 to be the dominant receptor 
that mediates the anti-inflammatory effect of PGE2 (Ratcliffe et al., 2007). HEK cells 
that were treated with Ono-AE2-227, inhibited PGE2 induced cAMP elevations 
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(Ratcliffe et al., 2007). Collectively, this shows a strong and potentially significant 
relation between COX-2 induced PGE2, EP4 and cAMP. 
 
1.9 Hypothesis 
Selective inhibition of the late induced COX-2 but not the early COX-2 by 
acetaminophen in vitro, suggests the two COX-2 proteins to possess different 
biochemical properties. Opposing responses from in vivo inhibitory experiments leads 
us to believe these COX-2 proteins are in fact different; with tight temporal regulation 
for expression in vitro. We believe that the induction pathway for COX-2 by IL-4 is 
different to the classical LPS induced COX-2 induction pathway. Despite p38 
commonly being associated with COX-2 in pro-inflammatory pathways, we sought to 
find an anti-inflammatory role for p38 in IL-4 induced COX-2. Furthermore, interest in 
PPARγ developed from its requirement for the induction of COX-2 by diclofenac. As 
both diclofenac and IL-4 induce COX-2 at a later time point, we hypothesise PPARγ 
to also be a requirement for IL-4 induced COX-2 in vitro.  We hypothesise the nature 
of the COX-2 to be dependent on the microenvironment and phenotype of the 
macrophages present. As such, we believe p38 and PPARγ to also be required for the 
production of the anti-inflammatory cytokine, IL-10. The relevance of cAMP in 
macrophage polarisation has been well established. In this project, we predict cAMP 
to be relevant for the induction of COX-2 by IL-4 in macrophages that we assume to 
be anti-inflammatory.  
 
 1.10 Aims and objectives 
The aim of this project was to investigate whether the anti-inflammatory 
cytokine, IL-4 could induce a catalytically active COX-2 protein and whether this was 
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dependent on both p38 MAPK and PPAR-γ. Understanding this will facilitate our 
understanding on how resolution fails in chronic inflammation. Furthermore, the 
dependency of p38 and PPARγ to induce a catalytically active COX-2 with anti-
inflammatory properties, will open new drug targets. 
 
 This study aimed to draw parallel between the induction of COX-2 and the 
polarisation state of the macrophage. Accordingly, this work will analyse the effect of 
COX inhibition by an NSAID and GC on the polarisation state; as defined by the 
cytokine profile of the macrophage. The role of cAMP in both the LPS induced pro-
inflammatory pathway and the IL-4 induced anti-inflammatory pathway will be 
examined. 
 
As we speculate that both the IL-4 and LPS induced COX-2 to be “different” 
due to the differed induction times, different induction pathways and different 
sensitivities for inhibition properties, we sought to scrutinise the induction pathway 
through various pharmacological inhibition & antagonism assays. To this end, we 
aimed to gain further clarification on the following: 
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1) Identify an endogenous inducer of a late COX-2 protein in macrophage J774.2 
cells.  
  
2) Analyse the sensitivity of inhibition for COX-2 that is induced by LPS, diclofenac 
and IL-4 in an attempt to identify the potentially different biochemical properties. 
 
3) Determine the sequence of events that lead to the activation of COX-2 and the 
production of PGE2 by IL-4.  
 
4) Clarify the role of cAMP in COX-2 induction by IL-4.  
 
5) Confirm the effect of both LPS and IL-4 on the cytokine profile of the 
macrophage as a measure of the phenotype. 
 
6) Investigate whether addition of indomethacin or DEX has differential effects on 
the COX-2 induced by LPS and IL-4; whilst also correlating the phenotype of 
the macrophage with changes in the cytokine profile.  
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Chapter 2: Methods 
2.1 Cell Culture  
2.1.1 General maintenance of the macrophage J774.2 cells 
All cells were cultured in` the same way unless otherwise stated. Macrophage 
J774.2 were grown in Dulbecco's modified eagle medium (DMEM) (Lonza) that 
contained high glucose (4.5g/l), 10% fetal bovine serum (FBS) (Sigma), 5% antibiotics 
(penicillin and streptomycin) and antifungal (Amphotericin B) (Sigma). To dislodge 
cells from the surface of the flask, scrapers were used. The content was spun at 500g 
at 4°C for 5 minutes. The supernatant was decanted and the pellet re-suspended in a 
volume of DMEM. A percentage of this volume was distributed into new flasks for sub-
culturing or experimental purposes. The flasks containing the cells were placed in 
incubators with the following conditions at all times: 5% CO2, 5% humidity and 37°C. 
 
2.1.2 Experimental cell stimulations 
Depending on the nature of the experiment and the required total cell number, 
either a T25 flask or plates with 6 or 24 wells were used. In T25 flasks, 2.5x106 cells 
were added while in 6 and 24 well plates, 9.5 x 105 and 1.9 x 105 cells were added 
respectively following counting of the cells with Trypan blue (Sigma). Trypan blue was 
used to ensure the right number of viable cells were available for the stimulations per 
experiment. 
 
Cells were plated 24 hours prior to stimulations so that they reached 
approximately 70-80% confluency. This was confirmed using the microscope. Cells 
were typically either treated with 1μg/ml O111:B4 serotype LPS (Sigma), 500μM 
diclofenac (Sigma) or 10ng/ml IL-4 (R&D Systems) unless otherwise stated. Typically, 
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in pharmacological experiments, when measuring the dose dependent effect of drugs, 
a range of concentrations were used and this is stated in the results chapters. Once 
these stimulants were added, cells were harvested at the end of 24 or 48-hour 
incubations, unless otherwise stated. To obtain a cell pellet, post-stimulation, the cells 
were scraped and spun at 500g at 4°C for 5 minutes. The supernatant was decanted 
and a volume of phosphate buffered saline (PBS) was used to re-suspend the pellet. 
Cells grown in T25 flasks were re-suspended with 500μl PBS while cells grown in 
plates were re-suspended with 200μl PBS, to prevent over-dilution. The cells were 
spun at 500g, at 4°c for 5 minutes and the cell pellet was stored at -20C.  
 
For experiments where the supernatant contents were measured, the medium 
post stimulations, were collected in Eppendorf tubes and stored in -80C until use. The 
cell pellet was obtained from these samples to standardise supernatant content to 
protein concentration.  
 
2.1.3 Inhibitory assays 
In all experiments a dose response was investigated to identify the optimal 
concentration of the drug in each experiment. As such, in inhibitory experiments, a 1-
hour pre-treatment was typically employed where 0.1μM-10μM SB203580, 100μM-
200μM BADGE (Sigma), 1μM-10μM DEX (Sigma) or 5μM-50μM rp-cAMP (Sigma) 
was added to the cells. The optimal concentrations employed in follow-up experiments 
were: 10μM SB203580 (Tocris) and 150μM BADGE. These concentrations remained 
constant unless stated otherwise. Subsequent to this, 1μg/ml LPS, 500μM diclofenac 
and 10ng/ml IL-4 was added to the inhibitors in medium for either 24 or 48 hours.  
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In COX-2 activity inhibitory assays, the relevant inhibitor was added at the end 
of the 24 and 48-hour stimulation. Firstly, at the end of the 24 and 48-hour stimulation, 
the supernatant was removed with the detached cells and serum-free media was 
added to the wells for 5 minutes. Serum-free media was added to ensure all the 
residual diclofenac was washed off. This step was also included in LPS and IL-4 
treated cells to maintain consistency in the steps. The plate was placed in the incubator 
for 5 minutes. Subsequently, this media was removed and the inhibitor, prepared in 
DMEM immediately before use, was added for 30 minutes. This was followed by the 
addition of the inhibitor made in medium, with 30μM arachidonic acid, also prepared 
in DMEM, for 15 minutes. The supernatant was collected and immediately stored in -
80C until further analysis.  
 
2.2 MTT assay 
It is a common side effect that some drugs actuate toxic effects in cells. It is key 
to have knowledge on the percent of viable cells at the end of each experiment; thus, 
fathoming the toxicity levels of each stimulant. This ensures that, what is being 
measured following various stimulations come from a similar number of cells. 
Reduction of tetrazolium compounds is used to detect cell viability. MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium is positively 
charged and can penetrate viable eukaryotic cells (Riss et al., 2004). MTT is a 
measure of mitochondrial activity (Berridge and Tan, 1993). Viable cells convert MTT 
into formazan, visualised with a purple colour. Formazan is an insoluble precipitate 
within cells which can be solubilised with dimethyl sulfoxide is an organosulfur (DMSO) 
prior to the absorbance being read at 570nm. The solubilising agent should not 
interfere with colour stability or induce evaporation (Denizot and Lang, 1986). Dead 
 35 
cells are incapable of converting MTT to formazan therefore, the colour change is not 
visible.  
 
Following on from cell stimulations as indicated in the relevant results chapters, 
10μl of 5mg/ml (prepared in PBS) MTT (Sigma) was added to 100μl medium in each 
well. This was incubated for 2 hours at 37°C, 5% CO2. The contents of the wells were 
removed and 100μl DMSO was added to each well and mixed thoroughly. The plate 
was covered in foil until the absorbance was measured at 570nm. The MTT assay was 
carried out 4 times to determine whether any of these compounds have toxic or 
proliferative effects on the macrophage J774.2 cell line.  
 
2.3 Bradford assay 
 Once cells were stimulated, prior to any assay, the protein concentration 
needed to be quantified. This was done using the  Bradford assay (Bradford, 1976). 
The Coomassie Brilliant Blue G-250 in the Bradford reagent, binds to proteins. Non-
covalent Van der Waals force of attraction and electrostatic interaction between the 
dye and the carboxyl and amino group of the protein respectively were formed. pH<0 
shows a red colour at a maximum absorption of 470nm whereas a pH of approximately 
1 has a green colour 620nm absorption. At 595nm, a pH>2 shows a bright blue colour. 
Binding of the protein to the dye induces a shift in maximum absorption from 465nm 
to 595nm. This method of protein quantification is stable for 1 hour thus making it a 
good choice. Cations such as sodium and carbohydrates have little to no interference 
with the binding and therefore the absorbance is unaffected.  
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 Cells were lysed using a mammalian cell lysis kit (Sigma) with protease inhibitor 
cocktail (Sigma). Following copious preliminary experiments, it was concluded that a 
total volume of 100μl and 250μl cell lysis buffer was quintessential for cell lysis 
obtained from a 24-well plate or T25 flask respectively. The cell pellets stored at -20C 
(see 2.1) were re-suspended in either 100 or 250μl cell lysis buffer, depending on the 
starting number of cells. This was left on a shaker on ice for 15 minutes, as per 
manufacturer’s guide. Following this, samples in cell lysis buffer were added to 4x 
sample buffer (Biorad) with dithiothreitol (DTT) (Biorad) at a 3:1 ratio to make a total 
volume of 200μl. The remaining sample in cell lysis buffer was used to measure protein 
concentration.  
 
Tris buffer was used to dilute the bovine serum albumin (BSA) standards from 
0.05mg/ml-0.5mg/ml protein. The samples were diluted in tris buffer between 1:2 and 
1:5 dilutions. Ten microliters of diluted samples and the standards were added to each 
well in a 96 well plate in duplicates. Following this, 200l Bradford reagent (Biorad) 
was added to each well and left on a shaker for 5 minutes as per manufacturer’s 
instructions. The absorbance was measured at 595nm and a colour gradient could be 
observed where brown colour indicates low protein concentration and a blue colour 
indicates high protein concentration. The concentration of protein was quantified using 
the BSA standards by extrapolating the absorbance against the known concentrations 
of the standards.  
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2.4 SDS-PAGE and Immunoblotting  
Cells were grown in T25 flasks and stimulated for the appropriate time course. 
For SDS-PAGE analysis of cell lysates, cells were scraped and then spun (see 2.1) 
before being stored at -20C until use. The pellet was re-suspended in cell lysis buffer 
for 15 minutes on ice (see 2.3). A proportion of this content was used to assay for 
protein concentration using Bradford reagent (Bio-Rad) (see 2.3); while the remaining 
was added to 4x sample buffer (Bio-Rad) containing DTT at a 3:1 ratio. The samples 
in sample buffer were placed in a thermomixer and heat blocked for 5 minutes at 100C 
to denature the proteins. 
 
The protein samples were separated by SDS-PAGE using the Mini-PROTEAN 3 gel 
electrophoresis system (Bio-Rad). The resolving gel was prepared immediately before 
use, using 3.33ml protogel 30%, 2.5ml 4x resolving buffer, 4.06ml deionized water, 
1μl of 10% ammonium per sulfate (APS) per 100ml and 0.1ml 
tetramethylethylenediamine (TEMED) per 100ml solution. Once the resolving gel 
solidified, the stacking gel was prepared using 1.3ml protogel, 2.5ml protogel stacking 
buffer, 6.1ml deionized water, 0.05ml 10% APS and 0.01ml TEMED, and added on 
top of the resolving gel with 10 well combs. The gels were placed in the tank and filled 
with running buffer. Twenty microgram proteins were loaded on the 10% 
polyacrylamide gels.  
 
These were run in running buffer at 100 V, until the dye front reached the bottom of 
the gel. The running buffer constituted of 25mM Tris, 25mM glycine and 0.1% SDS.  
To determine the protein size and follow the progress of protein separation, pre-
stained Precision Plus Protein Standard (Bio-Rad) was used. This shows molecular 
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weight in the sizes: 250, 150, 100, 75, 50, 37, 25, 20, 15, 10 kDa.  
 
After SDS-PAGE, proteins were transferred from gels to 0.2m pore size 
polyvinylidene difluoride (PVDF) (G E Healthcare) using the wet transfer method. The 
transfer buffer constituted of 24mM tris base, 194mM glycine and 10% methanol made 
in water. A filter sandwich method was used where at the cathode end, a sponge was 
placed followed by cellulose blot paper (Bio-Rad). On top of this, the SDS-PAGE gel 
was placed with PVDF that had been activated with 100% methanol. Finally, another 
cellulose blot paper was added followed by a sponge at the anode end. This transfer 
sandwich was assembled whilst totally immersed in transfer buffer. The sandwich was 
secured in cassettes after air bubbles were removed. Ice blocks were added to prevent 
the cassette from overheating. The cassette was placed in a Mini Trans-Blot 
electrophoretic transfer cell (Biorad), and run at 100V for 60 minutes. Membranes 
containing the transferred proteins were referred to as blots.  
 
Blots were incubated in blocking buffer for 1 hour at room temperature on a plate 
shaker to reduce non-specific antibody binding. Blocking buffer was prepared using 
5% dry skimmed milk and 0.1% BSA in wash buffer, which was made using 20 mM 
Tris Base, 50 mM NaCl and 1:1000 Triton x-100. Blots were then incubated with an 
appropriate dilution of primary antibody in blocking buffer over night at 4C. The 
primary antibody targets the protein of interest and β-Actin to ensure each well 
contained the same amount of protein (see 2.10). Blots were washed (3 x 5 minutes) 
in wash buffer (TBS-Tween). Horseradish peroxidase (HRP)-coupled secondary 
antibody diluted 1:2000 in TBS-Tween was added for 1 hour at room temperature and 
left on a plate shaker. Secondary antibodies were used depending on the species in 
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which the primary antibody was raised (see 2.10). After washing the membranes with 
wash buffer (3 x 5 minutes), the membrane was visualised using enhanced 
chemiluminescence (ECL) (Bio-Rad) using a developer (Bio-Rad).  
 
Following 5-minute incubations with ECL, blots were placed in a gel imaging 
system (Chemidoc). Initially, the ladder was scanned using a colometric auto-
exposure setting to ensure the band analysed is of the correct molecular weight. 
Secondly, a high sensitivity setting was used to scan for specific protein bands 
between 1 and 300 seconds of exposure.  
 
2.5 Enzyme immunoassay (EIA) for PGE2 quantification 
At the end time point for the cell stimulations, serum-free media was used to 
wash the wells of the 24 well plate. This was incubated at 37C, 5% CO2 for 10 
minutes. The media was aspirated and 30M arachidonic acid (Sigma) was added to 
each well and incubated for 15 minutes (see 2.1). The plate was placed on ice to 
collect the media into Eppendorf tubes and stored in -80C until the day of analysis. 
The plates were stored in -20C until the Bradford assay was conducted (see 2.3). In 
inhibitory assays, after serum-free media was used to wash the wells, the appropriate 
concentration of inhibitor was added to each well for 30 minutes. This was followed by 
the simultaneous addition of the inhibitor with 30M arachidonic acid for 15 minutes 
(see 2.1). At the end of this incubation, the media and plate was stored as mentioned 
above. 
 
A PGE2 ELISA kit (Cayman Chemicals) was used to quantify PGE2 synthesis 
following each stimulation. Competition for the PGE2 antibody between PGE2 in the 
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samples and PGE2 acetylcholinesterase (AChE) conjugate (PGE2 tracer), which is 
constant in all the wells, determines the concentration of PGE2 in each treatment 
group. Thus, the PGE2 concentration is inversely proportionate to the amount of PGE2 
AChE conjugate that binds to the antibody. The antibody bound PGE2 can bind to the 
goat anti-mouse IgG antibody coated in each well. Ellman’s reagent contains AChe 
substrate which allows a colour change to be observed at 405nm after 1 hour of 
incubation.  
 
Initially, standards from 15.6pg/ml to 2000pg/ml were made via a 1:2 serial 
dilution in EIA buffer. This was prepared using Ultra-pure water. Each tube containing 
the standards were vortexed thoroughly to ensure accuracy. The experimental 
samples were diluted between 1:10 to 1:50 in EIA buffer and vortexed to mix well.  
 
Using the strip 96 well plate provided, the samples were loaded. In the first well 
nothing was loaded and referred to as ‘blank’. This was followed by the non-specific 
binding (NSB) well, where 100µl EIA buffer was added with 50µl PGE2 tracer. One 
well contained 50µl EIA buffer, 50µl tracer and 50µl antibody. For the remaining wells, 
50µl of the standards or samples were added followed by 50µl tracer and 50µl 
antibody. This was left on the plate shaker for 1 hour. Wash buffer was prepared (as 
per manufacturer’s instructions) and the wells were washed 5 times. After each wash, 
the wells were dabbed on paper towel to remove any wash buffer residue. Ellman’s 
reagent was prepared by reconstituting the provided vial with 20ml ultra-pure water 
immediately before use. Once 200μl Ellman’s reagent was added, the plate was 
covered in foil and left on a shaker for 1 hour. The absorbance was measured at 
405nm. 
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 To calculate the PGE2 levels per sample, the NSB value was subtracted from 
B0. This is referred to as the corrected binding. The NSB absorbance was deducted 
from absorbance values for standards and samples and divided by the actual binding 
and then multiplied by 100 to convert to percentage binding. This percentage binding 
value for the samples was calculated on Graphpad Prism using Log standard 
concentration and the percentage binding of the standards. The anti-log of these 
values gave the concertation of the samples. The concentration was multiplied by the 
dilution factor and divided by 1000 to express the PGE2 levels in ng/ml. Dividing this 
value by the protein concentration in the same samples allows the PGE2 levels to be 
expressed in ng/mg protein.  
 
2.6 cAMP quantification 
cAMP levels following stimulations were measured using ELISA (Cell 
Signalling). Fifty microliters of sample, standards ranging 0nM-240nM and HRP-linked 
solution were added to each well. This was covered and left on a horizontal orbital 
plate shaker for 3 hours at room temperature. cAMP from the supernatant competed 
with HRP-linked cAMP to bind to the immobilised anti-cAMP antibody. The plate was 
washed 4 times to remove excess cAMP.  Hundred microliters of the chromogenic 
substrate, 3,3',5,5'-Tetramethylbenzidine (TMB) substrate, was added to each well for 
30 minutes at room temperature. This detects HRP activity and yields a blue colour 
which is inversely proportionatal to the amount of cAMP present in the supernatant. 
Hundred microliters stop solution was added and the absorbance was measured at 
450nm. Sulfuric acid stop solution is a mineral acidic solution that serves to terminate 
HRP enzymatic activity whilst also stabilising the oxidised products. Addition of this 
produces a yellow colour of different intensities depending on cAMP concentration. 
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2.7 PPARγ transcription factor activity assay 
Nuclear extractions were carried out on pellets made from the stimulations 
which were stored in -20° (see 2.1). Pre-extraction buffer containing DTT and protease 
inhibitor (AbCam) was used to resuspend the pellet and left on ice. The contents were 
vortexed and spun 500g, 4°C for 5 minutes. The pellet was resuspended with 
extraction buffer containing DTT and protease inhibitor cocktail in a 1:1000 dilution. 
The supernatant was used to measure the activity of PPARγ transcription factor via 
ELISA (AbCam).  
 
Complete transcription factor binding assay buffer (CTFB) was prepared as 
instructed in the manual and 90μl of this was added along with 10μl nuclear extract to 
each well. The plate was sealed and incubated overnight without agitation. The wells 
were emptied the following day and washed 5 times with wash buffer. After each wash, 
the plate was dabbed on a paper towel to remove contents. Primary antibody that was 
diluted 1:100 was added to each well, except the blank and incubated for 1 hour at 
room temperature without agitation. The plate was washed 5 times with wash buffer 
to remove unbound antibodies. Goat anti-rabbit HRP conjugated secondary antibody 
diluted 1:100 was added to each well except the blank. This was incubated for 1 hour 
at room temperature without agitation. The plate was washed 5 times before adding 
100μl transcription factor developing solution for 15-45 minutes. This was protected 
from light by covering the plate with foil. A blue colour formed which is proportionate 
to the activity of PPARγ in each sample. One hundred microliters stop solution was 
added to each well to stop the reaction and a yellow colour formed. Absorbance was 
measured at 450nm. To calculate the PPARγ activity against the protein 
concentration, a similar calculation method was followed as mentioned previously (see 
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2.5). The readings were divided by the calculated protein concentration. 
 
2.8 Cytokine profile ELISA 
TNFα and IL-10 levels were quantified with quantitative sandwich EIA (R&D 
Systems) using supernatants stored at -80°c. Plates purchased from R&D systems 
were coated with monoclonal antibodies for TNFα or IL-10. Standards were prepared 
from concentrations ranging from 15.6pg/ml-1000pg/ml for IL-10 ELISA and 
10.9pg/ml-700pg/ml for the TNFα ELISA. Fifty microliters standards and undiluted 
samples were added to each well so the cytokine of interest can bind to the 
immobilised antibody. The plate was sealed with adhesive tape before placing it on a 
shaker for 2 hours at room temperature. The contents were aspirated and the plate 
was washed 4 times to remove all unbound substances. On the final wash, the plate 
was dabbed on a paper towel to remove excess wash buffer. One hundred microlite 
conjugated polyclonal antibody for mouse TNFα/IL-10 was added to each well and left 
on a shaker for 2 hours at room temperature. This was washed with wash buffer 4 
times before adding 100μl of prepared substrate solution to each well for 30 minutes 
at room temperature; protected from light. This reaction produces a blue colour. Stop 
solution provided in the kit was added which allowed the wells to turn yellow. The 
colour intensity is proportionate to the amount of cytokine bound in the first step. This 
was read in a spectrophotometer at 450nm. All concentrations were divided by the 
protein concentration obtained from the Bradford Assay (see 2.3), to standardise the 
readings. 
 
2.9 Statistical analysis 
Once column graphs were generated using Graphpad Prism, the One-way 
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analysis of variance (ANOVA) was employed to measure any statistical difference 
between the average of the different groups; where more than 2 conditions were 
involved. This method of analysis was typically adopted when measuring the effect of 
multiple concentrations of a stimulant or drug on a particular occurrence.  
 
Similarly, the unpaired T test was used to measure the mean between 2 groups. 
This was typically between a negative and positive control or vehicle control. Dunnett’s 
post hoc test was performed after the ANOVA to scrutinise deeply, whether the mean 
from each group was statistically different to the control group, thus the Dunnett’s post 
hoc test is a many-to-one comparison analysis.  
 
Any statistical difference between the groups tested were represented with a 
symbol ranging from *, $ and #. The representation for each of the respective symbol 
is explained in the legend of each figure. If the p value was less than 0.05, it was an 
indication that the results were not due to chance factors, therefore, the null hypothesis 
was rejected. Contrariwise, when the p value was greater than 0.05, the null 
hypothesis was accepted as there was evidence that chance factors played a role in 
the acquired results. Error bars were representative of the variation in the data 
supplied and these would interfere with the statistical output. 
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2.10 Antibodies used in experiments: 
 
  
Experiment  Antibody Species Dilution Manufacturer 
 
Western blots 
Primary 
 Antibody 
COX-2 Rabbit 1:1000 Cayman 
Chemicals 
β-actin Mouse 1:10,000 Sigma 
Phospho-p38 Rabbit 1:1000 Cell signalling 
Secondary 
Antibody 
HRP-
conjugated 
anti-Mouse 
Goat 1:10,000 Cambridge 
Bioscience 
HRP-
conjugated 
anti-Rabbit 
Goat 1:10,000 Cambridge 
Bioscience 
    
 
PPARγ 
transcription 
factor activity 
assay 
Primary 
Antibody 
 
PPARγ  Rabbit 1:100 Abcam 
Secondary 
Antibody 
HRP-
conjugated 
Anti-rabbit 
Goat 1:100 Abcam 
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Chapter 3: Induction of COX-2 in vitro with temporal variations 
 
3.1 Induction of COX-2 by LPS and diclofenac with temporal variations 
There are 2 pools of COX enzymes: COX-1, the constitutive enzyme and COX-
2, the inducible enzyme. COX are enzymatic proteins that are responsible for 
prostanoid synthesis. NSAIDs function by blocking COX-1 and COX-2 and therefore, 
PG production. These drugs have analgesic, antipyretic and anti-inflammatory 
properties. Despite the therapeutic effects, NSAID usage elicits a wide range of toxic 
side effects (Hoppmann et al., 1991, Katori et al., 1998, Kotilinek et al., 2008).  
 
Some in vivo work has given evidence for NSAID usage at an earlier time point 
to be beneficial, but at later time points, to exacerbate the inflammatory response 
(Gilroy et al., 1999, Chan and Moore, 2010). This shows time of NSAID administration 
to be key. An in vitro protocol has been developed where LPS induces COX-2 protein 
much earlier than diclofenac induces COX-2 (Simmons et al., 1999, Ayoub et al., 
2009). The two-time points that were highlighted in this study were 24 hours for LPS 
induced COX-2 and 48 hours for diclofenac inductive COX-2 (Ayoub et al., 2009). 
Despite this, it is well established that LPS can induce COX-2 much earlier than 24 
hours (Fu et al., 1990, Gilroy et al., 1999, Simmons et al., 1999, Kojima et al., 2000, 
Eliopoulos et al., 2002, Ayoub et al., 2009). In some in vivo experiments, an early and 
late induced COX-2 protein has been established (Gilroy et al., 1999, Bystrom et al., 
2008). Both the early and late induced COX-2 protein has been related to opposing 
properties such as differential inhibition by acetaminophen and NSAIDs (Simmons et 
al., 1999, Ayoub et al., 2009). In an attempt to replicate previous data published by 
Simmons et al. (1999) and Ayoub et al., (2009), and to validate this in vitro system in 
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house, J774.2 macrophages were stimulated with LPS or diclofenac over the 2-time 
points previously accentuated: 24 hours and 48 hours. 
 
 Similar to the protocol used by Ayoub et al., (2009), J774.2 cells were plated in 
T25 flasks and stimulated with 0.1, 1 and 10µg/ml LPS and 125, 250 and 500µM 
diclofenac for 24 and 48 hours (Ayoub et al., 2009). A cell pellet was obtained via 
centrifugation (see 2.1). The cell pellet was lysed and protein concentration 
determined using the Bradford assay (Bradford, 1976) (see 2.3). Twenty micrograms 
of protein were run on gels at 100V before being transferred onto 100% methanol 
activated PVDF membranes. Anti-COX-2 antibody that was diluted 1:1000 in blocking 
buffer was added to the membranes overnight followed by HRP-conjugated anti-rabbit 
antibody diluted 1:2000 in blocking buffer (see 2.10). ECL was added to the 
membranes for 5 minutes before developing (see 2.4).  
 
In order to evaluate COX-2 activity, at the end of the 24 and 48-hour stimulation 
of cells with LPS and diclofenac, the wells were washed and 30M AA was added for 
15 minutes. The supernatant was collected and assayed for PGE2 (see 2.5). The 
absorbances were standardised against the respective protein concentration which 
was measured using the Bradford Assay (see 2.3) 
 
As expected, LPS induced COX-2 much earlier (fig 3.1.1a) than 500μM 
diclofenac which induced COX-2 expression at 48 hours (fig 3.1.1b). Diclofenac did 
not induce COX-2 at 24 hours. The intensity of the 72kDa COX-2 band expression 
was somewhat similar to the expression of COX-2 induced by LPS at 24 hours. β-
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Actin was used as a loading control to ensure the same amount of protein was loaded 
per well.  
 
a)                       b) 
 
 
 
 
 
 
 
 
 
  
Figure 3.1.1: Induction of COX-2 expression with increasing concentrations of a) 
LPS and b) diclofenac. 
Cells were treated with increasing concentrations of LPS and diclofenac for 24 and 48 
hours. Cell pellets were lysed and analysed for protein concentration via Bradford 
Assay. On 10% gels, 20μg protein was loaded. Subsequent detection with ECL 
showed the COX-2 band at 72kDa. DMEM represents the unstimulated cells. β Actin 
was used as a loading control to ensure the same amount of protein was loaded per 
well. The data shown were obtained from 3 independent experiments (n=5) 
 
LPS induced PGE2, as a measure of COX-2 activity, in a concentration 
dependent manner at 24 hours (13.33 ng/mg protein; p<0.05*, 47.33 ng/mg protein; 
p<0.01** and 328.68 ng/mg protein; p<0.05* ng/mg protein) compared to the negative 
control (5.54 ng/mg protein) (fig 3.1.2a). At 48 hours, COX-2 was catalytically induced 
by 10μg/ml LPS (19.28 ng/mg; protein P<0.01**) but not 0.1 and 1μg/ml LPS (10.48 
ng/mg protein, 12.7 ng/mg protein) compared to the negative control (5.81 ng/mg 
protein) (fig 3.1.2a). Increasing concentrations of diclofenac (125, 250 and 500μM) 
treatment for 24 hours did not induce COX-2 activity (8.07 ng/mg protein, 20.92 ng/mg 
protein, 5.36 ng/mg protein) (fig 3.1.2b). At 48 hours, 500μM diclofenac significantly 
induced COX-2 activity (277.12 ng/mg; protein p<0.01**) but not at the other 
24 hours 48 hours 
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concentrations (10 ng/mg protein, 25.45 ng/mg protein) compared to the negative 
control (5.81 ng/mg protein) (fig 3.1.2b). This reinforces data shown by (Simmons et 
al., 1999) and (Ayoub et al., 2009), where 500μM diclofenac significanly induced late 
COX-2 activity at 48 hours. 
a)         b) 
  
Figure 3.1.2: Induction of COX-2 activity via a) LPS at 24 hours with only 10μg/ml 
LPS inducing activity at 48 hours. COX-2 activity was induced by b) high 
concentrations of diclofenac at 48 hours. 
Supernatant from cells treated with increasing concentrations of LPS and diclofenac 
were assayed for PGE2. All readings were standardised to protein concentration 
following the Bradford Assay. The negative control contains untreated cells and all 
consecutive bars reflect increasing concentrations of either LPS or diclofenac at both 
24 and 48 hours. 
The data shown were obtained from 3 independent experiments (n=3) Statistical 
significance was determined by One-way ANOVA followed by the Dunnets post-hoc 
test. Data are expressed as mean+/- SEM (error bars); *p<0.05, **p<0.01, ***p<0.001. 
 
3.2 Induction of COX-2 by an anti-inflammatory cytokine, IL-4 
Our group hypothesised that the phenotype of the macrophage specifies the 
functional role of the COX-2 protein. There are 2 types of macrophages, the M1 and 
M2 macrophages which are pro-inflammatory and anti-inflammatory in nature 
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respectively (fig 1.2.1.1), although debates still continue about the heterogeneity of 
macrophage populations in tissues (see for review: (Geissmann et al., 2010)). The M1 
macrophage expresses and secretes pro-inflammatory markers and cytokines, whilst 
activating pro-inflammatory transcription factors. This is antipodal to the M2 
macrophage where there is activation of anti-inflammatory transcription factors, 
expression and secretion of anti-inflammatory markers and cytokines respectively 
(see for reviews: (Tugal et al., 2013, Liu et al., 2014)). Previously published work show 
resolution phase macrophages to express COX-2 and produce anti-inflammatory 
cytokines e.g. IL-10 and TGFβ (Bystrom et al., 2008, Ayoub et al., 2009). This along 
with work showing an exacerbated inflammatory response when COX-2 is inhibited 
(Gilroy et al., 1999) enables speculation of an anti-inflammatory macrophage to 
express COX-2.  
 
There is profuse literature depicting the significant difference in the induction 
pathway of the M1 and M2 macrophage (see 1.2). Extensive research has shown the 
anti-inflammatory cytokine, IL-4 to be a prototypical activator of the M2 macrophage 
(Sheldon et al., 2013) via activation of STAT6 (see for reviews: (Lawrence and Natoli, 
2011, Hoeksema et al., 2012, Tugal et al., 2013)). IL-4 has been reported to induce 
STAT6 causing C/EBPβ to bind the IL-4 response element of Arg-1, thus activating it 
(Sheldon et al., 2013). High Arg-1 is an indication of the M2 phenotype (Jimenez-
Garcia et al., 2015). Thus, as a next step in this project, whether IL-4 can induce COX-
2 expression and activity was investigated. This will enable us to deduce IL-4 as an 
endogenous inducer of COX-2. To bring together the association between 
macrophage polarisation and induction of a potentially anti-inflammatory COX-2, 
whether the two pathways are linked needs to be determined. 
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Cells were plated in T25 flasks for 24 hours. Flasks were stimulated with 5, 10, 
25, 50 and 100ng/ml IL-4 for 24 and 48 hours. Following stimulations, cell lysis buffer 
was used to lyse the cells (see 2.3). Anti-COX-2 antibody was added to the PVDF 
membranes and secondary antibody was added the next day (see 2.4).  
 
The anti-inflammatory cytokine, IL-4, induced COX-2 expression specifically at 
48 hours with no bands present at 24 hours (data not shown) (fig 3.2.1). The 
expression of COX-2 was not concentration dependent as the expression did not 
correlate to the concentrations of IL-4. The negative control, where cells were 
unstimulated, showed no COX-2 expression as expected. β-Actin expression was 
used as a loading control.  
 
 
 
 
 
 
 
 
 
 
Figure 3.2.1 Induction of COX-2 expression with increasing concentrations of 
IL-4 at 48 hours. 
Increasing concentrations of IL-4 ranging 5-100ng/ml was used to treat cells for 48 
hours. Cell pellets were obtained and lysed prior to protein quantification via Bradford 
Assay. On 10% gels, 20μg protein was loaded and anti-COX-2 antibody was used to 
target COX-2 protein expression. β Actin was used as a loading control. The data 
shown were obtained from 3 independent experiments (n=3). 
 
Using the same stimulations from the above experiments, ELISA was 
performed to measure PGE2 (see 2.5) following stimulations with IL-4. Low 
concentrations of IL-4: 5, 10 and 25ng/ml were used in this experiment as they were 
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shown to induce COX-2 protein expression (fig 3.2.1). At the end of the 48-hour 
stimulation, the cells were washed and treated with 30μM AA (see 2.1). Cell pellets 
were obtained and quantified for protein concentration to standardise all the readings 
(see 2.3).  
 
IL-4 induced COX-2 activity was analysed at both 24 and 48 hours. The lower 
concentrations of IL-4 (5, 10 and 25ng/ml) were used in this experiment as they were 
shown to induce COX-2 protein expression (fig 3.2.1). The higher concentrations of 
IL-4 were not included as they followed the same pattern of failing to induce COX-2 
activity. Whereas 1μg/ml LPS induced COX-2 activity at 24 hours (51.63 ng/mg 
protein; p<0.01**) compared to the negative control (4.16 ng/mg protein), 5, 10 and 
25ng/ml IL-4 did not (21.06, 29.09, 23.38ng/mg protein) compared to the vehicle 
control (8.67ng/mg protein). Activity of COX-2 induced by IL-4 was compared to PBS 
because IL-4 was reconstituted in this. COX-2 activity was not induced by 500μM 
diclofenac at 24 hours (23.16 ng/mg protein).  
 
COX-2 activity was induced at 48 hours by 1μg/ml LPS (35.63 ng/mg protein 
p<0.01**) and 500μM diclofenac (44.36 ng/mg protein; p<0.001***) (fig 3.2.2). Lower 
concentrations of IL-4 (5 and 10ng/ml IL-4) significantly induced COX-2 activity (44.98 
ng/mg protein; p<0.001$$$, 52.08 ng/mg protein; p<0.001$$$) but 25 ng/ml did not (2.96 
ng/mg protein) (fig 3.2.2). At 48 hours, concentrations of IL-4 greater than 25ng/ml did 
not induce COX-2 activity (data not shown). At 48 hours, the negative control and 
vehicle control showed little COX-2 activity (8.01, 14.23 ng/mg protein respectively).  
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In follow-up experiments, we continued to use 10ng/ml IL-4, which we identified 
as the optimal working concentration as it induced COX-2 expression and activity. 
Furthermore, this concentration of IL-4 was previously used by (Bonder et al., 1999, 
Makita et al., 2015, Ghosh et al., 2016) and was shown to be sufficient to induce an 
M2 phenotype. 
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Figure 3.2.2: 5 and 10ng/ml IL-4 induced COX-2 activity at 48 hours but not at 24 
hours.  
Cells were treated with LPS, diclofenac and increasing concentrations of IL-4 for 24 
and 48 hours. At the end of the stimulations, the supernatant was assayed for PGE2 
concentration which was then standardised to its respective protein concentration. The 
negative control was unstimulated cells while the vehicle control was PBS. The 
positive control at 24 hours was 1μg/ml LPS and at 48 hours, the positive control was 
500μM diclofenac. All other bars represent increasing concentrations of IL-4 treated 
cells.  
The data shown were obtained from 3 independent experiments (n=3). One Way 
ANOVA was carried out with the Dunnett’s post hoc test between the negative control 
and the vehicle control, represented by * and between the vehicle control and the 
samples where IL-4 was introduced, represented by $. Data are expressed as mean+/- 
SEM (error bars); *p<0.05, **p<0.01, ***p<0.001, $p<0.05, $$p<0.01, $$$p<0.001. 
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3.3 Selective inhibition of the late induced COX-2 by acetaminophen 
As it can be seen that 10ng/ml IL-4 significantly induced a catalytically active 
COX-2 protein at 48 hours, further experiments were conducted using 10ng/ml IL-4. 
NSAIDs hold anti-inflammatory, analgesic and anti-pyretic properties. In vivo work has 
shown that NSAIDs can reduce inflammation if administered in early phases however 
usage during later stages (possibly the resolution phase) exacerbates inflammation 
(Gilroy et al., 1999). Treatment of cells for 24 hours with LPS and 48 hours with 
diclofenac was shown to induce an “early” and “late” COX-2 protein respectively 
(Simmons et al., 1999) (fig 3.1.1); thus, emulating the bi-phasic COX-2 in vivo. This in 
vitro tool was adapted by Ayoub et al. (2009) and also employed in the current study. 
Simmons et al., (1999) has previously shown LPS, but not diclofenac to induce a COX-
2 protein that is insensitive to acetaminophen. This suggests the LPS and diclofenac 
induced COX-2 to be biochemically varied. Acetaminophen is used as a first line of 
treatment for pain (see for review: (Botting, 2000, Sharma and Mehta, 2013)). It has 
been demonstrated as a weak COX inhibitor. As both 500M diclofenac and 10ng/ml 
IL-4 induced COX-2 activity at 48 hours, whether acetaminophen can inhibit or reduce 
IL-4 induced COX-2 activity would be the next appropriate study. To this end, the 
impact of acetaminophen on LPS, diclofenac and IL-4 induced COX-2 activity was 
examined.  
  
Cells were plated in 24 well plates for 24 hours to grow. Cells were left 
unstimulated (negative control) or treated with 1µg/ml LPS, 500µM diclofenac and 
10ng/ml IL-4 (positive controls). After 24 and 48 hours, cells were washed with serum 
free medium for 10 minutes and treated with 0.1, 1, 10 and 100 M acetaminophen in 
the acetaminophen control samples and experimental samples. DMEM was added to 
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the negative and positive controls. After 30 minutes, cells were treated with 30M AA 
in all the samples. PGE2 levels were quantified using the supernatant (see 2.5). Protein 
concentrations were assayed using the Bradford assay (see 2.3) and the PGE2 
readings were normalised to protein concentration. This range of acetaminophen was 
adapted from the concentrations used by Ayoub et al. (2009).  
 
As previously shown, LPS significanlty induced COX-2 activity at 24 hours 
(104.76 ng/mg protein p<0.001***). This activity was not increased or decreased in the 
presence of acetaminophen (98.88, 82.54, 127.31, 138.36 ng/mg protein) (fig 3.3.1a). 
Neither the unstimulated cells (8.56 ng/mg protein) nor cells treated with 
acetaminophen alone, induced COX-2 activity (12.61, 9.4, 9.33, 6.97 ng/mg protein). 
This proves that COX-2 activity in the presence of LPS and acetaminophen is a result 
of LPS and not the acetaminophen which was introduced. Diclofenac did not induce 
COX-2 activity at 24 hours (15.71 ng/mg protein) and acetaminophen had no effect on 
this at 24 hours (24, 19.04, 11.5, 13.24 ng/mg protein). The same was true for IL-4 
treatment at 24 hours where, 10ng/ml IL-4 had no effect on COX-2 activity (6.07 ng/mg 
protein) and acetaminophen did not effect this (14.21, 7.4, 6.83, 9.04 ng/mg protein).  
 
Five hundred micromolar diclofenac and 10ng/ml IL-4 significantly induced 
COX-2 activity at 48 hours (36.37 ng/mg protein; p<0.05*, 45.98 ng/mg protein; 
p<0.05* ng/mg protein respectively) (fig 3.3.1b). Only 1μM acetaminophen 
significanltly inhibited diclofenac induced COX-2 activity (12.03 ng/mg protein; 
p<0.05$) whereas all other concentrations of acetaminophen showed a non-significant 
inhibition (17.51, 16.28, 19.16 ng/mg protein) (fig 3.3.1b). The highest concentration 
of acetaminophen inhibited IL-4 induced COX-2 acitivity (21.3 ng/mg protein; p<0.05$), 
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whereas lower conentrations did not show this inhibition (44.9, 38.09, 42.42 ng/mg 
protein). LPS did not induce COX-2 activity (2.01 ng/mg protein) at 48 hours and 
acetaminophen did not effect this (3.37, 4.12, 1.76, 2.78 ng/mg protein) (see 3.3.1b). 
Similar to 24 hours, at 48 hours, acetaminophen on its own did not induce activity of 
COX-2 in the cells (2.41, 3.89, 4.23, 3.67 ng/mg protein); similar to the unstimulated 
cells (3.89 ng/mg protein). The diclofenac and LPS data are somewhat similar to data 
shown by Ayoub et al. (2009). 
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a) 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
Figure 3.3.1 Graph showing the inhibitory effects of acetaminophen on COX-2 
activity at a) 24 hours and b) 48 hours. COX-2 induced by diclofenac and IL-4 
were sensitive to inhibition by acetaminophen but LPS induced COX-2 was not.  
Cells were treated with LPS, diclofenac and IL-4 for 24 and 48 hours followed by a 30-
minute treatment with increasing concentrations of acetaminophen. The COX-2 
substrate was added before the supernatant was collected for PGE2 analysis. 
Readings were divided by the protein concentration which was obtained via the 
Bradford Assay. The negative control was the unstimulated cells and cells treated with 
acetaminophen on its own. The positive controls where cells that were treated with 
only 1μg/ml LPS, 500μM diclofenac or 10ng/ml IL-4. Experimental samples were each 
stimulant with increasing concentrations of acetmainophen.  
The data shown were obtained from 3 independent experiments (n=3). One Way 
ANOVA was carried out with the Dunnet’s post hoc test between the negative control 
and the positive controls, represented by * and between the positive control and the 
samples where acetaminophen was introduced with the stimulant, represented by $. 
Data are expressed as mean+/- SEM (error bars); *p<0.05, **p<0.01, ***p<0.001, 
$p<0.05, $$p<0.01, $$$p<0.001. 
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3.4 Cell viability following stimulations of macrophage J774.2 cells 
 The MTT assay functions on the principal that the mitochondria dehydrogenase 
enzyme serves in viable cells. A colorimetric assay enables us to observe a colour 
change as a measure of cell viability. The diclofenac concentration adopted in this 
experiment was of a high value: 500μM. There is potential that readings made 
following diclofenac treatment may relate to the high number of dead cells. As a result, 
the Bradford assay was conducted after each experiment to normalise all readings to 
its protein concentration. To this end, having confirmed that diclofenac and IL-4 
induced COX-2 are in some ways similar, IL-4 was introduced as a potential 
endogenous inducer of this protein in vitro.  
 
 To measure cell viability following the stimulations at the 2 key time points 
investigated, the MTT assay was carried out. Cells were grown in 96 well plates and 
treated with either 1μg/ml LPS, 500μM diclofenac or 10ng/ml IL-4 for 24 and 48 hours. 
At the end of the stimulations, 10μl of 5mg/ml MTT in PBS was added to each well. 
Following a 2-hour incubation, 100μl DMSO was added to each well and mixed before 
measuring the absorbance. Readings made at 0 hr were deducted from readings 
made at 24 and 48 hours to measure the change in viable cell density.  
 
At 24 hours, cells treated with 1μg/ml LPS (1.07nm; p<0.05*) and 10ng/ml IL-4 
(1.1nm p<0.05*) showed high MTT readings compared to the unstimulated cells 
(0.41nm) (fig 3.4.1). Diclofenac on the other hand showed low readings (0.3nm). A 
similar pattern was observed at 48 hours, where high MTT readings were observed in 
the unstimulated cells (0.8nm) and in cells treated with 1μg/ml LPS (0.98nm) and 
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10ng/ml IL-4 (1.69nm) (fig 3.4.1). In cells treated with 500μM diclofenac, the reading 
was extremely low, (-0.69nm; p<0.05*). 
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Figure 3.4.1 MTT assay showing high concentrations of diclofenac to reduce 
cell viability.  
Cells were simulated with 1μg/ml LPS, 500μM diclofenac and 10ng/ml IL-4 for 0, 24 
and 48 hours before measuring formazan production. The readings made at 0hr were 
deducted from the readings made at 24 and 48 hours. The negative control in this 
experiment was the unstimulated cells. All the bars represent cell viability following 
each stimulation.  
The data shown were obtained from 3 independent experiments (n=3). One Way 
ANOVA was carried out between the untreated cells and the treated cells. Data are 
expressed as mean+/- SEM (error bars); *p<0.05, **p<0.01, ***p<0.001. 
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3.5 Discussion to results chapter 3 
Induction of COX-2 protein in vitro with temporal variations 
 
3.5.1 Induction of an early and late COX-2 by LPS and diclofenac 
Although, previously thought to be a single protein, it has now been accepted 
that there are 2 COX isoforms; one constitutive (COX-1) and one inducible (COX-2). 
Addition of cycloheximide only blocked the expression of the inducible COX-2 protein 
(Habenicht et al., 1985, Fu et al., 1990, Xie et al., 1991, Katori et al., 1998). Whereas 
COX-1 produces cyto-protective PG, COX-2 was believed to play a role in pathological 
diseases (see for review: (Suleyman et al., 2007)). Inhibition of this protein by NSAID 
is commonly used for the effective management of inflammation, however, side effects 
such as GI erosions have been reported (see for review: (Suleyman et al., 2007)). This 
has been accredited to the inhibition of the constitutive COX isoform. As a result, 
selective COX-2 inhibitors were developed however, these too reflect adverse effects 
(see for review: (Kawai, 1998, Suleyman et al., 2007)). It has been suggested that the 
selectivity of these drugs to COX-2 becomes abolished at high concentrations 
(Suleyman et al., 2007); however we suggest the nature of the COX-2 expressed to 
define the response to these class of drugs. We allude to the time of drug 
administration being key to obtain beneficial or adverse effects. Thus, inhibition of, 
what we predict to be an ‘anti-inflammatory’ COX-2, may lead to such adverse 
reactions. 
 
Firstly, it must be noted whether LPS and diclofenac do indeed induce COX-2 
expression at various time points as suggested by Simmons et al., (1999) and Ayoub 
et al., (2009). This will give a functioning in vitro tool which emulates the 2 peaks of 
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COX-2 expression reported in vivo (Gilroy et al., 1999). Further to identifying COX-2 
expression at different times, the properties of these should be studied. If there are 
indeed differences, investigating whether the induction pathways vary for the early and 
late induced COX-2, in vitro, would be the natural next step. The initiator of the 
induction pathways leading to COX-2 needs to be clarified. Evidence of temporal 
variations in this induction would mean greater scrutiny in administration of COX 
inhibiting drugs, as the time at which patients take the drug would need to be 
controlled/regulated.  
 
Treating the macrophage J774.2 cell line with 1µg/ml LPS or 500µM diclofenac 
(Ayoub et al., 2009) has been shown to induce COX-2 expression at 24 and 48 hours 
respectively (fig 3.1.1). COX-2 expression intensified with a concentration dependent 
increase in LPS at both 24 and 48 hours, however at 24 hours, there was no COX-2 
expressed following treatment of cells with 500µM diclofenac. At 48 hours, COX-2 
expression was apparent with 500µM diclofenac treatment (fig 3.1.1b). Thus, the data 
shown in fig 3.1.1 was consistent with previously published data (Ayoub et al., 2009) 
where COX-2 was induced by 24 hours following LPS stimulations and at 48 hours 
following stimulations with 500µM diclofenac. The different induction times may allude 
to the COX-2 protein serving differential purposes. We believe there is a translational 
block and removal of this may depend on the COX-2 function. This comes from 
unpublished work which show the mRNA of COX-2 to be expressed much earlier than 
the expression of the protein (Ayoub, unpublished). Various in vivo experiments have 
shown selective inhibition of the early COX-2 to wane the inflammatory response and 
inhibition of the late COX-2 to exacerbate inflammation (Gilroy et al., 1999, Chan and 
Moore, 2010). This therefore suggests the COX-2 induced at both time points to 
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possess different functions. Though speculations at this stage, the different properties 
may be dictated by the inflammatory milieu and its effects may be mediated by the 
downstream PG produced and the receptor to which they bind. 
 
LPS was shown to induce COX-2 activity at 24 hours in a dose dependent 
manner. This activity dropped by 48 hours where activity was only significantly induced 
by 10μg/ml LPS; a concentration that is not physiologically relevant (fig 3.1.2). The 
diclofenac treated cells showed no COX-2 activity at 24 hours, as expected, because 
at this time point, no induction of the protein was noted (fig 3.1.1). At 48 hours, there 
was a significant upsurge in PGE2 production following treatment of cells with 500µM 
diclofenac (fig 3.1.2). This coincides well with fig 3.1.1 which shows COX-2 expression 
induced by this concentration of diclofenac. This alludes to the early induced COX-2 
to serve a different purpose to the late induced COX-2, as the expression appears to 
be tightly controlled.  
 
3.5.2 Evidence of macrophages that express COX-2 following IL-4 
treatment  
Despite IL-4 being an anti-inflammatory cytokine, we gave evidence for COX-2 
expression following 48-hour stimulations with increasing concentrations of IL-4 (fig 
3.2.1). COX-2 expression was absent at 24 hours. This pattern being somewhat 
similar to the induction of COX-2 by diclofenac (fig 3.1.1b), leads to the assumption 
that diclofenac and IL-4 induce a phenotypically similar COX-2 protein, in comparison 
to the LPS induced COX-2 protein. It may be that the induction pathway is similar 
between IL-4 and diclofenac. There does not seem to be a concentration dependent 
effect on the expression of this protein by IL-4, as there is no pattern in the intensity of 
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the band. The effect of IL-4 seems to be somewhat powerful as low concentrations 
(5ng/ml) show protein induction (fig 3.2.1). It has previously been reported that IL-4Rα 
is expressed on this cell line (Jimenez-Garcia et al., 2015) therefore, the effect of IL-4 
may be immediate. IL-4 binds to IL-4Rα with picomolar affinity. This binding recruits 
IL-2Rγ γc chain which forms a type 1 receptor complex. Although the IL-4R complex 
is not endowed with kinase activity, the cytoplasmic tail is linked with the recruitment 
of JAK. Typically, this activates phosphorylation of STAT6 (see for review: (Mueller et 
al., 2002, Luzina et al., 2012)).  
 
Following experiments that showed IL-4 to induce COX-2 expression (fig 3.2.1), 
whether this protein is catalytically active needed to be understood. A catalytically 
active protein confirms that the induction serves a purpose at that time point. As the 
negative (DMEM) and vehicle (PBS) control exhibit no COX-2 activity, while the 
positive controls (1μg/ml LPS at 24 hours and 500μM diclofenac at 48 hours) produced 
significantly more PGE2 (fig 3.2.2), the effect of IL-4 could be compared to the controls 
confidently.  
 
Supporting data from fig 3.1.2, whereas at 24 hours, LPS treated cells displayed 
COX-2 activity, IL-4 treated cells did not. Low concentrations of IL-4 increased PGE2 
output compared to the negative control at 48 hours (fig 3.2.2). This is similar to the 
diclofenac treated cells, thus strengthening the argument that the diclofenac and IL-4 
induction of COX-2 may share a similar pathway. Higher concentrations of IL-4 did not 
induce COX-2 activity and there was a sharp decline in PGE2 yield. This may be 
explained by a concept reviewed by Mueller et al. (2002) who suggested a single 
molecule to play both agonistic and antagonistic roles in signalling pathway via 
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cytokine receptor inhibition that is induced by high doses of its cognate ligand. This 
was previously noted in growth hormones where receptor dimerization was halted due 
to receptor saturation. Receptor saturation was not measured in this project so the 
same idea cannot be concluded confidently. 
 
Collectively, these figures showed COX-2 protein activation downstream of IL-
4 binding its receptor in what was assumed to be an anti-inflammatory signalling 
pathway. Copious publications have shown IL-4 to polarise macrophages towards M2 
as shown by increased Arg-1 in macrophages (Sheldon et al., 2013), activation of 
STAT 6 (Kaplan et al., 1996) and activation of anti-inflammatory receptors like PPARγ 
(Szanto et al., 2010) (see for review: (Luzina et al., 2012)). Furthermore, IL-4 is known 
to inhibit Th1 differentiation and pro-inflammatory signalling (see for review: 
(Zamorano J, 2003)). This raises the question as to whether the COX-2 induced by IL-
4, is an active member of the anti-inflammatory pathway.  
 
There is evidence that diclofenac induced COX-2 mRNA is present hours 
before the protein is expressed (Ayoub, unpublished data). Thus, it can be speculated 
that the IL-4 induced COX-2 mRNA is translationally repressed; leading to the protein 
being expressed only at 48 hours. From this, it can be inferred that the COX-2 induced 
by both diclofenac and IL-4 may bare different properties to the LPS induced COX-2. 
There is a chance that the late COX-2 may be translationally inhibited hence the 
delayed expression.  
 
Translational repression can be tightly regulated by micro RNA (miR). There is 
profuse literature which show specific miR that control COX-2 translation. miR have 
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been reported to down-regulate COX-2 protein synthesis and downstream PGE2 
synthesis (Yoon, 2011). miR-16 was shown to repress COX-2 translation without 
effecting COX-2 mRNA, by binding to the miR-16 response element on the 
3’untranslated region (3’UTR) of COX-2 in hepatoma cells (Agra Andrieu et al., 2012). 
Interestingly, in microglia specifically, miR-124 was shown to be expressed in M2 
phenotypes however in disease such as experimental autoimmune encephalomyelitis 
(EAE), levels of miR-124 were reduced. This correlates with a reduction in the M2 
marker, MR, and an increase in M1 markers CD86 and MHC Class II (Ponomarev et 
al., 2011). The mRNA should remain stable and avoid degradation in order to be 
translated into a fully functioning protein. Natural mechanisms have evolved to 
preserve the mRNA such as polyadenylation of the mRNA (see for review: (Ross, 
1995)). Thus, there is a possibility that the IL-4 induced COX-2 transcript is preserved 
until translation is activated. 
 
One of the hypotheses of this study was that macrophages polarise prior to the 
induction of COX-2 and we believe that the phenotype directs the functional properties 
of the COX-2. We speculate COX-2 translational postponement to control the 
properties of the COX-2 expressed (whether pro-inflammatory or anti-inflammatory). 
COX-2 induced in the late phase has been suggested to be anti-inflammatory as 
Ayoub et al., (2009) showed IL-10 and TGF release.  
 
It would be important to study the expression of IL-4R to see whether the 
stimulus is capable of increasing or reducing this receptor to induce a response. In 
microglia, LPS was shown to increase IL-4R in microglia of BALB/c mice (Fenn et 
al., 2012) however Quentmeier et al. (1994) showed LPS increased IL-4 
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responsiveness but not expression of IL-4R in human MONO-MAC-6 cells. This 
suggests a mechanism by which resolution, or at least suppression of a pro-
inflammatory response, can be instigated in an attempt to control inflammation (see 
for review: (Luzina et al., 2012)).  
 
There is clinical evidence of adversities reported from NSAID usage; increasing 
risk of hypertension, stroke and myocardial infarction (see for review:(Stollberger and 
Finsterer, 2003)). This project proposed that the adverse effects reported may be 
caused by the inhibition of the late COX-2 which we suggest to be expressed by 
macrophages of opposing phenotype to the macrophages expressing COX-2 in LPS 
treated cells. This “anti-inflammatory” COX-2 may play a role in producing PGs which 
drive secretion of anti-inflammatory cytokines whilst also reducing secretion of pro-
inflammatory cytokines.  
 
3.5.3 Selective inhibition of COX-2 by acetaminophen 
Acetaminophen has been shown to specifically inhibit diclofenac induced COX-
2 but not the LPS induced COX-2 activity (Simmons et al., 1999, Ayoub et al., 2009). 
As IL-4 induced COX-2 protein at the same time as diclofenac, whether the two COX-
2 proteins are similar needed to be confirmed so that IL-4 could be used as the 
endogenous inducer for COX-2. Diclofenac is highly toxic to the cells (fig 3.4.1) as 
shown by lower MTT readings following addition of this drug. The effect of high 
diclofenac concentrations for a longer duration severely reduced the cell count (fig 
3.4.1). If IL-4 could be identified as a late inducer of COX-2, this may be a more 
pharmacologically relevant tool in vitro for COX-2 induction. As a first step, 
understanding whether IL-4 induced COX-2 is sensitive to acetaminophen, similar to 
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diclofenac induced COX-2 will enable us to draw further conclusions as to whether IL-
4 and diclofenac induced COX-2 are similar. Subsequently, IL-4 should be used to 
endogenously induce COX-2 protein.  
 
As expected, LPS, diclofenac and IL-4 induced COX-2 activity at the previously 
shown time points. Acetaminophen treated cells appeared to produce PGE2 levels, at 
similar concentrations to what was seen in the unstimulated cells (fig 3.3.1). Thus, any 
changes in PGE2 production was dependent on the impact of acetaminophen on the 
COX-2 induced by the different stimuli.  
 
This experiment further confirmed data provided by Ayoub et al. (2009) who 
showed LPS induced COX-2 to be insensitive to acetaminophen while diclofenac 
induced COX-2 activity was reduced by acetaminophen. Diclofenac and IL-4 did not 
induce COX-2 activity at 24 hours and acetaminophen had no stimulatory effect on 
this (fig 3.3.1). This supports the notion that acetaminophen is not an inducer of COX-
2 activity (fig 3.1.1) (Simmons et al., 1999). As shown previously, COX-2 was induced 
by diclofenac and IL-4 at 48 hours (fig 3.1.2, 3.1.4, 3.1.5). Low concentrations of 
acetaminophen were able to inhibit diclofenac induced PGE2 synthesis but only higher 
concentrations of acetaminophen (100μM) inhibited IL-4 induced COX-2 activity (fig 
3.3.1b). The difference in sensitivity levels suggests the induction of COX-2 varies in 
some ways between IL-4 and diclofenac. It could be argued that 100M 
acetaminophen is too high a concentration because the therapeutic plasma 
concentration is 10μM, thus firm conclusions from this cannot be made. As 1M 
acetaminophen inhibited 500M diclofenac induced COX-2 activity (Ayoub et al., 
2009) and all other concentrations of acetaminophen non-significantly reduced 
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diclofenac induced COX-2 activity, this points to the diclofenac induced COX-2 to have 
different biochemical properties to the LPS induced COX-2.  
 
This inhibition is vital as we consider the late COX-2 to be anti-inflammatory 
and part of the resolution process. Based on work by Ayoub et al. (2009), we suggest 
the macrophage expressing this COX-2 to be anti-inflammatory therefore any 
inhibition by drugs would impair the natural healing process. Inhibition of the late COX-
2 exacerbates the inflammatory response in vivo (Gilroy et al., 1999, Chan and Moore, 
2010). If this COX-2 possesses anti-inflammatory and pro-resolving properties, then 
the ability of acetaminophen to inhibit this COX-2 is detrimental. Acetaminophen being 
an over the counter (OTC) drug, therefore being easily accessible, further complicates 
the matter.  
 
Acetaminophen has been recorded and discussed as a toxic drug on several 
platforms. Although its mechanism of action remains a pharmacological enigma, 
acetaminophen was suggested to work centrally; whilst being a weak inhibitor of COX-
1 and COX-2. (Flower and Vane, 1972). Whereas NSAIDs inhibit COX by competing 
with AA, acetaminophen caused reduction within the peroxidase site (see for review: 
(Hinz and Brune, 2012)). Flower and Vane (1972) showed brain PG to be more 
sensitive to acetaminophen inhibition compared to spleen PG. This was suggested to 
be due to impaired acetaminophen inhibition of PG caused by high extracellular AA 
and presence of peroxide in inflamed tissue (Hinz et al., 2008). Efforts were made to 
suggest acetaminophen as an inhibitor of ‘COX-3’, a variant of the COX-1 gene; 
however this notion appears to be rejected (see for review (Hinz and Brune, 2012)); 
although some pharmacological evidence supported this (Ayoub et al., 2011). Hinz et 
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al. (2008) reported an average 66% inhibition of LPS induced PGE2 and coagulation 
induced TxB2 in blood from acetaminophen treated patients. COX-1 inhibition was 
somewhat less compared to COX-2 (Hinz et al., 2008). The short half-life of 
acetaminophen meant its inhibitory effect on COX-2 was short-lived (see for review: 
(Hinz et al., 2008)).  
 
Previous reports and case studies have shown acetaminophen to be lethal, 
commonly used to over-dose (Sheen et al., 2002). The question rises as to whether 
the toxic effects of acetaminophen are seen due to inhibition of an anti-inflammatory 
COX-2 protein during the resolution phase.  
 
3.6 Chapter conclusion 
 There appears to be tight regulation of COX-2 expression which is induced with 
temporal variation.  COX-2 could be induced early or at a later stage depending on the 
stimulus. The LPS and diclofenac induced COX-2 have differential inhibition by 
acetaminophen which suggests different biochemical properties between both 
proteins (fig 3.3.1). Furthermore, IL-4 was shown to induce a catalytically active COX-
2 protein specifically following 48-hour treatments, similar to diclofenac (fig 3.2.1, 
3.3.2). The next step would be to look into the signalling pathways that induce COX-2 
and see how this varies between the different stimulus. This would provide potential 
drug targets to stimulate the induction of what we predict to be an anti-inflammatory 
COX-2 protein.  
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Figure 3.6.1 Diagram to conclude chapter 
Treatment of macrophage J774.2 cells with 10ng/ml IL-4 for 48 hours induced the 
expression of COX-2 that is catalytically active, as shown by PGE2 production. PGE2 
production was reduced by the addition of 100μM acetaminophen. 
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Chapter 4: Signalling pathway involved in the induction of 
COX-2 by IL-4 
 
4.1 PPARγ is required for the induction of COX-2 by IL-4 
PPARγ is a member of a group of receptors that serve to drive gene 
transcription by heterodimerising with retinoid-X receptor following ligand activation 
(Wick et al., 2002). This receptor has been linked with neuroprotection and the 
curtailing of inflammatory genes (Kapadia et al., 2008). TZDs, which are agonists to 
PPARγ, have been used in animal models of neurological disease and CVD (Kapadia 
et al., 2008) to reduce pro-inflammatory parameters. The fact that PPARγ is involved 
in anti-inflammatory pathways (Kapadia et al., 2008), suggest an involvement in a 
compensatory mechanism during inflammation (Wang et al., 2015). 
 
It would be important to note whether activation of PPARγ can induce COX-2 
expression by using the PPARγ agonist, rosiglitazone (see for review: (Chiarelli and 
Di Marzio, 2008)). In order to establish whether PPARγ is involved in IL-4 induced 
COX-2, the PPAR-γ antagonist, BADGE, must be used to assess whether this 
transcription factor is required in the induction pathway. Previously, Ayoub et al., 
(2009) showed the PPARγ antagonists, BADGE and GW9662, to block diclofenac 
induced COX-2 but not LPS induced COX-2. The same protocol was used to 
pharmacologically assess whether IL-4 induces COX-2 expression and activity via 
PPARγ. This experiment may bring us closer to understanding the IL-4-PPAR-γ axis 
and its involvement in the COX-2 induction pathway.  
 
 Cells were plated in T25 flasks for 24 hours. At the end of this, cells were treated 
with increasing concentrations of rosiglitazone (1, 10, 100μM). Rosiglitazone was 
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dissolved in DMSO; therefore, a vehicle control was used where cells were simply 
treated with 0.1% DMSO for 48 hours. At the end time point, a cell pellet was collected 
(see 2.1) and this was analysed for COX-2 and phosphorylated p38 protein expression 
(see 2.4). p38 MAPK expression was observed to assess whether activation of PPARγ 
by rosiglitazone phosphorylates p38. 
 
In a subset of experiments, cells were plated in T25 flasks for 24 hours.  
Cells were either treated with 100-200μM BADGE alone (negative control) or left 
unstimulated for 1 hour. This was followed by the addition of 500μM diclofenac or 
10ng/ml IL-4 (positive control) or diclofenac and IL-4 co-treated with 100, 150 and 
200µM BADGE. The concentrations of BADGE were obtained from Ayoub et al. 
(2009). At the end of the stimulations, cell lysis buffer was used to lyse the cells and 
quantify the proteins (see 2.3). In Western blot experiments, the target protein 
expression was observed (see 2.4).  
 
To investigate whether the addition of BADGE inhibited the activity of COX-2 
following the stimulations above, the supernatant was collected (see 2.1). COX-2 
activity was measured via ELISA (see 2.5). The working concentration of BADGE used 
in this experiment was 150μM BADGE, as this concentration was found to inhibit COX-
2 expression without causing excessive cell death.  
 
The agonist for PPARγ, rosiglitazone, was shown to induce COX-2 expression 
as early as 24 hours (fig 4.1.1), whereas the negative control and the vehicle control 
(DMSO) did not. Phophorylated p38 was expressed in cells treated with rosiglitazone. 
With increasing concentrations of rosiglitazone, the intensity of phosphorylated p38 
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increased (fig 4.1.1); showing a positive relationship. At 48 hours, the intensity of both 
COX-2 and phosphorylated p38 was greater than at 24 hours. β-actin expression was 
measured to ensure the same amount of protein was loaded per well.  
 
 
 
 
 
 
 
 
 
 
Figure 4.1.1 Rosiglitazone induced COX-2 expression whilst activating P38. 
Cells were treated with increasing concentrations of rosaglitazone for 24 and 48 hours. 
The cells pellet was lysed before loading onto 10% gels. Unstimulated cells were the 
negative control and DMSO of the greatest percentage was the vehicle control. COX-
2, phosphorylated p38 and β Actin expression was observed. The data shown were 
obtained from 3 independent experiments (n=3). 
 
 
Expression of COX-2 by diclofenac was inhibited with increasing 
concentrations of BADGE, starting as early as 100μM BADGE (fig 4.1.2a). This 
experiment was carried out at 48 hours, because diclofenac did not induce COX-2 
expression at 24 hours. Treatment of cells with BADGE did not induce COX-2 
expression in this cell line. The concentrations of BADGE used in this experiement 
was adapted from Ayoub et al. (2009) to both replicate and confirm the working 
concentration. Similar to diclofenac, IL-4 treated cells that were co-treated with 
BADGE, inhibited COX-2 (fig 4.1.2b).  
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a)                b)               
 
Figure 4.1.2 BADGE completely blocked expression of COX-2 induced by a) 
diclofenac and b) IL-4 at 48 hours. 
Cells were treated with diclofenac or IL-4 with increasing concentrations of BADGE for 
48 hours. Post-stimulation, cell pellets were lysed and quantified for protein 
concentration. COX-2 and β-Actin expression were observed on the membrane. 
Unstimulated cells and cells treated with BADGE alone were the negative controls. 
The positive controls were cells treated with either diclofenac or IL-4 alone. The data 
shown were obtained from 3 independent experiments (n=3). 
 
At 48 hours, both diclofenac and IL-4 induced COX-2 activity (48.94 ng/mg 
protein; p<0.01**, 57.79 ng/mg protein; p<0.01** respectively). In the presence of 
BADGE, the activity was significantly reduced in diclofenac and IL-4 treated cells 
(15.93 ng/mg protein; p<0.05$, 25.12 ng/mg protein; p<0.05$ respectively) (fig 4.1.3). 
At 48 hours, LPS did not induce COX-2 activity (22.85 ng/mg protein) and the addition 
of BADGE did not alter this (19.23 ng/mg protein) (fig 4.1.3). At 48 hours, the negative 
control and the vehicle control did not induce COX-2 activity (8.08, 21.48 ng/mg protein 
respectively). BADGE was shown to have no effect on COX-2 activity on its own at 24 
hours (2.88 ng/mg protein) compared to the unstimulated cells (5.92 ng/mg protein). 
The addition of BADGE (82.89 ng/mg protein) had no effect to LPS treated cells (87.04 
ng/mg protein) (fig 4.1.3). Diclofenac and IL-4 did not induce COX-2 activity (7.23, 3.99 
ng/mg protein respectively)  and this was not effected by the addition of BADGE (4, 
2.87 ng/mg protein respectively).  
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Figure 4.1.3 At 48 hours, BADGE significantly reduced diclofenac and IL-4 
induced COX-2 activity but had no effect on LPS induced COX-2 activity. 
Cells were treated with LPS, diclofenac or IL-4 for 24 and 48 hours in the absence and 
presence of BADGE. At the end of the stimulations, the supernatant was assayed for 
PGE2. Absorbances were divided by the protein concentration to standardise all the 
readings. The negative control were unstimulated cells or cells treated with BADGE 
alone. The positive control were cells treated with either 1μg/ml LPS, 500μM 
diclofenac or 10ng/ml IL-4 in the absence of BADGE. All other bars represent the effect 
of BADGE on PGE2 production by LPS, diclofenac and IL-4. 
The data shown were obtained from 3 independent experiments (n=3). One Way 
ANOVA was used to compare the PGE2 levels produced between the negative and 
positive controls, as represented by *, and between the positive control and samples 
where BADGE was introduced as represented by $.  Data are expressed as mean+/- 
SEM (error bars); *p<0.05, **p<0.01, ***p<0.001, $p<0.05, $$p<0.01, $$$p<0.001.  
 
 
4.2 Induction of PPARγ by LPS and IL-4 
To understand whether PPARγ is differentially activated by LPS and IL-4, the 
activity of this transcription factor was investigated. Cells were grown in 6 wells plates 
for 24 hours, before being treated with 1μg/ml LPS or 10ng/ml IL-4. These stimulations 
were terminated at the following time points: 30 minutes, 2, 6, 24, 36 and 48 hours. 
Nuclear extraction was carried out on the cell pellet before being analysed for PPARγ 
activity via a PPARγ transcription factor assay kit (Abcam) (see 2.7).  
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At all the time points investigated, there was basal PPARγ activity (3.79, 5.78, 
2.07, 1.56, 2.94, 1.2 ng/mg protein) (fig 4.2.1). Specifically at 24 and 36 hours, 1μg/ml 
LPS reduced PPARγ activity compared to the negative control (1.02 ng/mg protein; 
p<0.001***, 1.34 ng/mg protein; p<0.01** ng/mg protein respectively) (fig 4.2.1). At all 
other time points following LPS treatment, there was no change in PPARγ activity 
(3.65, 4.26, 1.51, 1.68 ng/mg protein). PPARγ activity decreased by 6 hours (2.07 
ng/mg protein); with a sudden peak at 36 hours (2.94 ng/mg protein) in the 
unstimulated cells (fig 4.2.1). 
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Figure 4.2.1: LPS reduced PPARγ activity at 24 and 36 hours with no effect at 
other time points.  
Cells were treated with LPS over 48 hours and the stimulations were terminated at 
different time points. Nuclear extractions were used to measure PPARγ activity. The 
negative control was the unstimulated cells. Each bar represents the effect of LPS on 
PPARγ activity.  
The data shown were obtained from 3 independent experiments (n=3). One Way 
ANOVA with the Dunnett’s post hoc test was carried out between the negative control 
and the samples were LPS was added to the cells, as represented by *. Data are 
expressed as mean+/- SEM (error bars);*p<0.05, **p<0.01, ***p<0.001. 
 
 77 
IL-4, as early as 30 minutes, significantly increased PPARγ activity (8.22 ng/mg 
protein; p<0.01**) compared to the negative control (3.79 ng/mg protein) (fig 4.2.2a). 
Following this, IL-4 treated cells did not increase PPARγ activity between 2 and 36 
hours (5.78, 2.06, 2.13, 2.63 ng/mg protein) (fig 4.4.2). IL-4 significantly increased 
PPARγ activity at 48 hours (20.62 ng/mg protein; p<0.01**) compared to the control 
(1.2 ng/mg protein).  The addition of SB203580 to IL-4 treated cells showed a 
significant reduction in PPARγ activity at all the time points investigated (0.06 ng/mg 
protein; p<0.001$$$, 0.06 ng/mg protein; p<0.001$$$, 0.06 ng/mg protein; p<0.001$$$, 
0.06 ng/mg protein; p<0.001$$$, 0.07 ng/mg protein; p<0.001$$$, 0.05 ng/mg protein; 
p<0.001$$$) (fig 4.2.2b).  
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b) 
 
 
 
 
 
 
 
Figure 4.2.2: PPARγ activity was induced by a) IL-4 at 30 minutes and 48 hours. 
The addition of b) SB203580 completely blocked PPARγ activity.  
Cells were treated with IL-4 in the presence and absence of SB203580 over various 
time points up to 48 hours. Nuclear extractions were used to measure PPARγ activity 
over the time course. The unstimulated cells was the negative control. Each bar 
represents the effect of IL-4 on PPARγ activity and the effect of SB203580 on the 
effect of IL-4 on PPARγ activity. 
The data shown were obtained from 3 independent experiments (n=3). One Way 
ANOVA was carried out between the negative control and the samples were IL-4 was 
added to the cells, as represented by *. The same test was also carried out between 
positive control and the samples were SB203580 was introduced, as represented by 
$. Data are expressed as mean+/- SEM (error bars); *p<0.05, **p<0.01, ***p<0.001, 
$p<0.05, $$p<0.01, $$$p<0.001. 
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4.3 P38 MAPK involvement in LPS, diclofenac and IL-4 inductive COX-
2 
P38 has been shown to stabilise COX-2 mRNA (Dean et al., 1999) and the 
addition of 0.1μM SB203580 was capable of inhibiting COX-2 mRNA in pro-
inflammatory pathways induced by LPS. SB203580 is a compound that inhibits p38 
by inhibiting activation of MAPKAPK. Despite previously being associated with pro-
inflammatory signalling pathways (see for reviews: (Cuenda and Rousseau, 2007, 
Coulthard et al., 2009, Cuadrado and Nebreda, 2010)), studies have opened doors for 
an anti-inflammatory role for p38 (Kim et al., 2008, Guma et al., 2012, Jimenez-Garcia 
et al., 2015). Jimenez-Gracia et al., (2015) showed p38 to play a crucial part in 
macrophage polarisation. This gave impetus to investigate the role of p38 in LPS, 
diclofenac and IL-4 induced COX-2. We have shown p38 to be activated following 
rosiglitazone treatment of cells in PPARγ pathways leading to the induction of COX-2 
(fig 4.1.1). Furthermore, we have shown p38 to mediate PPARγ activity as, blocking 
p38 with 10μM SB203580 completely abolished PPARγ activity (fig 4.2.2). To this end, 
whether inhibiting p38 using SB203580 has an effect on COX-2 expression and 
activity induced by various stimulants needs to be investigated. 
 
Cells were plated to in T25 flasks, 24 hours before adding DMEM (negative 
control) or 1, 10 and 100M SB203580 alone (negative controls). The positive controls 
were stimulations with 1µg/ml LPS, 500µM diclofenac or 10ng/ml IL-4. Following a 1-
hour pre-treatment with DMEM, or 1, 10 and 100M SB203580, DMEM or 1, 10 and 
100M SB203580 was added to the cells in the negative controls. In the experimental 
samples, 1, 10 and 100M SB203580 was added with 1µg/ml LPS, 500µM diclofenac 
or 10ng/ml IL-4 for 24 and 48 hours. Post stimulations, cells were lysed with cell lysis 
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buffer and assayed for protein concentration (see 2.3). For Western blot analysis (see 
2.4), 20g protein was loaded on the gel and run at 100V for 1 hour. Anti-COX-2 and 
anti-β-Actin antibodies were added to PVDF membranes overnight. Secondary 
antibody was added for 1 hour before adding ECL to develop the membrane. 
 
COX-2 expression induced by LPS at 24 hours was slightly reduced in the 
presence of 1μM and 10μM SB203580 (fig 4.3.1a). One hundred micromolar 
SB203580 reduced and inhibited LPS induced COX-2 expression at 24 and 48 hours 
respectively (fig 4.3.1a,b). Diclofenac induced COX-2 expression was reduced in the 
presence of the p38 inhibitor with near to complete inhibition with 100μM SB203580 
(fig 4.3.1c). This is similar to IL-4 where, SB203580 caused a reduction in the intensity 
of COX-2 expression with concentrations as low as 10μM at 48 hours (fig 4.3.1d). 
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a       b)  
 
c)       d)  
 
Figure 4.3.1 p38 inhibitor did not block LPS induced COX-2 expression at a) 24 
hours. High concentrations of SB203580 inhibited COX-2 expression induced by 
b) LPS and c) diclofenac at 48 hours. Low concentrations of SB203580 inhibited 
d) IL-4 induced COX-2 experssion at 48 hours. 
Cells were treated with 1μg/ml LPS, 500μM diclofenac and 10ng/ml IL-4 with and 
without increasing concentrations of SB203580 for 24 hours for LPS treatment and 48 
hours for all treatments. At the end of the stimulations, cell lysates were analysed for 
both COX-2 and β-Actin. Unstimulated cells or cells treated with the p38 inhibitor alone 
were the negative controls. The positive controls were cells treated with LPS for 24 
hours and LPS, diclofenac and IL-4 for 48 hours. All other bands represent the effect 
of the p38 inhibition on the COX-2 induced by the stimulants. The data shown were 
obtained from 3 independent experiments (n=3). 
 
 
For ELISA experiments looking at PGE2 levels, the optimal concentration of 
SB203580 was used (10μM). This was because 10μM SB203580 inhibited IL-4 
induced COX-2 to a different intensity compared to the inhibition on LPS induced COX-
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2 expression (fig 4.3.1). Furthermore, 10μM SB203580 was used by other groups to 
inhibit p38 MAPK (Huang et al., 2013, Jimenez-Garcia et al., 2015). This concentration 
was reported to inhibit IL-1β induced COX-2. Cells were pre-treated with 10μM 
SB203580 for 1 hour before introducing the stimulant along with SB203580. At the 
end time points, the wells were washed with serum free media. Thirty micromolar 
arachidonic acid was added for 30 minutes before collecting the supernatant which 
was measured for COX-2 activity via ELISA techniques (see 2.5). 
 
After examining COX-2 expression, the activity was measured with the working 
concentration of SB203580. The negative control, where cells were left unstimulated 
or treated with SB203580 showed no COX activity (5.92, 4.15 ng/mg protein 
respectively). At 24 hours, LPS induced COX-2 activity (87.04 ng/mg protein; 
p<0.001***). With the addition of the p38 inhibitor, the activity was significantly reduced 
(2.6 ng/mg protein; p<0.001$$$). At 24 hours, 500μM diclofenac did not induce COX-2 
activity (15.95 ng/mg protein) and the addition of SB203580 had no effect on the 
activity of COX-2 (23.02 ng/mg protein) (fig 4.3.2). IL-4 did not induce COX-2 activity 
at 24 hours (3.99 ng/mg protein) and SB203580 did not affect this reading (9.52 ng/mg 
protein).  
 
At 48 hours, the negative control and cells treated with SB203580 alone did not 
induce COX-2 activity (8.08, 5.97ng/mg protein respectively). LPS did not induce 
COX-2 activity at 48 hours (22.85 ng/mg protein) however when the p38 inhibitor was 
added to the cells, the activity was significantly increased (35.11 ng/mg protein; 
p<0.01$$) (fig 4.3.2). This was in contrast to the diclofenac treated cells where 
diclofenac significantly induced COX-2 activity (48.94 ng/mg protein; p<0.05*) but the 
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addition of SB203580 significantly decreased this (21.36 ng/mg protein; p<0.05$). The 
same was true for 10ng/ml IL-4 at 48 hours, where IL-4 significantly induced COX-2 
activity (57.79 ng/mg protein; p<0.05*) but the addition of SB203580 significantly 
reduced this (23.77 ng/mg protein; p<0.05$) (fig 4.3.2). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.2: LPS required p38 to induce COX-2 activity at 24 hours. SB203580 
increased LPS induced COX-2 activity but reduced diclofenac and IL-4 induced 
COX-2 activity at 48 hours. 
Cells were treated with 1μg/ml LPS, 500μM diclofenac and 10ng/ml IL-4 for 24 or 48 
hours in the absence and presence of 10μM SB203580. At the end of the stimulations, 
the supernatant was collected to measure COX-2 activity. The negative control were 
cells that were left unstimulated or treated with only SB203580. The positive control 
were cells treated with either LPS, diclofenac or IL-4. All other bars represent the effect 
of SB203580 on PGE2 produced by LPS, diclofenac and IL-4.  
The data shown were obtained from 3 independent experiments (n=3). One Way 
ANOVA with the Dunnett’s post hoc test was used to compare the negative and 
positive controls, as represented by * and between the positive controls and samples 
where SB203580 was added, as represented by $. Data are expressed as mean+/- 
SEM (error bars); *p<0.05, **p<0.01, ***p<0.001, $p<0.05, $$p<0.01, $$$p<0.001. 
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4.4 Role of cAMP in the polarisation of macrophages into an M2 
phenotype 
 
cAMP is a second messenger, modulated by AC in a cascade of events within 
a complex signalling pathway (see for review: (Serezani et al., 2008, Yan et al., 2016)). 
cAMP has been associated with anti-inflammatory macrophages and the suppression 
of innate immune functions. It has been suggested that the immuno-stimulatory effects 
of mediators of immunity depend on intracellular cAMP thus, increased cAMP 
increases predisposition to infection (see for review: (Serezani et al., 2008)). It is 
widely accepted that M2 macrophages are involved in the pre-disposition to disease 
as suppression of pro-inflammatory responses restrict the host’s ability to fight 
infection (see for review: (Cassetta et al., 2011)). cAMP and the downstream kinase, 
PKA have been targeted in the treatment of several diseases such as heart disease, 
due to their significance in such conditions (see for review: (Serezani et al., 2008, Yan 
et al., 2016)).  
 
4.4.1 Requirement of cAMP in IL-4 induced COX-2 
To understand the relevance of cAMP in the induction of COX-2 by IL-4, the 
cAMP antagonist, rp-cAMP was used (Bystrom et al., 2008). Downstream activation 
of COX-2 produce PGE2 which binds the EP4 receptor, thus augmenting the 
production of cAMP (Sokolowska et al., 2015). The question lies as to whether a 
positive feedback mechanism exists whereby the induction of COX-2 produces cAMP 
and whether this cAMP further induces COX-2.  
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Cells were plated in T25 flasks for 24 hours. Cells were treated with increasing 
concentrations of the cAMP antagonist, rp-cAMP, for 1 hour before stimulating with 
1μg/ml LPS or 10ng/ml IL-4. Cells were treated for 48 hours and at the end time point, 
cell pellets were obtained (see 2.1). Treatment for 48 hours was used because IL-4 
did not induce COX-2 at 24 hours. Cells were lysed and assayed for protein 
concentration (see 2.3) before looking for COX-2 expression (see 2.10).  
 
Treatment of cells with 1μg/ml LPS for 24 hours showed COX-2 expression. 
With the addition of rp-cAMP, COX-2 bands were only slightly decreased but 
expression was obvious (fig 4.4.1.1a). rp-cAMP on its own, did not induce COX-2 
expression. IL-4 induced the expression of COX-2 at 48 hours (fig 4.4.1.1b). In the 
presence of 5μM rp-cAMP, this expression was observed. With increasing 
concentrations of rp-cAMP (10-50μM), COX-2 expression induced by IL-4 was 
abolished completely (fig 4.4.1.1b). 
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a)           b) 
 
 
Figure 4.4.1.1: cAMP is not required for a) LPS induced COX-2 at 24 hours, but 
is critical for b) IL-4 induced COX-2 at 48 hours. 
Cell were pre-treated with increasing concentrations of rp-cAMP for 1 hour before the 
addition of LPS for 24 hours or IL-4 for 48 hours. Cell pellets were collected and lysed 
before carrying out Western blot analysis. The expression of 72kDa COX-2 and 42kDa 
β-Actin was observed using the anti-COX-2 and anti-β-Actin antibodies. The negative 
control was the unstimulated cells and cells to which only rp-cAMP was added. The 
positive controls had no rp-cAMP added to them. The data shown were obtained from 
3 independent experiments (n=3). 
 
 4.4.2 Role of p38 and PPARγ in LPS and IL-4 induced cAMP  
In order to understand what may modulate cAMP in vitro, experiments were 
carried out to antagonise PPARγ with BADGE and inhibit p38 with SB203580. Interest 
in both PPARγ and p38 was shed in work previously relating to a potentially anti-
inflammatory COX-2 protein (Ayoub et al., 2009, Na et al., 2013, Jimenez-Garcia et 
al., 2015) as antagonism of PPARγ (fig 4.1.2b), inhibition of p38 (fig 4.3.1) and 
antagonism of cAMP (fig 4.4.1.1b) blocked COX-2. 
 
In a subset of experiments, the levels of cAMP produced by cells following 
stimulations was investigated. Cells were plated in a 96 well plate at 50x103 density 
24 hours prior to stimulations. A preliminary experiment showed that this number of 
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cells was ideal to obtain a detectable cAMP concentration. Cells were treated with 
either 150μM of the PPARγ antagonist, BADGE or 10μM of the p38 inhibitor, 
SB203580 for 1 hour. This was followed by either 24 or 48-hour stimulations with 
1µg/ml LPS, 500µM diclofenac or 10ng/ml IL-4. cAMP production was measured using 
a cAMP assay kit. (Cell Signalling). The wells were washed and lysed using cell lysis 
buffer provided in the kit. The samples and standards were added to the wells along 
with HRP-linked cAMP solution. After 3 hours, the cells were washed and TMB 
substrate was added before the stop solution was added. Absorbance was measured 
at 450nm (see 2.6). 
 
At 24 hours and 48 hours, 1μg/ml LPS did not induce cAMP production (0.33, 
0.59 ng/mg protein respectively). The cAMP levels reported were basal as they were 
somewhat similar to the levels seen in the negative control at 24 and 48 hours (0.39, 
0.33 ng/mg protein respectively). The addition of SB203580 to the LPS treated cells, 
caused a significant increase in cAMP production at both 24 and 48 hours (0.76 ng/mg 
protein; p<0.01$$, 0.94 ng/mg protein; p<0.05$ respectively) (fig 4.4.2.1) compared to 
the LPS treated cells. At 24 hours, the addition of BADGE to the LPS treated cells, 
showed an increase in cAMP production (1.13 ng/mg protein; p<0.001$$$) compared 
to cells treated with LPS alone (0.33 ng/mg protein) (fig 4.2.1a). This effect was not 
seen at 48 hours, where BADGE had no effect on the LPS treated cells (0.65 ng/mg 
protein) (fig 4.4.2.1 b).  
 
Diclofenac, at 24 and 48 hours, caused a significant increase in cAMP 
production (0.61 ng/mg protein; p<0.05*, 1.02 ng/mg protein; p<0.01** ng/mg protein 
respectively). At 24 hours, the addition of SB203580 had no effect on diclofenac 
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induced changes to cAMP production (0.67 ng/mg protein) (fig 4.4.2.1a). At 48 hours, 
the surge in cAMP production by diclofenac was significantly reduced by SB203580 
(0.29 ng/mg protein; p<0.05$) to levels similar to the negative control (0.33 ng/mg 
protein) (fig 4.4.2.1b). BADGE did not significantly reduce or increase levels of cAMP 
produced by diclofenac at either 24 or 48 hours (0.8, 0.61 ng/mg protein respectively) 
(fig 4.4.2.1). A non-significant reduction was observed at 48 hours in the presence of 
BADGE (0.61 ng/mg protein). The levels of cAMP, in the presence of BADGE, did not 
reach levels seen in the unstimulated cells at 24 and 48 hours (0.39, 0.33 ng/mg 
protein respectively) (fig 4.4.2.1). 
 
IL-4 treated cells produced cAMP at 48 hours (0.85 ng/mg protein; p<0.01**), 
but not 24 hours (0.48 ng/mg protein). cAMP levels, following IL-4 treatment at 24 
hours, were similar to the negative control (0.39 ng/mg protein). The presence of the 
p38 inhibitor with IL-4 caused a significant increase in cAMP production at 24 hours 
(1 ng/mg protein; p<0.01$$). At 48 hours, SB203580 caused a significant decrease in 
IL-4 induced cAMP production (0.23 ng/mg protein; p<0.001$$$) to levels, on average, 
lower than the negative control (0.33 ng/mg protein) (fig 4.4.2.1b). The addition of 
BADGE, similar to SB203580, caused a significant increase in cAMP production at 24 
hours (0.99 ng/mg protein; p<0.01$$) (fig 4.4.2.1a). At 48 hours, the level of cAMP was 
significantly reduced in the presence of BADGE and IL-4 (0.59 ng/mg protein; 
p<0.01$$); however this level was, on average, greater than the amount of cAMP 
observed in the negtive control (0.33 ng/mg protein) (fig 4.4.2.1b). 
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a)                                             b) 
 
Figure 4.4.2.1: The effect of SB203580 and BADGE on cAMP levels following 
treatment of cells with 1μg/ml LPS, 500μM diclofenac and 10ng/ml IL-4 for a) 24 
hours and b) 48 hours. 
Cells were treated with 1μg/ml LPS, 500μM diclofenac and 10ng/ml IL-4 in the 
presence and absence of 10μM SB203580 or 150μM BADGE. After 24 and 48-hour 
stimulations, the cell lysate was analysed for cAMP production. The negative control 
was the untreated cells while the positive controls were the cells treated with either 
LPS, diclofenac or IL-4. All bars reflect the amount of cAMP present following the 
incubations. 
The data shown were obtained from 3 independent experiments (n=3). T Test was 
carried out between the negative control and the positive control; as represented by *. 
T Test was also carried out between the positive control and the samples where either 
SB203580 or BADGE was used to pre-treat the cells. This is represented by $. Data 
are expressed as mean+/- SEM (error bars); *p<0.05, **p<0.01, ***p<0.001, $p<0.05, 
$$p<0.01, $$$p<0.001. 
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4.5 Discussion to results chapter 4 
Signalling pathway involved in the induction of COX-2 by IL-4 
 
4.5.1 Activation and requirement of PPARγ in the IL-4 induced COX-2 
pathway 
As we have shown IL-4 to induce a catalytically active COX-2 protein (fig 7.4.1), 
we sought to investigate the signalling pathway involved in this induction. PPARγ was 
given key importance previously (Ayoub et al., 2009) as a relevant transcription factor 
in the induction of COX-2 by diclofenac. Furthermore, it has been suggested that 
PPAR is anti-inflammatory and 15dPGJ2, the natural ligand for this receptor, bares 
anti-inflammatory properties (Paintlia et al., 2006). This glitazone receptor was found 
to be activated in the induction of COX-2 when cells were treated with rosiglitazone, a 
known ligand for PPARγ (fig 4.1.1). Increasing concentrations of rosiglitazone not only 
increased COX-2 induction at both 24 and 48 hours, but also activated p38 (fig 4.1.1). 
 
To evaluate whether IL-4 increase PPAR activity in this cell line, initially cells 
were treated with 10ng/ml IL-4 for 24 and 48 hours. At the end of the stimulation, the 
samples were collected (see 2.1) and prepared for immunoblotting. The samples were 
run and anti-FABP4 antibody was used to measure FABP4; a PPAR target gene used 
as a measure of PPAR activity (Szanto et al., 2010). This protein is <20kDa and so a 
15% gel was used. Despite loading 20g protein, it remained difficult to probe this 
protein. As an alternative approach, using a semi-quantitative ELISA technique (see 
2.7), we showed PPARγ activation was completely absent in the presence of 1µg/ml 
LPS throughout the first 48 hours of stimulation (fig 4.2.1). In fact, LPS was found to 
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reduce PPARγ expression both in vivo and in vitro (Simonin et al., 2002, Miksa et al., 
2007, Necela et al., 2008, Zhou et al., 2008). 
 
We observed 10ng/ml IL-4 to activate PPARγ significantly at both 30 minutes 
and 48 hours (fig 4.2.2a). This directly links IL-4 to PPARγ which is something that has 
previously been visited (Huang et al., 1999, Paintlia et al., 2006, Szanto et al., 2010). 
IL-4 was shown to augment PPARγ expression in oligodendrocyte progenitor cells 
(Paintlia et al., 2006) and activity in macrophages and dendritic cells, as reflected by 
target gene expression (Szanto et al., 2010). Addition of the PPARγ antagonist, 
GW9662, to glial cells, in the presence of IL-4 and a pro-inflammatory cytokine mix, 
showed IL-4 inductive effects to be lost, as shown by increased nitrite and iNOS 
expression (Paintlia et al., 2006). Furthermore, this group showed GW9662 to reverse 
the IL-4 effect on the survival of differentiating oligodendrocyte progenitors. Thus, 
there is evidence to support the notion that IL-4 activates PPARγ and potentially exert 
its effects through this. 
 
LPS treated cells have shown NFκB to be activated and required in the 
induction of COX-2 (Kim et al., 2007, Ayoub et al., 2009). Whilst IL-4 activates PPARγ, 
it was shown to inhibit NFκB as shown by electrophoretic mobility shift assay (EMSA) 
data where, IL-4 reduced band intensity of p65 and p50, both NFκB subunits (see 1.7). 
Upon addition of GW9662, this effect was reversed, thus suggesting PPAR activation 
may shut down NFκB activation (Paintlia et al., 2006). This is largely ironic as both 
transcription factors are required for COX-2 induction. LPS did not activate PPARγ (fig 
4.2.1) and antagonising this did not impact LPS induced COX-2 expression in 
macrophage J774.2 cells (Ayoub et al., 2009) or activity (fig 4.1.3). Due to the work on 
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TLR/PPARβ/δ signalling pathways, interest developed in TLR/PPARα/γ pathways in 
astrocytes. TLR4 and TLR1/2 agonists, LPS and peptidoglycan respectively, induce 
PGE2 and TNFα in astrocytes. This was accompanied with reduced PPARγ mRNA. 
This group found that blocking NFκB with Bay 11-7085 reversed this effect, suggesting 
TLR to exert its effects via NFκB (Chistyakov et al., 2015). Blocking TLR4 with 5μM 
CL1-095 removed LPS induced TNFα and LPS induced reduction in PPARγ mRNA; 
suggesting the effect of LPS to be dependent on TLR4. The fact that IL-4 and LPS 
have different receptor activations downstream of binding its ligand, suggests two 
distinct pathways. Furthermore, there is strong evidence for NFκB and PPARγ to be 
on opposite ends of the spectre.  
 
It is clear that IL-4 activates PPARγ but in order to understand whether PPARγ 
is actually required in the induction of COX-2, this receptor must be antagonised and 
protein expression must be determined. Similar to diclofenac induced COX-2, 
antagonising PPARγ inhibited induction of COX-2 by IL-4 (fig 4.1.2). Furthermore, 
whereas PPARγ inhibition by BADGE had no impact on LPS induced COX-2 activity, 
introduction of BADGE at 48 hours with both diclofenac and IL-4 inhibited COX-2 
activity (fig 4.1.3). Thus, PPARγ is both activated directly by IL-4 and is essential in 
the expression and catalytical activity of COX-2. Interestingly, IL-4 did not activate 
PPARγ activity at 24 hours, (fig 4.2.2a) and COX-2 was not induced at this time point. 
In parallel, IL-4 activated PPARγ at 48 hours (fig 4.2.2a) and COX-2 was expressed 
at this time (fig 3.2.1). This re-confirms the requirement for PPARγ in the IL-4 pathway. 
 
The conundrum here is, when PPARγ activation can lead to COX-2 induction 
at 24 hours (fig 4.1.1) and PPARγ is activated by IL-4 as early as 30 minutes (fig 
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4.2.2a), why does IL-4 induce COX-2 as late as 48 hours only. We assume there is a 
translational delay for the COX-2 protein which controls the time of expression.  
IL-4 
 
PPARγ 
 
COX-2 
 
4.5.2 Involvement of P38 MAPK in COX-2 induction 
To this end, we developed interest in the kinase, p38. Initially, it was noted 
whether p38 was required for the induction of COX-2 as we predict p38 activation 
upstream to COX-2 translation. Thus, cells were treated with the p38/ inhibitor 
SB203580, in the presence of the stimulants and assessed for COX-2 expression. 
This drug was previously found to inhibit COX-2 mRNA at a transcriptional level (Dean 
et al., 1999). p38 has been reflected as a stabiliser of COX-2. Inhibition of p38 with 
low concentrations of SB203580 showed sustained LPS induced COX-2 expression 
at 48 hours (fig 4.3.1a, b). Only high concentrations of SB203580 (100μM) blocked 
LPS induced COX-2. Diclofenac induced COX-2 expression was merely reduced by 
the addition of the pyridinyl imidazole inhibitor, SB203580, (fig 4.3.1c), however in IL-
4 treated cells, COX-2 expression was lost (fig 4.3.1d). This suggests p38 may not 
always be required for the induction of COX-2; however, it is crucial in the IL-4 
pathway. 
 
The optimal working concentration from this experiment was 10M SB203580 
because it specifically inhibited IL-4 induced COX-2 but not LPS. This concentration 
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was also used by Jimenez-Garcia et al. (2015) to look at the effect of SB203580 on 
M2 markers. We were able to show that the COX-2 activity induced by LPS was 
significantly reduced in the presence of 10μM SB203580 (fig 4.3.2). This was expected 
based on the immense number of publications that looked at LPS induced p38 
regulation of mRNA. We were able to show COX-2 activity being regulated by p38, 
upon stimulation with IL-4 and diclofenac, as blocking p38 significantly reduced COX-
2 activity (fig 4.3.2).  This differed to COX-2 activity measured upon treatment of cells 
with LPS and SB203580 together, where, p38 blockage led to increased COX-2 
activity at 48 hours. This correlates well with the protein expression data (fig 4.3.1). 
 
We were able to show p38 as a key mediator of PPARγ activity induced by IL-
4 (fig 4.2.2b). Whereas IL-4 could induce activity of PPARγ as early as 30 minutes (fig 
4.2.2a), all PPARγ activity was lost when p38 was inhibited by introducing SB203580 
(fig 4.4.2b). This suggests p38 activation upstream to PPARγ activation, but 
downstream to IL-4 treatment of cells; something which was previously observed 
(Schild et al., 2006). Interestingly, Yano et al. (2007) reported inhibition of PPAR 
induction following treatment with p38 inhibitor. This suggests an intricate relationship 
between PPAR and this MAPK. This group found PPARγ not to impact p38 however 
p38 inhibition attenuated PPARγ protein stability in primary trophoblasts. In astrocytes, 
SB203580 was shown to modulate the rate of PPAR degradation and reduce PPARγ 
activity (Chistyakov et al., 2015). This supports our finding of p38 regulation of PPARγ. 
 
P38 inhibitors are currently popular in the treatment of chronic inflammation due 
to the acknowledged pro-inflammatory properties of p38 (see for review: (Kumar et al., 
2003)). However, p38 is increasingly being recognised to play a dual role in 
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inflammation (Jimenez-garcia et al., 2015). IL-4 leading to the activation of the anti-
inflammatory receptor, PPARγ (fig 4.2.2a) suggests an anti-inflammatory pathway 
downstream of ligand binding. One of the end products of this being COX-2 activation, 
suggests a potential anti-inflammatory role for COX-2. As p38 is required for the 
proposed anti-inflammatory COX-2, this suggests that p38 inhibitors may be harmful 
depending on the time of administration. Findings by Jimenez-Garcia et al. (2015) 
show pharmacological inhibition and silencing of p38 to block expression of the M2 
markers: Arg-1, Ym-1 and Fizz1. Furthermore, this group showed inhibition of 
phospho-STAT6 expression in the presence of p38 inhibitors. Guma et al. (2012) 
showed deletion of p38α to increase subacute inflammatory arthritis with increased 
inflammatory cell infiltrate. Furthermore, inhibiting p38α/β reduced IL-10 expression in 
both BMDM and RA synovium. Thus, these groups found p38 deficiency to increase 
the severity of inflammation (Guma et al., 2012) and give rise to a pro-inflammatory 
environment and pro-inflammatory macrophages. Ananieva et al. (2008) like Kim et 
al. (2008) showed MSK, which is activated downstream to p38, as key in p38α induced 
anti-inflammatory pathways.  
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4.5.3 Role of cAMP in the induction of COX-2 by IL-4 
cAMP is an essential second messenger endowed with functions in modulating 
inflammatory processes; essentially through PKA activation. cAMP agonists have 
been found to resolve neutrophilic inflammation (Lima et al., 2017). Ligands which lead 
to AC activation and PDE mediated degradation control the balance of intracellular 
cAMP. PDE4 is believed to be the predominant isoenzyme in inflammatory cells and 
plays a crucial role in inflammation (Page and Spina, 2011).  
 
To study the significance of cAMP in COX-2 induction, whether its activation is 
triggered during various stimulations and whether cAMP is relevant for the induction 
of COX-2 protein expression was investigated. Previous research has given evidence 
for the importance of cAMP response element in the expression of COX-2 (see for 
review: (Klein et al., 2007)). It has previously been documented that activation of cAMP 
results in increased COX-2 mRNA and protein expression however the amount varies 
for each cell line (see for review: (Klein et al., 2007)). In human myometrial cells, cAMP 
agonists were shown to increase COX-2 mRNA and protein and PG production (Chen 
et al., 2012). PGE2 drives M2 polarisation as measured by expression of MR and IL-
10 (Montero et al., 2016).  
 
As we hypothesise the phenotype of the macrophage to dictate the temporal 
expression of COX-2, we looked into the relevance of cAMP in macrophages treated 
with both a pro-inflammatory and anti-inflammatory stimulus. The significance of cAMP 
in macrophage polarisation was previously visited by (Bystrom et al., 2008). This group 
found that M1 macrophage production of TNFα was disrupted and IL-10 production 
was elevated by db-cAMP, the cAMP analog. This suggests a reversion from an M1 
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macrophage into an M2 macrophage (Bystrom et al., 2008). cAMP agonists were 
found to increase the expression of AnxA1, an endogenous element that mediates the 
pro-resolving effects of cAMP (Lima et al., 2017). Neutralising this with anti-AnxA1 
serum stopped resolution and the effects of db-cAMP were reversed. This suggests 
the effect of cAMP to occur via PKA and AnxA1; whose N-terminus is associated with 
its anti-inflammatory properties (Lima et al., 2017).  
  
It appears that cAMP plays a role in the IL-4, but not the LPS, induced COX-2 
pathway. Blocking cAMP with rp-cAMP, the cAMP antagonist, blocked expression of 
IL-4 induced COX-2 completely at high concentrations (fig 4.4.1.1b); with no such 
effect on LPS induced COX-2 (fig 4.4.1.1a). This immediately reflects a role of cAMP 
in the pathway by which IL-4 induces COX-2. The fact that COX-2 has differential 
requirements for the induction depending on the stimulant implies the existent of two 
different induction pathways.  
 
PGE2 has been identified as a ligand that activates AC to elevate cAMP levels. 
Thus, there appears to be a positive feedback mechanism, where cAMP induces COX-
2 and the PG product drives cAMP release. The effect of PGE2 is a complicated virtue 
as it has both immuno-stimulatory and immuno-suppressive properties (see for review: 
(Willoughby et al., 2000)). It is clear that cAMP production occurs upstream to COX-2 
induction. Previous work has shown the COX-2 product, PGE2, to stimulate cAMP 
production (Sokolowska et al., 2015) (see 1.8.2). A positive feedback mechanism may 
exist whereby cAMP stimulates COX-2 induction and this in turn maintains high levels 
of cAMP in the presence of the COX-2 product, PGE2. The natural next step would be 
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to see whether either LPS, diclofenac or IL-4 were capable of inducing cAMP 
production and the role of PPARγ and p38 on this.  
 
Although cAMP was not significantly elevated in the presence of 1μg/ml LPS at 
both 24 and 48 hours, introducing the p38 inhibitor SB203580, significantly increased 
this at both time points (fig 4.4.2.1). Previously, p38 was shown to be activated as 
early as 10 minutes followed by activation of PKA and COX-2 induction (Chen et al., 
1999). This supports our observations of p38 activation being upstream to cAMP, thus 
a potential regulatory function on cAMP regulation. BADGE had a similar effect on 
cAMP production following treatment of cells with LPS at 24 hours (fig 4.4.2.1b). 
Although, cAMP is commonly released in the early stages of any signalling pathway, 
a continuous positive feedback loop may keep cAMP production constant. These 
findings lead to the assumption that p38 and PPARγ delay cAMP production. From 
this, it can also be assumed that both p38 and PPARγ have some form of regulatory 
effect on AC, as this is what produces cAMP. Interestingly, diclofenac treatment on 
macrophages produce cAMP at both 24 and 48 hours. Neither p38 (fig 4.4.2.1c) nor 
PPARγ (fig 4.4.2.1d) had any effect on this, except at 48 hours, where blocking p38 
significantly reduced cAMP production (fig 4.4.2.1c). The fact that LPS did not produce 
cAMP but diclofenac did, leads us to believe the LPS treated macrophage may be pro-
inflammatory and the diclofenac treated macrophage may be anti-inflammatory. This 
agrees with the cytokine profile post-diclofenac treatment in macrophages (Ayoub et 
al., 2009).  
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Collating data from these two experiments, we can conclude that cAMP may 
not be relevant in the LPS induced pathway leading to COX-2 expression. 
Interestingly, db-cAMP has previously been shown to possess opposing functions to 
LPS. db-Camp, being a cAMP agonist, was shown to increase cAMP after 1 hour. In 
a LPS induced self-resolving model of inflammation, there is an influx of neutrophils 
into the pleural cavity. Treatment with db-cAMP significantly reduced this number while 
increasing AnxA1 expression when introduced at the peak inflammatory time (Lima et 
al., 2017). Thus, LPS and cAMP elevating agents such as db-cAMP, have opposing 
roles in an inflammatory cell. This may explain why rp-cAMP had no notable effect on 
LPS induced COX-2 expression (4.4.1.1) in what we regard as the pro-inflammatory 
pathway. Contrary to this, whereas LPS could induce COX-2 by 3 hours, this stimulus 
was found to induce cAMP by 6 and 24 hours (Chen et al., 1999); suggesting COX-2 
to precede cAMP production. Thus, Chen et al. (1999) suggested COX-2 induced 
PGE2 to behave as an autocrine mediator for cAMP production. 
 
It may well be that the effect of LPS on cAMP differs per cell line. Whereas low 
concentrations of LPS did not induce IL-33 production, a cAMP analog caused an 
increase in this; thus, and it was suggested that cAMP enhance the effect of LPS. This 
effect was inhibited by H89, a PKA inhibitor; thus highlighting the relevance of PKA in 
the LPS pathway in RAW264.7 macrophages (Sato et al., 2016). Chen et al. (1999) 
used the nitrite assay to show that inhibition of PKA reduced LPS induced iNOS 
expression whereas PKA activators increased iNOS expression. Raddassi et al. 
(1993) showed that in murine peritoneal macrophages, LPS induced cAMP and this 
second messenger was important in the retro-inhibitory control of the LPS induced PG 
production. One micromolar PGE2 and LPS administration decreased NO synthase 
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whereas 1µM indomethacin suppressed PG production while increasing NO synthase 
(Raddassi et al., 1993).  
 
Of high interest, IL-4 did not stimulate cAMP production in macrophage J774.2 
cells at 24 hours however it was increased by 48 hours. We have shown IL-4 to induce 
COX-2 at this time point (fig 3.2.1). This cAMP may be induced via production of PGE2 
by COX-2 (fig 3.2.2) which may bind EP4 receptors. This is somewhat ambiguous as, 
addition of the cAMP antagonist previously blocked IL-4 induced COX-2 expression 
(fig 4.4.1.1b). This implies cAMP production to occur before COX-2 induction and a 
positive feedback loop may sustain cAMP production. If IL-4 does induce cAMP before 
the 48-hour mark, this may be blocked by other mediators as it was not detectable at 
24 hours. In the presence of SB203580 (fig 4.4.2.1e) and BADGE (fig 4.4.2.1f), at 24 
hours, there was a significant increase in cAMP. At 48 hours, this effect was reversed 
and both SB203580 (fig 4.4.2.1e) and BADGE (fig 4.4.2.1f) caused significant 
reduction in cAMP levels. In correlation with this, we have shown BADGE and 
SB203580 to block COX-2 expression and PGE2 production at 48 hours. Correlating 
these 2 pieces of evidences, it may be that cAMP is required for the translation of 
COX-2 protein and PG production. Chang et al. (2000) recorded increased intracellular 
cAMP and p38 activation prior to increased arginase activity; an indicator of 
macrophage polarisation. This goes hand in hand with the literature which provides 
strong evidence for cAMP to be involved in the M2 macrophage phenotypic state 
(Bystrom et al., 2008); where arginase activity is increased as determined by the 
concentration of urea produced. Arginase activity was found to be inhibited by 
SB203580, thus suggesting a requirement of p38 in urea production. 
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It would be interesting to observe whether IL-4 can stimulates cAMP at 30 
minutes, where IL-4 first activates PPARγ (fig 4.2.2a). It is possible that PPARγ 
activation leads to downstream activation of a mediator which mediates COX-2 
expression. This may be cAMP, because, blocking cAMP blocks COX-2 expression 
by IL-4 (fig 4.4.1.1) and PPARγ was found to mediate cAMP production (fig 4.4.2.1). 
This also suggests that the activation of PPARγ and the release of cAMP is somewhat 
immediate as this occurs within the same time point. Singh et al. (2015) previously 
suggested relaxin to induce cAMP upstream to PPARγ activation via p38. 
Furthermore, Gabrielli et al. (2014) found that 3-isobutyl-1-methylxanthine, an inhibitor 
of PDE, increases cAMP and PKA activation on top of PPARγ protein expression 
(Gabrielli et al., 2014); thus, pointing to a relation between cAMP and PPARγ. It may 
be that, there is a positive feedback mechanism whereby, cAMP production is 
instigated by the upstream PPARγ/p38; and the cAMP continues to induce activation 
of this pathway.  
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4.6 Chapter conclusion 
This chapter gives strong evidence for the involvement of cAMP, PPARγ and 
p38 in the induction of COX-2 by IL-4. Comparative analyses show differential 
requirements for these mediators in COX-2 induction by LPS and IL-4. Whereas IL-4 
activates cAMP (fig 4.4.2.1) and requires cAMP (fig 4.4.1.1b) and PPARγ (fig 4.1.2b, 
4.1.3) for COX-2 induction, LPS did not. Accordingly, we suggest the IL-4 to bind its 
cognate receptor and activate p38 which mediates PPARγ activity (fig 4.2.2). 
Furthermore, IL-4 induced COX-2 with a temporal delay in comparison to LPS induced 
COX-2 (fig 3.2.1). We suggest this delay to be mediated at the level of p38 and PPARγ. 
PPARγ activity produced cAMP which assists in the induction of COX-2. Blocking 
these mediators blocked the expression of COX-2 protein, confirming our speculative 
induction pathway. Following confirmation of the IL-4 induced COX-2 pathway, the 
phenotypic nature of the macrophage should be understood. As we hypothesise that 
the macrophage phenotype depicts the functional properties of COX-2, the phenotype 
post-stimulation needs to be evaluated. 
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Figure 4.6.1 Diagram to conclude chapter 
Macrophages treated with 10ng/ml IL-4 for 48 hours, produced cAMP, a common 
second messenger that has roles in anti-inflammatory signalling pathways. Inhibition 
of cAMP with rp-cAMP blocked COX-2 expression by IL-4. Furthermore, inhibition of 
both PPARγ activity and p38 by BADGE and SB203580 respectively, blocked COX-2 
activity. This confirmed PPARγ, p38 and cAMP to lie upstream to COX-2 activation 
and are key in the induction pathway. 
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Chapter 5: Phenotype of the macrophage expressing COX-2 
following stimulations with LPS and IL-4 
 
5.1.1 Macrophage polarisation 
There is a general conception that M2 macrophages typically produce high 
levels of IL-10 and low levels of TNFα while M1 macrophages produce low levels of 
IL-10 and high levels of TNFα. During infection, macrophages are a major source of 
IL-10 (see for review: (Couper et al., 2008)). IL-10 is an anti-inflammatory cytokine that 
inhibits pro-inflammatory responses; thus, IL-10 facilitates clearance of pathogens 
whilst alleviating immunopathology. IL-10 inhibits major histocompatibility complex 
(MHC) class II, thereby limiting pro-inflammatory cytokine production. It has been 
suggested that IL-10 can prevent neighbouring macrophages from polarising towards 
a pro-inflammatory phenotype (see for review: (Couper et al., 2008)). TNFα on the 
other hand polarises macrophages towards a pro-inflammatory phenotype and 
induces pro-inflammatory responses such as leukocyte adhesion (see for review: 
(Bradley, 2008)). Blocking TNFα has been shown to treat inflammatory conditions 
including RA (see for review: (Bradley, 2008)). cAMP, a key molecule in anti-
inflammatory macrophages, has been shown to influence these two cytokines which 
are key as an indication of macrophage phenotype (Shames et al., 2001, Bystrom et 
al., 2008, Ayoub et al., 2009).  
 
 It has previously been observed that LPS treated macrophages produce TNFα 
(Parameswaran and Patial, 2010). IL-4 has been shown to polarise macrophages to 
an M2 phenotype and activate anti-inflammatory transcription factors and markers 
(Kaplan et al., 1996, Levings and Schrader, 1999, Szanto et al., 2010, Sheldon et al., 
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2013). It is important to note whether the IL-4 treated cells, which were shown to 
express COX-2, exhibit anti-inflammatory or pro-inflammatory properties.  
 
5.1.2 Cytokine profiling as a measure of macrophage phenotype state  
Using cytoplasmic dot hybridisation mRNA analysis, it was previously 
suggested that the secretion patterns of lymphokines were definitive of the type of T 
helper cell present (Cherwinski et al., 1987). These cytokines could activate B cells 
differentially and mediate the regulatory functions downstream. Th1 cells produced 
IFNγ while Th2 cells produced IL-4 (Cherwinski et al., 1987). Thus, in a similar 
approach, we set out to measure the release of cytokines to understand the phenotype 
of the macrophage. To elucidate the phenotypic state of the macrophages following 
treatment of cells with LPS or IL-4, analysing the cytokine profile would be informative. 
ELISA (R&D Systems) was used to measure the anti-inflammatory cytokine, IL-10 and 
the pro-inflammatory cytokine, TNFα. TNFα mediates innate immunity and is 
implicated in inflammatory disease pathogenisis (see for review:(Bradley, 2008, Sabio 
and Davis, 2014, Kalliolias and Ivashkiv, 2016)). IL-10 is related to both adaptive and 
innate immunity with anti-inflammatory properties (see for review: (Bradley, 2008)). 
These cytokines were previously measured by Ayoub et al. (2009). 
 
  Of interest, whether a cell can polarise from one state to another in vitro has 
been questioned. Bystrom et al. (2008) previously showed the presence of the cAMP 
agonist, db-cAMP, to increase IL-10 whilst reducing TNFα in what was regarded as an 
M1 macrophage converting to an M2 phenotype; suggesting macrophages can revert 
from one phenotype to the other based on the surrounding mileu. This was also 
observed by Ghosh et al. (2016) who suggested the microenvironment to dictate 
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macrophage phenotype as injection of IL-4 into an M1 dominated spinal cord, allowed 
macrophages to polarise into an M2 phenotype. This puts great emphasis on the 
microenvironment surrounding the cells.  
 
5.2 Phenotypic state of the macrophage following IL-4 treatment 
 Cells were plated in T25 flasks and stimulated with increasing concentrations 
of IL-4 for 2, 24 and 48 hours. Two hours was selected as we wanted to see whether 
IL-4 was capable of inducing this change in phenotype at an earlier stage; suggesting 
macrophage polarisation to take place before COX-2 protein expression. The 
supernatant was collected and analysed for IL-10 levels via ELISA (for protocol see 
2.8).  
 
All concentrations of IL-4 caused a significant increase in the levels of IL-10 
produced from as early as 2 hours (7.95 ng/mg protein; p<0.01** (5ng/ml IL-4), 20.55 
ng/mg protein; p<0.01** (10ng/ml IL-4), 14.6 ng/mg protein; p<0.01**(25ng/ml IL-4), 
15.36 ng/mg protein; p<0.01** (50ng/ml IL-4), 11.34 ng/mg protein; p<0.01** 
(100ng/ml IL-4)) (fig 5.2.1). At 24 hours, IL-10 levels were significantly higher (18.59 
ng/mg protein; p<0.01** (5ng/ml IL-4), 23.14 ng/mg protein; p<0.01** (10ng/ml IL-4), 
19.97 ng/mg protein; p<0.01** (25ng/ml IL-4), 16.89 ng/mg protein; p<0.01** (50ng/ml 
IL-4), 14.89 ng/mg protein; p<0.01** (100ng/ml IL-4)) compared to the control 
(undetectable IL-10 levels) (fig 5.2.1). The same was true at 48 hours (14.24 ng/mg 
protein; p<0.05* (5ng/ml IL-4), 19.66 ng/mg protein; p<0.01** (10ng/ml IL-4), 19.56 
ng/mg protein; p<0.01** (25ng/ml IL-4), 18.28 ng/mg protein; p<0.01** (50ng/ml IL-4), 
20.76 ng/mg protein; p<0.01** (100ng/ml IL-4)) (fig 5.2.1). The production of IL-10 was 
not concentration dependent. The levels of IL-10 produced, seem to be fairly 
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consistent with a small spread across the 3 time points investigated. The negative 
control showed undetectable IL-10 production at all the time points studied.  
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Figure 5.2.1: Increasing concentrations of IL-4 caused an increase in IL-10 levels 
between 2 and 48 hours. 
Cells were treated with increasing concentrations of IL-4 ranging from 5ng/ml to 
100ng/ml for 2, 24 or 48 hours. The supernatant was collected to analyse IL-10 levels. 
The negative control was cells that were left untreated. All other bars reflect the levels 
of IL-10 following treatment of cells with IL-4.   
The data shown were obtained from 3 independent experiments (n=3). One Way 
ANOVA was carried out between the negative control and samples where increasing 
concentrations of IL-4 were added; represented by *. Data are expressed as mean+/- 
SEM (error bars); *p<0.05, **p<0.01, ***p<0.001. 
 
5.3 Effect of p38 inhibition and PPARγ antagonism on IL-4 induced 
production of IL-10 
The relevance of p38 in IL-4 signalling and M2 macrophage polarisation has 
been visited beforehand (Jimenez-Garcia et al., 2015). Similarly, the relevance of 
PPARγ in IL-4 signalling has also been documented (Szanto et al., 2010). Both 
SB203580 and BADGE have been shown to impact cAMP levels (fig 4.1.2), a 
molecule related to anti-inflammatory macrophages. As we have previously shown 
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ways in which both PPARγ and p38 regulate COX-2 induction, with the aim of drawing 
parallelism between macrophage phenotype and COX-2 induction, the effect of both 
of these on cytokine production should be clarified. To this end, in a subset of  
experiments, the role of both p38 and PPARγ in the production of IL-10 was 
investigated. Cells were pre-treated with BADGE and SB203580 for 1 hour, prior to 
the addition of 10ng/ml IL-4 for both 24 and 48 hours. At the end of these time points, 
the supernatant was collected and assayed for IL-10 levels via ELISA (see 2.8).  
 
Upon addition of 10ng/ml IL-4 there was a significant upsurge in IL-10 at 24 
hours (102 ng/mg protein; p<0.01**) compared to the unstimulated cells (undetectable 
IL-10 levels). This was significantly reduced by the addition of the p38 inhibitor (4.65 
ng/mg protein; p<0.01$$) (fig 5.3.1a). The negative control and cells treated with 
SB203580 alone, showed undectable IL-10 levels. At 48 hours there was a significant 
increase in IL-10 when cells were treated with 10ng/ml IL-4 (76.68 ng/mg protein; 
p<0.001***). The addition of the p38 inhibitor completely blocked IL-10 production 
(undetectable IL-10 levels; p<0.001$$$) (fig 5.3.1a). The addition of BADGE to cells 
treated with 10ng/ml IL-4 significantly inhibited IL-10 production (undetectable IL-10 
levels; p<0.001$$$ ng/mg protein).  
 
In LPS treated cells, IL-10 was not produced. This level was not effected by the 
addition of either the p38 inhibitor or PPARγ antagonist (data not shown). The LPS 
treated cells therefore showed the same amount of IL-10 as the unstimulated cells. 
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Figure 5.3.1 IL-4 induced IL-10 levels was significantly reduced at both 24 and 
48 hours in the presence of SB203580 and BADGE. 
Cells were treated with SB203580 or BADGE for 1 hour before adding 10ng/ml IL-4 to 
the cells for 24 and 48-hours. The supernatant was collected and analysed for IL-10 
production. All readings were standardised to the respective protein concentration. 
Unstimulated cells and cells treated with SB203580 or BADGE were the negative 
controls. Cells treated with 10ng/ml IL-4 alone was the positive control. All bars 
represent the effect of either SB203580 or BADGE on IL-10 production by IL-4.  
The data shown were obtained from 3 independent experiments (n=3). IL-10 levels 
produced following treatment of cells with IL-4 were statistically compared to the 
negative control via the One Way ANOVA; as represented by *. The positive control 
was compared to the samples that were co-treated with IL-4 and BADGE or SB203580 
via the One Way ANOVA; represented by $. Data are expressed as mean+/- SEM 
(error bars); *p<0.05, **p<0.01, ***p<0.001, $p<0.05, $$p<0.01, $$$p<0.001. 
 
 
5.4 Effect of SB203580 and BADGE on IL-4 and LPS induced TNFα 
levels 
Treating cells with 10ng/ml IL-4 for 24 hours had no real effect on TNFα levels 
(3.4 ng/mg protein) when compared to the unstimulated cells (2.51 ng/mg protein). 
This value was left unaffected when the cells were pre-treated with SB203580 (5.1 
ng/mg protein) (fig 5.4.1a). The levels reported here were similar to that observed in 
the negative control (2.51 ng/mg protein) and in cells treated with only SB203580 (4.1 
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ng/mg protein). The same was seen at 48 hours where, upon co-treating cells with 
10ng/ml IL-4 and 10μM SB203580, no change in TNFα was noted (4.67 ng/mg 
protein); similar to when cells were treated with IL-4 alone (3.98 ng/mg protein). Adding 
SB203580 to IL-4 treated cells, therefore, had no effect on TNFα production. From this 
it can be assumed that IL-4 did not activate any transcription factor leading to TNFα 
synthesis. This may be because the IL-4 induced an anti-inflammatory environment.  
 
Co-treating macrophages with 10ng/ml IL-4 and 150μM BADGE showed a 
significant increase in the production of TNFα at 24 hours (7.24 ng/mg protein p<0.05$) 
(fig 5.4.1b). BADGE on its own had no effect on TNFα levels (4.07 ng/mg protein) 
compared to the negative control (2.51 ng/mg protein). At 48 hours, levels of TNFα 
were not significantly effected by the addition of BADGE (3.19 ng/mg protein) (fig 
5.4.1b). Despite this, when BADGE was added to the cells without a stimulant, there 
was a significant reduction in the TNFα produced at 48 hours (2.03 ng/mg protein 
p<0.05#).  
 
At 24 hours, upon addition of 1μg/ml LPS, there was a significant increase in 
TNFα production (1274.59 ng/mg protein; p<0.001***). This was significantly reduced 
when SB203580 was added (251.34 ng/mg protein; p<0.001$$$); however levels were 
still higher than the negative control (2.51 ng/mg protein) (fig 5.4.1c). At 48 hours, the 
negative control showed basal levels of TNFα (5.09 ng/mg protein), slightly higher than 
what was observed at 24 hours (fig 5.4.1c). Treatment of cells with 10μM SB203580 
for 48 hours showed low levels of TNFα production (8.76 ng/mg protein), similar to the 
unstimulated cells. LPS stimulation of macrophages for 48 hours did not significantly 
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increase TNFα levels (37.59 ng/mg protein). The addition of SB203580 did not impact 
TNFα levels (14.74 ng/mg protein) (fig 5.4.1c). 
 
At 24 hours, co-treatment of 150μM BADGE and 1μg/ml LPS showed a 
significant decrease in TNFα levels (4.42 ng/mg protein; p<0.001$$$) compared to cells 
treated with just 1μg/ml LPS (1274.59 ng/mg protein; p<0.001***) (fig 5.4.1d). At 48 
hours, the addition of BADGE significantly reduced TNFα levels (2.03 ng/mg protein; 
p<0.05#) (fig 5.4.1d). At 48 hours, treatment of cells with 1μg/ml LPS or 1μg/ml LPS 
with 150μM BADGE did not induce TNFα production (37.59, 4.51 ng/mg protein 
respectively) (fig 5.4.1d). 
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a)                                                          b) 
 
 
 
 
 
 
  c)                       d) 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4.1: IL-4 did not induce TNFα in macrophage J774.2 cells. The addition 
of a) SB203580 did not impact this however, at 24 hours, b) BADGE increased  
TNFα. LPS required c) p38 and d) PPARγ to produce TNFα 24 hours. 
Cells were treated with SB203580 or BADGE for 1 hour before adding 10ng/ml IL-4 or 
1μg/ml LPS. Following 24 and 48-hour stimulations, the supernatant was assayed for 
either IL-10 or TNFα. Unstimulated cells and cells treated with only SB203580 or 
BADGE were the negative controls. Cells treated with 10ng/ml IL-4 or 1μg/ml LPS 
were the positive controls. All bars represent the effect of either SB203580 or BADGE 
on TNFα production by IL-4 and LPS.  
The data shown were obtained from 3 independent experiments (n=3). TNFα levels 
produced following treatment of cells with IL-4 and LPS were statistically compared to 
the negative control via the One Way ANOVA; as represented by *. Cells treated with 
SB203580 and BADGE were compared to the positive control with One Way ANOVA; 
represented by $. The One Way ANOVA was also used to compare the differences in 
TNFα production between the unstimulated cells and cells where SB203580 or 
BADGE were added; represented by #. Data are expressed as mean+/- SEM (error 
bars); *p<0.05, **p<0.01, ***p<0.001, $p<0.05, $$p<0.01, $$$p<0.001., #p<0.05, 
##p<0.01, ###p<0.001. 
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5.5 Suppression of cytokine release by COX inhibitor 
Indomethacin is a non-selective COX inhibitor. Indomethacin, although a potent 
inhibitor of COX-1, inhibited COX-2 (IC50=0.48μM) (Blanco et al., 1999, Warner et al., 
1999). Indomethacin was found to exacerbate inflammation when administered at 48 
hours in vivo (Gilroy et al., 1999). Clinical cases have been reported where patients 
who took indomethacin experienced adverse effects, typically relating to the skin, CNS 
and gastro-intestincal tract (Boardman and Hart, 1967). As indomethacin has been 
used in the treatment of inflammatory diseases, the effect of these drugs on the 
cytokine profile following co-treatment with LPS and IL-4 would be interesting to look 
at. Inhibition of pro-inflammatory cytokines, would suggest indomethacin to be useful 
in chronic disease, however inhibtion of IL-4 induced anti-inflammatory cytokines 
would suggest administration of this drug to be harmful, as it impedes resolution.  
 
The addition of 10ng/ml IL-4 to the cells showed an upsurge in the amount of 
IL-10 produced (102.48 ng/mg protein; p<0.001***) at 48 hours compared to the 
negative control. Indomethacin on its own showed no effect on IL-10 levels compared 
to the negative control (fig 5.5.1a). When macrophages were co-treated with IL-4 and 
indomethacin, there was complete inhibition of IL-10 production (undetectable IL-10 
levels; p<0.001$$$, undetectable IL-10 levels; p<0.001$$$, undetectable IL-10 levels; 
p<0.001$$$), (fig 5.5.1a). A similar pattern was reported at 48 hours where there was 
no IL-10 produced in the negative control. Indomethacin on its own produced no 
detectable IL-10 (fig 5.5.1a). Addition of IL-4 caused a significant increase in IL-10 
(76.68 ng/mg protein; p<0.001***) but this was completely blocked in the presence of 
increasing concentrations of indomethacin (undetectable IL-10 levels; p<0.001$$$, 
undetectable IL-10 levels; p<0.001$$$, undetectable IL-10 levels; p<0.001$$$). 
 114 
Upon addition of 1μg/ml LPS, there was a significant increase in TNFα 
production (1274.59 ng/mg protein; p<0.001***) in comparison to the negative control 
(2.51 ng/mg protein). Low concentrations of indomethacin did not effect basal TNFα 
(2.95 ng/mg protein), but higher concentrations of inodemethacin inhibited TNFα 
(undetectable TNFα levels; p<0.05#, undetectable TNFα levels; p<0.05# ng/mg 
protein) at 24 hours (fig 5.5.1b). When indomethacin was added to LPS, the levels of 
TNFα was reduced significantly (123.75 ng/mg protein; p<0.001$$$, 107.13 ng/mg 
protein; p<0.001$$$, 5.56 ng/mg protein; p<0.001$$$ ng/mg protein); though this did not 
reach basal levels (fig 5.5.1b). At 48 hours, 1μg/ml LPS caused a significant increase 
in TNFα (37.59 ng/mg protein; p<0.01**) (fig 5.5.1b). Similar to 24 hours, when 
increasing concentrations of indomethacin was added to LPS, the levels of TNFα 
decreased significantly (16.44 ng/mg protein; p<0.05$, 18.95 ng/mg protein; p<0.05$, 
7.36 ng/mg protein; p<0.001$$$ ) (fig 5.5.1b). Low concentrations of indomethacin on 
its own did not effect basal levels of TNFα (7.52, 3.86 ng/mg protein). Inodemthacin of 
highest concentration blocked basal TNFα production (undetectable TNFα levels 
ng/mg protein; p<0.01##) 
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a)                                                         b) 
 
Figure 5.5.1: Indomethacin of increasing concentrations blocked a) IL-10 
produced by IL-4 and reduced b) TNFα producted by LPS. 
Cells were treated with increasing concentrations of indomethacin for 1 hour before 
adding 10ng/ml IL-4 or 1μg/ml LPS to the cells for 24 and 48 hours. The supernatant 
was assayed to measure IL-10 and TNFα. Unstimulated cells and cells treated with 
indomethacin alone were the negative controls. Cells treated with 10ng/ml IL-4 or 
1μg/ml LPS were the positive controls. All bars represent the effect of indomethacin 
on IL-10 and TNFα produced by IL-4 and LPS respectively.  
The data shown were obtained from 3 independent experiments (n=3). One Way 
ANOVA with the Dunnett’s post hoc test was used to compare TNFα and IL-10 levels 
produced following treatment of cells with IL-4 and LPS compared to unstimulated 
cells, as represented by *,  Cells treated with indomethacin and the positive control, 
as represented by $ and between the unstimulated cells and cells treated with only 
indomethacin; represented by #. Data are expressed as mean+/- SEM (error bars); 
*p<0.05, **p<0.01, ***p<0.001, $p<0.05, $$p<0.01, $$$p<0.001., #p<0.05, ##p<0.01, 
###p<0.001. 
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5.6 Discussion to results chapter 5 
Macrophage polarisation following treatment of cells with LPS and IL-4 
 
5.6.1 Cytokine profile following treatment of cells with LPS and IL-4 
The first chapter suggests differential properties for the LPS and diclofenac/IL-
4 induced COX-2. As the work in this project is carried out on a macrophage cell line, 
it would be important to look at the phenotypic state in each stimulation. Similar to the 
T helper cell dichotomy of cell polarisation (Th1 and Th2 cells), macrophages also 
have 2 different phenotypes: M1 and M2 macrophages (see 1.2), however there has 
been cases of heterogenity amongst these macrophages (see for review: (Geissmann 
et al., 2010, Gordon and Pluddemann, 2017)). The polarisation of macrophages has 
been suggested to be driven by the microenvironment (Bystrom et al., 2008) (see for 
reviews: (Italiani and Boraschi, 2014, Van Overmeire et al., 2014)) which allows these 
cells to mount a spectrum of functional responses. Abundant M2 stimuli and lack of 
M1 signals drive preferential polarisation towards M2. Typically, the macrophage 
phenotypic state is denoted by the Arg1: iNOS ratio (Corraliza et al., 1995). M1 and 
M2 markers, production of cytokines and activation of specific transcription factors all 
play a role in identifying the macrophage phenotype (see 1.2) 
 
 It was previously shown that IL-4, but not LPS, increased cAMP (fig 4.2.1e, f). 
cAMP has been associated with an anti-inflammatory phenotype of the macrophage 
based on the release of IL-10, an anti-inflammatory cytokine and a decline in TNFα, a 
pro-inflammatory cytokine (Bystrom et al., 2008). AnxA1 was also found to exert pro-
resolving downstream effects of cAMP. The cAMP agonists were found to have 
opposing functions to LPS mediated neutrophil apoptotic effects (Lima et al., 2017); 
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suggesting cAMP and LPS to be part of two opposing pathways. Thus, the findings 
made in the previous chapter suggested IL-4 to force macrophages towards an anti-
inflammatory phenotype, with the LPS forcing macrophages towards an M1 
phenotype.  
 
The following speculations, led us to further clarify whether the macrophage 
induced by LPS and/or IL-4, which express COX-2, produce pro-/ or anti-inflammatory 
cytokines. As previously mentioned, cytokine profiles have previously been used to 
determine the phenotype of the immune cell (Cherwinski et al., 1987). To this end, we 
measured IL-10 and TNFα, the anti-inflammatory and pro-inflammatory cytokine 
respectively, following each stimulation. 
 
5.6.2 IL-4 treated macrophages produce IL-10 cytokine 
We were able to show all concentrations of IL-4 to significantly release IL-10 
from as early as 2 hours up until 48 hours (fig 5.2.1). This suggests the effect of IL-4 
to be somewhat early. IL-4 induced IL-10 synthesis was something previously noted 
(Kambayashi et al., 1996). The ability of low concentrations of IL-4 to induce a 
biological response has previously been noted (see for review: (Mueller et al., 2002)). 
The fact that the negative control, where cells were left unstimulated had no IL-10, but 
the addition of IL-4 stimulated IL-10 release (fig 5.2.1), suggest IL-4 to force the 
macrophage down an anti-inflammatory pathway. The range of IL-10 production is 
somewhat narrow between all concentrations of IL-4. This could be due to receptor 
saturation or maximal response of the IL-4 binding to its receptor being reached (see 
for review: (Mueller et al., 2002)). 
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As we were able to identify the role of p38 and PPARγ on COX-2, we aimed to 
investigate the role of p38 and PPARγ on IL-10 release following IL-4 treatment. Co-
treating cells with 10ng/ml IL-4 and 10μM SB203580 reduced and completely blocked 
IL-10 production at 24 and 48 hours respectively (fig 5.3.1a). SB203580 on its own did 
not induce IL-10 production. This confirms the role of p38 in IL-4 signalling routes in 
an anti-inflammatory pathway. We speculate that SB203580 in IL-4 treated cells 
prevent the polarisation of the macrophages towards an M2 phenotype. It has 
previously been shown that silencing or pharmacologically blocking p38 blocks the 
polarisation of macrophages towards M2 (Jimenez-Garcia et al., 2015). As M2 
macrophages produce IL-10, this may explain why the production of IL-10 is 
completely lost in the presence of SB203580. Campbell et al. (2004) showed p38 did 
not block IL-10 production in RA tissue. The role of p38 may be dependent on the 
environment, i.e. in RA, the environment is inflammatory however, an IL-4 treated 
environment will be anti-inflammatory. Moreover, p38 may have a time-dependent 
role, as it was shown to have differential effects at 24 and 48 hours.  
 
 Treatment of cells with BADGE inhibited the IL-4 induced production of IL-10 
(fig 5.3.1b). This suggests PPARγ to be an absolute requirement for the polarisation 
of macrophages towards an anti-inflammatory cytokine secreting macrophage; similar 
to its absolute requirement for the induction of COX-2 (fig 4.3.1.2b). PPARγ has also 
been associated with anti-inflammatory signalling pathways downstream to IL-4 
(Szanto et al., 2010). The presence of a PPARγ antagonist showed IL-4 inductive anti-
inflammatory effects to be lost. (Paintlia et al., 2006). The ability of BADGE to 
completely block IL-4 induced COX-2 (fig 4.3.1.2b), suggest the process of inducing 
COX-2 and that of polarisation, may follow a similar pathway. BADGE works by 
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inhibiting the transcriptional activation of both PPARγ and RXRα by inhibiting ligand 
binding to the receptor (Wright et al., 2000). 
 
We have previously shown inhibition of PPARγ activity induced by IL-4, in the 
presence of SB203580 (fig 4.4.2b). This reinforces the theory, whereby we suggest 
p38 to activate PPARγ, as inhibiting p38 inhibited IL-10 release, similar to PPARγ 
antagonism inhibiting IL-10. The effect of p38 inhibition, may therefore be due to the 
lack of PPARγ activation.  
 
As hypothesised, we have shown the involvement of both p38 and PPARγ in 
both the induction of COX-2 and the production of anti-inflammatory cytokines. It is 
thought provoking that following 24 hours of treatment with IL-4, the macrophages did 
not induce COX-2 (fig 3.2.1), cAMP production was not observed (fig 4.2.1e, f) and 
PPARγ was not activated (fig 4.4.2a). However, IL-4 treated macrophages developed 
an anti-inflammatory phenotype at 24 hours (fig 5.2.1). This suggests that the 
macrophage may polarise prior to the induction of COX-2; as opposed to the induction 
of COX-2 assisting with driving macrophage polarisation. This differs to other studies 
which have shown the inhibition of COX-2 to impact polarisation of the macrophage 
(Na et al., 2013). It may be possible that IL-4 creates a microenvironment that allows 
the macrophage to polarise to this functional phenotype (see for review: (Italiani and 
Boraschi, 2014)). 
 
5.6.3 LPS, but not IL-4 transform macrophages to produce TNFα 
In unstimulated cells, the levels of TNFα were relatively low. This can be 
attributed to weak gene transcription of TNFα (Mijatovic et al., 1997). Interestingly, 
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throughout the 48-hour treatment of cells with 10ng/ml IL-4, there was basal levels of 
TNFα, similar to the control. The addition of SB203580 had no effect on the TNFα 
produced (fig 5.4.1a). This differs somewhat to the addition of BADGE where, 
specifically at 24 hours, addition of the PPARγ antagonist caused an increase in TNFα 
(fig 5.4.1b). This suggests that activation of PPARγ by IL-4 shuts down TNFα 
production, highlighting the anti-inflammatory pathways downstream to IL-4 treatment. 
The fact that PPARγ is required for IL-10 synthesis and TNFα suppression, reiterates 
the anti-inflammatory role for PPARγ in macrophages. Furthermore, this confirms that 
depending on the stimuli, the macrophage polarises towards a pro-inflammatory or 
anti-inflammatory phenotype.  
 
The addition of IL-4 to the macrophage J774.2 cells did not affect the basal 
levels of TNFα in the negative control (fig 5.4.1a, b). This suggests the IL-4 not to 
initiate a pathway to decrease this pro-inflammatory cytokine; rather, it has no such 
effect on the cytokine. A similar pattern was observed by Gautam et al. (1992) who 
showed no effect by IL-4 on LPS induced TNFα in macrophages. This differs to work 
carried out by Mijatovic et al. (1997) who showed both IL-4 and IL-13 to translationally 
repress LPS induced TNFα. Repression occurs at the UA-rich sequence which is 
present in the 3’-UTR. This group noted that the TNFα transcript remained stable 
however production was reduced, therefore, TNFα suppression is mediated at a 
translational level by IL-4 (Mijatovic et al., 1997). Seventy two percent inhibition of 
TNFα was noted via ELISA when the cells were co-treated with 10ng/ml LPS and 
5ng/ml IL-4 in both mouse RAW 264.7 and J774 macrophages (Mijatovic et al., 1997). 
It was suggested that IL-4 may disrupt translation of TNFα by blocking the protein 
complex which allows the binding to the UA-rich sequence of TNFα mRNA following 
 121 
treatment of the macrophage with LPS (Mijatovic et al., 1997).  Similarly, in microglial 
cells, 10ng/ml IL-4 induced an M2 macrophage whilst modestly reducing TNFα that 
was produced by LPS (Ghosh et al., 2016).IL-4 mediated inhibitory effects were not 
observed in STAT6 null BMDM but repression was seen in wildtype cells (Levings and 
Schrader, 1999), thus these effects may be driven via STAT6. 
 
Kambayashi et al. (1996) found that the inhibitory effect of IL-4 may be partially 
mediated via IL-10 which was shown to be increased during co-treatment with LPS. 
Neutralising IL-10 reversed this IL-4 induced TNFα inhibitory effect (Kambayashi et 
al., 1996). Similarly, Levings and Schrader (1999) found IL-10 to block TNFα 
production in peritoneal exudate macrophages (PEC) and BMDM, independent of 
STAT6, while Chan et al. (2012) showed IL-10 to block TNFα mRNA expression in a 
STAT3 dependent manner. Chan et al. (2012) showed a 45-minute LPS stimulation 
followed by a 15-minute stimulation with IL-10 to shift TNFα mRNA from polysomes to 
monosomes which reduce TNFα protein synthesis. Levings and Schrader (1999) 
reported IL-4 not to have any effect on TNFα produced by LPS in PEC. Our work did 
not look at the co-treatment of a pro- and anti-inflammatory stimuli as we were 
interested in differential expression of COX-2 in comparative studies. None the less, it 
would be interesting to look at the effect of introducing IL-4 to cells that were treated 
with LPS and measure cytokine levels.  
 
LPS treated cells showed an upsurge in TNFα levels at 24 hours and this was 
sustained till 48 hours. Whereas blocking p38 at 24 hours, significantly reduced TNFα 
production, at 48 hours, blocking p38 had no effect (fig 5.4.1c). Tyrosine 
phosphorylation of MAPK has been associated with TNFα synthesis following LPS 
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stimulations (Mijatovic et al., 1997). Sabio and Davis (2014) reviewed p38α but not 
p38β to play a key role in controlling TNFα production. TNFα stability and the initiation 
of translation were found to be regulated at the level of p38α.Chan et al. (2012) 
reported p38 as a requirement for TNFα synthesis as inhibition of this leads to reduced 
polysome association which ultimately leads to reduced TNFα. It has previously been 
shown that LPS induced TNFα via NFκB directed gene transcription with a 10,000-
fold increase in its biosynthesis (Mijatovic et al., 1997).  It was suggested that p38 may 
function via the activation of NFκB by possibly phosphorylating the p65 subunit. 
SB203580 had no effect on the degradation of IκB induced by LPS, but luciferase 
reporter gene assays showed this compound to cause approximately 65% inhibition 
of NFκB transcription (Campbell et al., 2004). There may be some cell specificity in 
the effect of SB203580 because in HeLa and Jurkat cells, this compound did not block 
TNFα induced gene activity downstream to NFκB activation (Campbell et al., 2004). 
Although p38 showed an increase in NFκB, p38 can also inhibit NFκB activity following 
exposure to TNFα. Thus, p38 may play a dual role, whereby it activates TNFα 
transcription and via an autoregulatory machinery, limits TNFα expression (see for 
review: (Sabio and Davis, 2014)). It may therefore be conceptual that p38 behaves as 
a regulator during the inflammatory process 
 
The presence of BADGE significantly reduced TNFα produced by LPS at 24 
hours, suggesting a role for PPARγ in TNFα synthesis (fig 5.4.1d). It is ambiguous as 
to how LPS significantly reduced PPARγ activity at 24 hours (fig 4.4.1) but required 
PPARγ for the synthesis of TNFα at the same time (fig 4.4.1d). It is possible that LPS 
did not activate PPARγ activity as it activates NFκB (Mijatovic et al., 1997, Campbell 
et al., 2004). In the absence of BADGE, low levels of cAMP were seen (fig 4.4.2.1b) 
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with high levels of TNFα (fig 5.4.1d). Co-treatment of LPS and BADGE at 24 hours 
increased cAMP production (fig 4.4.2.1b). This may coincide with reduced TNFα 
reported following PPARγ antagonism (fig 5.4.1d). We speculate the cAMP to work in 
an opposing manner to TNFα production. Following LPS injection in mice, 
concentration increases of the PDE inhibitor, CP-80,633, resulted in enhanced cAMP 
and reduced systemic TNFα (Cheng et al., 1997). Wall et al. (2009) showed cAMP 
mediated effects on TNFα production in RAW 264.7 macrophages to be dependent 
on PKA. Treatment of cells with 8Br-cAMP, the cAMP analog, showed robust inhibition 
of TNFα along with enhanced IL-10 (Wall et al., 2009). This group showed p105 
phosphorylation to mediate cAMP dependent inhibition of LPS induced TNFα; thus, 
modulating NFκB (Wall et al., 2009). The C-terminal region of p105 contained a PKA 
phosphorylation site. cAMP was capable of slowing the nuclear localisation of the p50 
and p65 subunits following LPS stimulation (Wall et al., 2009). Therefore, it may be 
that BADGE induced increase in cAMP that blocked the production of TNFα. Although 
BADGE impacts cAMP, it does not seem to impact LPS induced COX-2 activity (fig 
4.3.1.3). It would be interesting to note whether co-stimulation of LPS and BADGE 
impacts TNFα levels. 
 
5.6.4 Inhibition of cytokine production by Indomethacin 
FACS data showed etodolac, a selective COX-2 inhibitor, to reduce IL-10 in 
macrophages and increase MHC Class II, CD80 and CD86. Thus, this group 
suggested COX-2 to be a requirement for the polarisation of macrophages towards 
the M2 phenotype (Na et al., 2013); highlighting its importance in anti-inflammatory 
macrophages. Carboxylic acid containing indomethacin has been recognised as a pan 
COX inhibitor. It was found that the indomethacin derivative compounds, amides and 
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esters, bind to COX-2. A prototypical compound of this had an IC(50) value of 0.06μM 
for purified human COX-2 (Remmel et al., 2004). If the COX-2 protein induced by both 
LPS and IL-4 are in fact different, it may perhaps be that they are differentially inhibited 
by indomethacin, as we have previously seen differential acetaminophen inhibition (fig 
3.3.1). 
 
5.6.5 Indomethacin inhibitory effect on IL-10 
This leads to the next set of experiments which showed indomethacin treatment 
in IL-4 treated macrophages to lead to complete inhibition of IL-10 production (fig 
5.5.1a). As a drug used in the treatment of chronic infection, it would not be expected 
that this NSAID would block production of an anti-inflammatory cytokine as that would 
impede resolution. Previously, indomethacin was found to reduce Treg cells that were 
induced by antigens (Tonby et al., 2016). Treg cells produce both TGFβ and IL-10, 
both anti-inflammatory cytokines (see for review: (So et al., 2015)). The reduced IL-10 
in the presence of indomethacin (fig 5.5.1a) may be due to a similar effect in the 
macrophage J774.2 cells.  
 
5.6.6 Indomethacin inhibitory effect on TNFα 
Indomethacin was shown to reduce LPS induced TNFα as expected (fig 
5.5.1b). Previously, it was shown that indomethacin can reverse the TNFα mediated 
effects on permeability of the endothelial cell monolayer (Mark et al., 2001). Some of 
these effects were attributed to the inhibition of PGE2 which was found to be stimulated 
by TNFα (Mark et al., 2001). A more recent study using C2C12 tumour cells showed 
TNFα to increase COX-2 and PGE2 synthesis, which was capable of mediating some 
TNFα effects (Park et al., 2017). Thus, indomethacin blockage of PGE2 may explain 
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the reduced TNFα (fig 5.5.1b). A similar observation was made by Zheng et al. (2017) 
who reported indomethacin to downregulate levels of COX-2. TNFα mediated 
nociception was partially lost in the presence of indomethacin, thus reinforcing the 
opposing effect of indomethacin on this pro-inflammatory cytokine (Verri et al., 2007).  
 
 This differs to findings made by Teeling et al. (2010) who showed that although 
indomethacin reversed LPS induced behavioural effects in mice, it had no effect on 
TNFα levels. Whereas LPS co-treated with DEX reduced TNFα, LPS with 
indomethacin increased TNFα (Teeling et al., 2010). A similar pattern was observed 
by Hartel et al. (2004) who showed LPS induced TNFα production in a directly 
proportional manner from concentrations ranging 1μM to 50μM of LPS. The range of 
concentrations of indomethacin used in this study may be too high, hence the forced 
inhibition (fig 5.5.1).  Indomethacin has been shown to activate PPARγ by direct 
binding (Lehmann et al., 1997). Increased PPARγ correlated with reduced TNFα 
(Kajita et al., 2004). This further complicates the findings observed in the experiment 
(fig 3.3.4).   
 
The fact that indomethacin blocked the production of the anti-inflammatory 
cytokine, we suggest that this drug may prevent the polarisation of the macrophage 
towards the anti-inflammatory phenotype via inhibition of COX-2. The effect of COX-2 
inhibition by indomethacin on both cytokines, suggest the COX-2 induced by LPS and 
IL-4 may share some similarity in structure that enable common inhibition. To further 
understand this, the impact of GC should be investigated in regards to the expression 
of COX-2 and macrophage polarisation.  
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5.7 Chapter conclusion 
 It is evident IL-4 transformed the macrophages down the anti-inflammatory 
pathway while LPS drove macrophages down the pro-inflammatory pathway. This is 
due to the production of IL-10 following IL-4 treatment (fig 5.2.1) and TNFα production 
following LPS treatment. The requirement for both p38 (fig 5.3.1a) and PPARγ (fig 
5.3.1b) in the production of IL-10 by IL-4 further confirmed a similar signalling pathway 
for both COX-2 (4.6) and IL-10 production. The fact that indomethacin inhibited 
cytokine production induced by both stimulants (fig 5.5.1) provided controversy in its 
administration. Indomethacin blocking IL-10 production, suggests a relationship 
between COX-2 and the phenotype of the macrophage. COX-2 may sustain the 
polarisation state of the macrophage due to the PG it produces. Thus, inhibition of this, 
may revert the macrophage to its state pre-stimulation.  
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Figure 5.7.1 Diagram to conclude chapter 
Macrophage J774.2 cells that were treated with IL-4 produced IL-10 anti-inflammatory 
cytokines. This production is dependent on both p38 and PPARγ because inhibiting 
these with SB203580 and BADGE, blocked IL-10 secretion. Co-treating the J774.2 
macrophages with increasing concentrations of indomethacin blocked IL-10 
production completely.  
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Chapter 6: Effect of dexamethasone in macrophages stimulated 
with LPS, diclofenac and IL-4 
 
6.1 Antagonistic relationship between dexamethasone and LPS 
 DEX is a GC known to induce anti-inflammatory pathways. This has been 
shown with the reduction of pro-inflammatory markers such as CD40, CD80 and CD86 
and production of anti-inflammatory cytokines such as IL-10 (Xia et al., 2005). DEX 
has been characterised as a regulator of COX expression and activity in the 
inflammatory response (Masferrer et al., 1992). The antagonistic effects of LPS and 
DEX has been documented in human blood monocytes. COX-2 mRNA induced by IL-
4 was inhibited by DEX (IC50=0.0073μM). Peskar (2001) found intragastric acid to 
induce COX-2 mRNA and this was inhibited by DEX without effecting COX-1 mRNA 
(Peskar, 2001). LPS was shown to induce COX-2 in the brain and both 1μmol/L DEX 
and 100μmol/L NS-398, the selective COX-2 inhibitor, reduced COX-2 expression and 
PGE2 production ex vivo in LPS treated leptomenigeal tissue (Brian et al., 1998). Thus, 
the antagonistic effects of LPS and DEX has been well documented. It was suggested 
that DEX exerts its effects by inhibiting PLA2  (Sampey et al., 2000) or destabilising 
COX-2 mRNA via p38 inhibtion (Barrios-Rodiles and Chadee, 1998).  
 
6.2 Effect of dexamethasone on COX-2 induction by LPS, diclofenac 
and IL-4 
 We were interested in investigating whether DEX differentially impacts COX-2 
expression depending on the inducer. To further characterise the LPS, diclofenac and 
IL-4 induced COX-2 and assess whether they are differentially inhibited by DEX, the 
cells were pre-treated with DEX for 1 hour prior to the addition of the stimulant. Cells 
were either left untreated (negative control), or treated with 0.1% ethanol (vehicle 
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control), 1µg/ml LPS, 500µM diclofenac or 10ng/ml IL-4 alone (positive control) and 
the stimulants: 1µM, 2µM, 5µM and 10µM DEX with 1µg/ml LPS, 500µM diclofenac 
and 10ng/ml IL-4. At the end of the 24 and 48-hour stimulations, the protein content 
was assayed using Bradford assay following cell lysis (see 2.3). For Western blot 
analysis, (see 2.4), 20g protein was loaded on the gel. Anti-COX-2 antibodies were 
added to PVDF membranes to observe COX-2 protein expression (see 2.10).  
 
The negative and vehicle control showed no COX-2 expression as expected. 
Increasing concentrations of DEX on its own did not induce COX-2 expression at both 
24 and 48 hours (fig 6.2.1). When the macrophages were treated with LPS, COX-2 
expression was induced. Pre-treating cells with low concentrations of DEX and LPS 
showed a reduction in the intensity of COX-2 expression (fig 6.2.1a). With greater 
concentrations of DEX, the intensity of the COX-2 bands increased. The same was 
noted at 48 hours, where 1μM and 2μM DEX caused a reduction in LPS induced COX-
2 but 5μM and 10μM DEX increased the expression of COX-2 (fig 6.2.1b). COX-2 was 
induced by 500μM diclofenac and 10ng/ml IL-4 at 48 hours. The addition of DEX 
reduced this expression at low concentrations, but 5 and 10μM DEX completely 
abolished diclofenac induced COX-2 (fig 6.2.1c). IL-4 induced COX-2 was reduced by  
high concentraions of  DEX (fig 6.2.1d).  
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a)          b) 
 
c)       d)  
 
Figure 6.2.1: Low DEX concentrations reduced while high DEX concentrations 
increased LPS induced COX-2 expression respectively at a) 24 and b) 48 hours. 
High concentrations of DEX reduced c) diclofenac induced COX-2 while DEX 
reduced IL-4 induced COX-2 expression.  
Cells were treated for 1 hour with increasing concentrations of DEX before 1μg/ml 
LPS, 500μM diclofenac or 10ng/ml IL-4 was added to the cells for 24 and 48 hours. 
Anti-COX-2 and anti-β-Actin antibodies were added to the membrane in western blot 
experiments. Unstimualted cells and cells treated with DEX alone were the negative 
controls. The vehicle control was cells treated with ethanol. The positive controls 
consisted of cells treated with LPS, diclofenac and IL-4 alone. The data shown were 
obtained from 3 independent experiments (n=3). 
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6.3 Dexamethasone inhibition of cytokine release by LPS and IL-4 in 
macrophages 
Considering indomethacin had inhibitory effects on both the production of TNFα 
and IL-10, we sought to investigate the effect of DEX on the macrophage phenotype. 
As GC are anti-inflammatory drugs, it is expected that they would give rise to IL-10 
production whilst reducing TNFα. DEX functions by binding GR which has been shown 
to reduce expression of PPARγ (Inoue et al., 2000). As PPARγ inhibition was shown 
to inhibit production of IL-10 by IL-4 (fig 3.3.3), the effect of DEX would be quite 
intriguing in this experiment. 
 
Supernatants were assayed for TNFα and IL-10 content using ELISA 
techniques (see 2.8). The following experiment was only carried out on cells treated 
with LPS or IL-4 co-treated with 1, 2 and 5μM DEX. Ten micromolar DEX was not used 
because the effect of 5 and 10μM DEX appear to be similar. All readings were 
normalised to protein concentration. 
 
Treating cells with 10ng/ml IL-4 caused cells to produce IL-10 (102.48 ng/mg 
protein; p<0.001***). All concentrations of  DEX caused an increase in basal IL-10 
(13.74 ng/mg protein; p<0.001###, 14.3 ng/mg protein; p<0.001###, 24.46 ng/mg 
protein; p<0.001### respectively) compared to the negative control (undetectable 
levels of IL-10). Co-treating cells with 10ng/ml IL-4 and 1μM DEX showed a significant 
decrease in IL-10 production (34.13 p<0.01$$ ng/mg protein) (fig 6.3.1a). Both 2 and 
5μM DEX had no effect on IL-4 induced IL-10 production at 24 hours (73.18, 138.61 
ng/mg protein) (fig 6.3.1a) . 
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At 48 hours, IL-4 treatment of cells caused a significant increase in IL-10 
production (76.68 ng/mg protein p<0.001***). DEX of all concentrations significantly 
increased IL-10 production (36.76 p<0.001###, 54.92 p<0.001###, 54.22 p<0.001### 
ng/mg protein) compared to the negative control (fig 6.3.1a). The addition of DEX to 
IL-4 had no effect on IL-10 produced by the macrophages (37.73, 81.79, 78,68 ng/mg 
protein) (fig 6.3.1a) compared to cells treated with IL-4 alone.  
 
Increasing the concentration of DEX showed low to no TNFα production by the 
macrophages (6.24, 0 p<0.05#, 0 p<0.01##ng/mg protein) (fig 6.3.1b). LPS significantly 
increased TNFα production (1274.59 ng/mg protein p<0.001***). Co-treating cells with 
LPS and DEX significantly reduced TNFα levels produced by the macrophages 
(380.01 p<0.01$$, 300.11 p<0.001$$$, 11.4 p<0.001$$$ ng/mg protein) (fig 6.3.1b). At 
48 hours, 1μM DEX did not effect basal TNFα but higher DEX concentrations blocked 
TNFα produced by the macrophages (10.28 p<0.001###, 0 p<0.001###, 0 p<0.001### 
ng/mg protein) (fig 6.3.1b). Adding DEX to the LPS treated cells significantly reduced 
TNFα produced; with higher concentrations of DEX completely blocking TNFα 
production (11.22 p<0.05$, 0 p<0.001$$$, 0 p<0.001$$$ ng/mg protein) (fig 6.3.1b).   
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a)                                                          b) 
 
 
 
 
Figure 6.3.1: DEX induced IL-10 production and had no additive effect on a) IL-4 
induced IL-10. DEX reduced b) LPS induced TNFα production at both 24 and 48 
hours. 
Cells were treated with increasing concetrations of DEX for 1 hour before adding 
10ng/ml IL-4 or 1μg/ml LPS to the cells. Following 24 and 48-hour stimulations, the 
supernatant was assayed for PGE2 and this was standardised to the protein 
concentration. Unstimulated cells and cells treated with DEX alone were the negative 
controls. Cells treated with 10ng/ml IL-4 or 1μg/ml LPS were the positive controls. All 
bars represent the effect of DEX on IL-10 and TNFα produced by IL-4 and LPS 
respectively.  
The data shown were obtained from 3 independent experiments (n=3). IL-10 and 
TNFα levels produced following treatment of cells with IL-4 and LPS were statistically 
compared to the negative control via the One Way Anova with the Dunnett’s post hoc 
test; as represented by *. Cells treated with DEX were compared to the positive control 
with the One Way ANOVA and the Dunnett’s post hoc test; represented by $. The 
same test was used to compare the differences in cytokine production between the 
unstimulated cells and cells treated with only DEX; represented by #. Error bars are 
SEM; *p<0.05, **p<0.01, ***p<0.001. 
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6.4 Discussion to results chapter 6 
The role and effect of dexamethasone on IL-4 treated cells 
 
6.4.1 Effect of dexamethasone on COX-2 expression 
DEX is a GC with anti-inflammatory properties. Typically, DEX has been 
reported to repress production of anti-inflammatory cytokines by interfering with the 
gene transcription of pro-inflammatory genes (see for review: (Coutinho and 
Chapman, 2011)). We were able to show low concentrations of DEX to inhibit LPS 
induced COX-2 but not high concentrations of DEX (fig 6.2.1a, b). The inhibitory effect 
of DEX on LPS is a phenomenon backdated to the 1990s (Fu et al., 1990, Barrios-
Rodiles and Chadee, 1998, Inoue et al., 2000, Yano et al., 2007). Research has shown 
DEX to have a marginal inhibitory effect on COX-1 with a more profound effect on 
COX-2 (Masferrer et al., 1990). The antagonistic relation between LPS and DEX has 
been visited. Fu et al. (1990) showed LPS to elevate COX protein levels and increase 
PGE2 AND TXA2 while DEX inhibits LPS induced COX-2. Barrios-Rodiles et al., (2015) 
has shown 1µM DEX to rapidly reduce 100ng/ml LPS induced COX-2.  
 
Inoue et al. (2000) suggest LPS to reduce PPAR expression thus reducing the 
COX-2 synthesised 15d-PGJ2 binding to its receptor. At this time, LPS is believed to 
induce GR expression thus increasing the sensitivity to DEX. It may therefore be 
possible, that PPAR behaves antagonistically to GR despite both 15d-PGJ2 and DEX 
having COX-2 suppressing properties. It has been suggested that DEX possesses the 
ability to suppress this pro-inflammatory protein through the inhibition of PLA2 
(Sampey et al., 2000), however Fu et al. (1990) showed DEX to have no effect on 
PLA2. DEX is believed to destabilise β-globulin COX-2 reporter mRNA by inhibiting 
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p38. Another paper has specifically shown DEX to act downstream of MKK6 and 
upstream of MK2 (Lasa et al., 2001).  
 
DEX inhibited diclofenac induced COX-2 (fig 6.2.1c) and IL-4 induced COX-2 
expression (fig 6.2.1d) with increasing concentrations. This may be explained by the 
antagonistic effect of PPAR and GR. Diclofenac has been shown to require PPAR 
to induce COX-2 (fig 4.3.1.2a). DEX might reduce PPAR expression via the up-
regulation of GR (Inoue et al., 2000), thus suppressing COX-2 expression by 
diclofenac. Comera and Russo-Marie (1995) have shown DEX to cause secretion of 
AnxA1 in human blood monocytes and peritoneal leukocytes. This is similar to the 
effect of the cAMP inducing agent, forskolin. cAMP is a requirement for IL-4 induced 
COX-2 expression (fig 4.1.2.1b). This may explain why IL-4 induced COX-2 
expression was never completely abolished by DEX. 
 
Wu et al. (1996) showed that in NIH3T3 cells, DEX induces PPARγ 
independent to protein synthesis via GR. This appears to be dependent on C/EBP 
(Wu et al., 1996). It has been shown that GR inhibit NFκB transactivation by inducing 
IκB expression. This transcription factor has previously been shown to be required for 
LPS induced COX-2 expression (Ayoub et al., 2009). Chistyakov et al. (2015) gave 
evidence for the activation of NFκB to shutdown PPARγ. This group suggested the 
TLR/NFκB to mediate suppression of PPARγ, thus LPS was found to reduce PPARγ 
mRNA as early as 2 hours following stimulations (Chistyakov et al., 2015); something 
we were able to observe (fig 4.4.1). 
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6.4.2 Effect of DEX on IL-10 and TNFα production following stimulations 
Whereas the lowest concentration of DEX reduced IL-4 induced IL-10 
synthesis, all other concentrations of DEX had no effect on IL-4 induced IL-10 at 24 
hours. DEX had neither a suppressive nor an additive effect on IL-4 induced IL-10 
synthesis (fig 6.3.1a). We have shown cells treated with only DEX to produce IL-10 
(fig 6.3.1a) and with increasing concentrations of this, basal TNFα was inhibited (fig 
6.3.1b). We found DEX to inhibit production of TNFα in macrophages following LPS 
treatment (fig 6.3.1b).  This has previously been noted in many studies (see for review: 
(Coutinho and Chapman, 2011)). Thus, DEX appears to drive the macrophages in a 
single direction. A similar effect was previously reported where, Xia et al. (2005) 
showed DEX to induce IL-10 production in dendritic cells with reduced IL-12. This was 
suggested to occur via phosphorylation of ERK. IL-10 and TNFα were both shown to 
modulate the sensitivity of DEX (Franchimont et al., 1999).  
 
Patel et al. (2012) showed the effects of DEX to be mediated via AnxA1 as, 
DEX could inhibit pro-inflammatory mediators including TNFα but was unable to exert 
this effect when AnxA1 was knocked out. Citarella et al. (2009) showed LPS to induce 
TNFα in PMN leukocytes and this was significantly reduced by both IL-10 and DEX. 
Similarly, DEX was found to suppress TNFα induced by LPS in wild type BMDM 
(Abraham et al., 2006). This inhibition was reduced in the absence of DUSP1, a protein 
involved in p38 inactivation. Overexpression of DUSP1 was found to dampen LPS 
induced pro-inflammatory responses. Interestingly, this group found DEX to induce 
DUSP1, thus suggesting, DEX to function by activating DUSP1 mediated p38 
inactivation (Abraham et al., 2006).  
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The use of anti-inflammatory cytokine and GC treatment has commonly been 
investigated. Citarella et al. (2009) reported DEX and IL-10 to equally block LPS 
stimulated TNFα and IL-1β in PMN leukocytes as shown by ELISA. Whereas 
increasing concentrations of DEX blocked TNFα, lower concentrations appeared to 
stimulate IL-10 while higher concentrations inhibited IL-10 in LPS treated cells 
(Franchimont et al., 1999). This suggests a dual role of DEX depending on the 
concentration and may explain why COX-2 expression was increased following 
treatment of LPS with 5 and 10μM DEX (fig 6.2.1a,b). 
 
The sensitivity to DEX appears to be increased as TNFα concentration was 
reduced and IL-10 was increased (Franchimont et al., 1999). Whereas up to 48-hour 
stimulations with either TNFα or IL-10 did not force changes in GR expression, at 48 
hours, TNFα and IL-10 forced a reduction and increase in GR concentration, 
respectively, with no effect on the binding affinity to DEX (Franchimont et al., 1999). 
This suggests IL-10 produced by IL-4 treated macrophages could possibly mediate 
inhibitory effects on TNFα via GR. This group suggested IL-10 to work synergistically 
with GC however, there is no evidence for that in the production of IL-10 when DEX 
was administered (fig 6.3.1a). Thus, the inhibitory effect of DEX on TNFα (fig 6.3.1b) 
may be driven by IL-10 induced increased GR sensitivity.  
 
6.5 Chapter conclusion 
 Different concentrations of DEX have different effects on LPS and IL-4 induced 
COX-2 expression. Whereas low and high concentrations of DEX reduced and 
increased LPS induced COX-2 expression (fig 6.2.1a,b), increasing concentrations of 
DEX reduced IL-4 induced COX-2 expression (fig 6.2.1d). A cytokine profile analysis 
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showed DEX to sustain IL-4 induced IL-10 production (fig 6.3.1a) but reduced LPS 
induced TNFα production (fig 6.3.1b). Thus, there is evidence that the IL-4 treated 
macrophages are transformed into anti-inflammatory macrophages and the effect of 
IL-4 compared to DEX is somewhat similar in regards to the phenotypic function.  
 
 
Figure 6.5.1 Diagram to conclude chapter 
Introducing increasing concentrations of DEX to macrophage J774.2 cells treated with 
10ng/ml IL-4 for 48 hours, reduced COX-2 expression (fig 6.2.1d). Furthermore, 48-
hour DEX treatment induced IL-10 production in these macrophages. DEX did not 
further increase or decrease IL-4 induced IL-10 secretion in this set of macrophages.  
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7.0 Final conclusion  
  
We aimed to identify a unique signalling pathway that was involved in both IL-
4 induced polarisation of macrophages and the induction of a catalytically active COX-
2. We hypothesised this pathway to be distinct to the signalling pathway downstream 
to LPS treated macrophages. Through a series of pharmacological experiments, we 
were able to identify IL-4, the anti-inflammatory cytokine, as an inducer of COX-2 
protein and a stimulator of macrophage polarisation towards an anti-inflammatory 
phenotype.  
 
To identify the endogenous inducer of the late induced COX-2 that was 
physiologically relevant, we demonstrated the induction of COX-2 protein at 48 hours 
by IL-4. This pathway shared significant aspects with the signalling machinery involved 
in the polarisation of macrophages towards an anti-inflammatory phenotype; in respect 
to the LPS induced pro-inflammatory macrophages. 
 
The MAPK, p38, the nuclear receptor, PPAR and the second messenger, 
cAMP were shown to be required for the induction of COX-2 by IL-4 in macrophage 
J774.2 cells. Inhibiting either of these abolished COX-2 expression in this cell line. IL-
4 was shown to directly induce PPAR activity via p38, specifically following 30 
minutes and 48-hour stimulations. The following pharmacological experiments 
enabled a sequential order of events to be attained; thus, increasing cognizance in 
COX-2 induction.  
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We believe that the induction of COX-2 is tightly controlled as there was a delay 
in its expression and activity depending on the stimuli. Whereas, a PPAR agonist, 
rosiglitazone, could induce COX-2 expression in vitro by 24 hours, IL-4 did not induce 
COX-2 before 48 hours. PPAR activity was induced as early as 30 minutes and the 
expression of p38 in the induction of COX-2 was observed by 24 hours. In addition, 
LPS was able to induce COX-2 much earlier than IL-4 suggesting differential temporal 
control depending on the stimulus. We assume this temporal control following IL-4 
treatment to be regulated at the level of PPAR, p38, cAMP or possibly miR which is 
a growing area in research.  
 
Interest was shed on the phenotypic nature of the macrophage that expressed 
COX-2. To understand the phenotypic state of the macrophage within the complex 
pool of macrophage plasticity and heterogeneity, both cAMP and cytokine levels were 
measured following each stimulation. High levels of cAMP accompanied with high IL-
10 and low TNFα levels were indicative of an anti-inflammatory macrophage 
phenotype following IL-4 stimulations. This differed to no cAMP, no IL-10 and high 
TNFα levels following LPS treatment of macrophages. Interestingly, both 
macrophages expressed COX-2. As it was alleged that COX-2 is an immediate early 
gene in the pro-inflammatory phase of the inflammatory response, it was particularly 
interesting that the anti-inflammatory macrophage expressed this protein in vitro. We 
were able to demonstrate the critical role of both p38 and PPAR in the production of 
IL-10 as blocking these completely wiped out IL-10 production at the end of the 48-
hour treatment. This draws strong parallel between the pathways involved in COX-2 
induction and macrophage polarisation following IL-4 treatment. 
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Drugs currently in the market may actuate negative side effects due to inhibition 
of the anti-inflammatory COX-2 protein which we believe to be involved in pro-
resolving pathways; however extensive work must be done to conclude this. We 
demonstrated this concept by the ability of indomethacin to block IL-10 and 
acetaminophen to inhibit COX-2 activity, that was induced by IL-4 in this cell line. This 
is clinically relevant, as IL-4 could potentially be the appropriate target in engendering 
a pro-resolving response during chronic diseases. This thesis puts emphasis on the 
roles of p38 MAPK, PPAR and cAMP in these pathways and so would also require 
attention in this area of research.  
 
Although a unique signalling pathway was provided for the induction of COX-2 
via an anti-inflammatory route, there is yet a lot to assimilate in this process. This 
project therefore, opens doors for further research in this field.  
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8.0 Further work 
The major limitation of this work is that the experiments were carried out on a 
cell line: macrophage J774.2 cells and so it would be important to replicate some of 
the key experiments in this thesis in primary macrophages and/or in in vivo models.  
 
To further understand the signalling machinery downstream to IL-4 treatment, 
antagonising the IL-4R to observe whether IL-4 exerts its effects via this receptor can 
be confirmed. This would suggest IL-4R as a valid therapeutic target in the drug market 
to instigate resolution, especially in chronic conditions. Using immunofluorescence or 
Western blot techniques, whether STAT6 is activated and required in both the 
induction of COX-2 and polarisation of macrophages can be confirmed. This would be 
extremely useful as STAT6 is commonly activated and required for downstream anti-
inflammatory effects of IL-4. In addition to this, measuring expression of typical 
phenotypic markers on macrophages following treatment with either LPS or IL-4 would 
confirm the polarisation state of the macrophage; though this may be challenging 
considering the heterogeneity in different tissues.  
 
Although we have shown p38 and PPAR to be required for the production of 
IL-10 by IL-4, we have yet to confirm whether cAMP antagonism can block IL-10 
production. This thesis has speculated PGE2 to exert its effects via the EP4 receptor, 
however in further experiments, this should be confirmed. Furthermore, whether 
blocking COX-2 blocks p38 phosphorylation, PPAR activity and cAMP production 
would be key to clarify any negative or positive feedback mechanisms in place. This 
may also bring us closer to understanding the potential anti-inflammatory properties 
of COX-2.  
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It would be interesting to measure the dynamic functions of COX-2 following 
the different stimulations. One such function is wound healing which is associated with 
resolution and anti-inflammatory responses. Inducing a scratch on a confluent 
monolayer of cells represents a wound. Closure of the scratch can be observed 
following addition of the supernatant that was collected from cells treated with either 
IL-4 or LPS. This supernatant would provide the microenvironment, either pro- or anti-
inflammatory, which drives the polarisation of macrophages. Comparing these findings 
to observations made in the presence of a COX-2 inhibitor will enable conclusions to 
be drawn in regards to the anti-inflammatory role of COX-2 in macrophages.  
 
Using in vivo models of both acute and chronic inflammation, it would be 
important to assess IL-4 and LPS signalling during resolution and measure various 
parameters including cytokine production, phosphorylation of p38, activation of 
PPARγ, production of cAMP and production of PGE2. Analysing the expression of anti-
inflammatory and pro-inflammatory markers alongside this would enable conclusions 
to be made in regards to a unique signalling pathway for both the polarisation of 
macrophages and the induction of COX-2.  
 
This thesis has provided some novel addition to the literature in pathways that 
link both macrophage polarisation towards an anti-inflammatory phenotype and the 
induction of COX-2 by IL-4. Additional experiments will therefore greaten this depth of 
understanding and eventually provide further physiological relevance to these 
findings. 
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